


**CUMULATIVE
SUPPLEMENT 4
APRIL 2021**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2021

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41th EDITION

**Cumulative Supplement 4
April 2021**

CONTENTS

PAGE

Contents

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	ix
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
DRUG PRODUCT LISTS		
	Prescription Drug Product List	1-1
	OTC Drug Product List	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	3-1
	Orphan Product Designations and Approvals List	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM		
A.	Patent and Exclusivity Lists	A-1
B.	Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

41st EDITION

**CUMULATIVE SUPPLEMENT 4
APRIL 2021**

1.0 INTRODUCTION

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at orangebook@fda.hhs.gov.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AKORN INC
(AKORN)

AKORN OPERATING CO LLC
(AKORN)

AKORN INC
(AKORN INC)

AKORN OPERATING CO LLC
(AKORN)

1.4 LEVOTHYROXINE SODIUM¹

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.²

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-

¹ In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

² Please consult the Active Section of the Orange Book for information on other strengths.

AB4	LEVOTHYROXINE SODIUM ³	MYLAN	0.3MG	A076187	-	RS
-----	-----------------------------------	-------	-------	---------	---	----

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
 Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

³ Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2020</u>	<u>MAR</u> <u>2021</u>	<u>JUN</u> <u>2021</u>	<u>SEP</u> <u>2021</u>	<u>DEC</u> <u>2021</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	20478	20726			
	2659	2671			
	(13.0%)	(12.9%)			
MULTISOURCE	17819	18055			
	(87.0%)	(87.1%)			
THERAPEUTICALLY EQUIVALENT	17746	17990			
	(86.7%)	(86.8%)			

NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)
EXCEPTIONS ⁴	54 (0.3%)	54 (0.3%)
NEW MOLECULAR ENTITIES APPROVED	22	29
NUMBER OF APPLICANTS	1185	1184

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN ⁵	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.

⁴ Amino acid containing products of varying composition (see Introduction, page xx of the List).

⁵ The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

ABIRATERONE ACETATE

TABLET;ORAL
 ABIRATERONE ACETATE
 >A> AB AMNEAL PHARMS 500MG A208327 002 Dec 23, 2020 Apr NEWA

ACARBOSE

TABLET;ORAL
 ACARBOSE
 >D> @ EMCURE PHARMS LTD 25MG A202271 001 Feb 07, 2012 Apr CMFD
 >A> AB 25MG A202271 001 Feb 07, 2012 Apr CMFD
 >D> @ 50MG A202271 002 Feb 07, 2012 Apr CMFD
 >A> AB 50MG A202271 002 Feb 07, 2012 Apr CMFD
 >D> @ 100MG A202271 003 Feb 07, 2012 Apr CMFD
 >A> AB 100MG A202271 003 Feb 07, 2012 Apr CMFD

ACETAMINOPHEN

POWDER;INTRAVENOUS
 ACETAMINOPHEN
 + @ MYLAN LABS LTD 1GM/VIAL N206610 001 Jan 15, 2021 Jan NEWA
 SOLUTION;INTRAVENOUS
 ACETAMINOPHEN
 +! B BRAUN MEDICAL INC 500MG/50ML (10MG/ML) N204957 001 Feb 18, 2021 Feb NEWA
 +! 1GM/100ML (10MG/ML) N204957 002 Feb 18, 2021 Feb NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 AA XSPIRE PHARMA 300MG;50MG;40MG A206615 001 Aug 04, 2017 Feb CAHN
 TABLET;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 >A> @ GRANULES 325MG;50MG;40MG A040864 001 Dec 01, 2008 Apr CAHN
 >D> @ NOVAST LABS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Apr CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
 BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE
 AB NOSTRUM LABS INC 325MG;50MG;40MG;30MG A075929 001 Apr 22, 2002 Jan CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
 ACETAMINOPHEN AND CODEINE PHOSPHATE
 >D> AA VINTAGE 300MG;15MG A089990 001 Sep 30, 1988 Apr DISC
 >A> @ 300MG;15MG A089990 001 Sep 30, 1988 Apr DISC
 >D> AA 300MG;30MG A089805 001 Sep 30, 1988 Apr DISC
 >A> @ 300MG;30MG A089805 001 Sep 30, 1988 Apr DISC
 >A> @ 300MG;60MG A089828 001 Sep 30, 1988 Apr DISC
 >D> AA VINTAGE PHARMS 300MG;60MG A089828 001 Sep 30, 1988 Apr DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL
 ANEXSIA 5/325
 >D> AA SPECGX LLC 325MG;5MG A040409 001 Oct 20, 2000 Apr CHRS
 >A> AA ! 325MG;5MG A040409 001 Oct 20, 2000 Apr CHRS
 ANEXSIA 7.5/325
 >D> AA SPECGX LLC 325MG;7.5MG A040405 001 Sep 08, 2000 Apr CHRS
 >A> AA ! 325MG;7.5MG A040405 001 Sep 08, 2000 Apr CHRS
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN
 >D> AA SPECGX LLC 325MG;10MG A040400 001 Jul 26, 2000 Apr CHRS
 >A> AA ! 325MG;10MG A040400 001 Jul 26, 2000 Apr CHRS
 >D> NORCO
 >D> AA APIL 325MG;2.5MG A040148 004 Jul 07, 2014 Apr DISC
 >A> @ 325MG;2.5MG A040148 004 Jul 07, 2014 Apr DISC
 >D> AA ! 325MG;5MG A040099 001 Jun 25, 1997 Apr DISC
 >A> @ 325MG;5MG A040099 001 Jun 25, 1997 Apr DISC
 >D> AA 325MG;5MG A040148 005 Jul 07, 2014 Apr DISC
 >A> @ 325MG;5MG A040148 005 Jul 07, 2014 Apr DISC
 >D> AA ! 325MG;7.5MG A040148 003 Sep 12, 2000 Apr DISC
 >A> @ 325MG;7.5MG A040148 003 Sep 12, 2000 Apr DISC
 >D> AA ! 325MG;10MG A040148 001 Feb 14, 1997 Apr DISC
 >A> @ 325MG;10MG A040148 001 Feb 14, 1997 Apr DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA	CHARTWELL	325MG; 5MG	A207834	001	Aug 15, 2019	Jan	CAHN
AA		325MG; 7.5MG	A207834	002	Aug 15, 2019	Jan	CAHN
AA		325MG; 10MG	A207834	003	Aug 15, 2019	Jan	CAHN
	ROXICET						
	@ HIKMA	325MG; 5MG	A087003	001		Jan	DISC

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL

ACETAZOLAMIDE

>D>	@ ACCORD HLTHCARE	500MG	A207659	001	Oct 18, 2018	Apr	CMFD
>A>	AB	500MG	A207659	001	Oct 18, 2018	Apr	CMFD

TABLET; ORAL

ACETAZOLAMIDE

AB	APPCO	125MG	A211372	001	Feb 22, 2021	Feb	NEWA
AB		250MG	A211372	002	Feb 22, 2021	Feb	NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETYLCYSTEINE

>A>	AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A204797	001	Apr 15, 2021	Apr	NEWA
-----	----	--------------	---------------------	---------	-----	--------------	-----	------

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+	!	ASTRAZENECA	0.4MG/INH	N202450	001	Jul 23, 2012	Feb	CAHN
---	---	-------------	-----------	---------	-----	--------------	-----	------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

POWDER, METERED; INHALATION

DUAKLIR PRESSAIR

		ASTRAZENECA	0.4MG/INH; 0.012MG/INH	N210595	001	Mar 29, 2019	Feb	CAHN
--	--	-------------	------------------------	---------	-----	--------------	-----	------

ACYCLOVIR

SUSPENSION; ORAL

ACYCLOVIR

AB	VISTAPHARM	200MG/5ML	A213951	001	Jan 11, 2021	Jan	NEWA
----	------------	-----------	---------	-----	--------------	-----	------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan	CHRS
AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan	CPOT

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO FORTE

+	!	GALDERMA LABS	0.3%; 2.5%	N207917	001	Jul 15, 2015	Feb	CTEC
---	---	---------------	------------	---------	-----	--------------	-----	------

ADENOSINE

SOLUTION; INTRAVENOUS

ADENOSINE

AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb	CMFD
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb	CMFD

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jan	NEWA
	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jan	DISC
AB	MSN	200MG	A213435	001	Jan 21, 2021	Jan	NEWA

ALBUTEROL SULFATE

TABLET; ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb	CMFD
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb	CMFD
>D>	AB	EYWA	A213524	001	Oct 08, 2020	Apr	DISC
>A>	@	EQ 2MG BASE	A213524	001	Oct 08, 2020	Apr	DISC
>D>	AB	EQ 4MG BASE	A213524	002	Oct 08, 2020	Apr	DISC

TABLET;ORAL						
ALBUTEROL SULFATE						
>A>	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Apr DISC
<u>ALBUTEROL SULFATE; IPRATROPIUM BROMIDE</u>						
SOLUTION;INHALATION						
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE						
	@ AUROBINDO PHARMA LTD	EQ 0.083% BASE;0.017%	A206532	001	Jul 08, 2020	Jan DISC
<u>ALPRAZOLAM</u>						
TABLET;ORAL						
ALPRAZOLAM						
>D>	@ NOVITIUM PHARMA	0.25MG	A074174	001	Oct 19, 1993	Apr CMFD
>A>	AB	0.25MG	A074174	001	Oct 19, 1993	Apr CMFD
>D>	@	0.5MG	A074174	002	Oct 19, 1993	Apr CMFD
>A>	AB	0.5MG	A074174	002	Oct 19, 1993	Apr CMFD
>D>	@	1MG	A074174	003	Oct 19, 1993	Apr CMFD
>A>	AB	1MG	A074174	003	Oct 19, 1993	Apr CMFD
>D>	@	2MG	A074174	004	Oct 19, 1993	Apr CMFD
>A>	AB	2MG	A074174	004	Oct 19, 1993	Apr CMFD
<u>ALPROSTADIL</u>						
INJECTABLE;INJECTION						
CAVERJECT						
	+ @ PFIZER	0.005MG/VIAL	N020379	003	Jun 27, 1996	Jan CAHN
AP	+	0.01MG/VIAL	N020379	001	Jul 06, 1995	Jan CAHN
AP	+!	0.02MG/VIAL	N020379	002	Jul 06, 1995	Jan CAHN
AP	+!	0.04MG/VIAL	N020379	004	May 19, 1997	Jan CAHN
CAVERJECT IMPULSE						
	PFIZER	0.01MG/VIAL	N021212	001	Jun 11, 2002	Jan CAHN
		0.02MG/VIAL	N021212	002	Jun 11, 2002	Jan CAHN
PROSTIN VR PEDIATRIC						
AP	+! PFIZER	0.5MG/ML	N018484	001		Jan CAHN
<u>AMANTADINE HYDROCHLORIDE</u>						
SYRUP;ORAL						
AMANTADINE HYDROCHLORIDE						
	@ WOCKHARDT BIO AG	50MG/5ML	A075060	001	Dec 24, 1998	Jan DISC
TABLET;ORAL						
AMANTADINE HYDROCHLORIDE						
	@ INVAGEN PHARMS	100MG	A207571	001	Jan 31, 2017	Jan DISC
TABLET, EXTENDED RELEASE;ORAL						
OSMOLEX ER						
	+ ADAMAS PHARMA	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
	+ ADAMAS PHARMS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Jan CAHN
	+ @	EQ 161MG BASE	N209410	004	Apr 22, 2020	Jan CAHN
	+	EQ 193MG BASE	N209410	002	Feb 16, 2018	Jan CAHN
<u>AMINOCAPROIC ACID</u>						
SOLUTION;ORAL						
AMICAR						
AA	+! AKORN	0.25GM/ML	N015230	002		Feb CPOT
AA	+!	1.25GM/5ML	N015230	002		Feb CDFR
AMINOCAPROIC ACID						
>A>	AA AIRIS PHARMA PVT LTD	0.25GM/ML	A213825	001	Apr 08, 2021	Apr NEWA
AA	AMNEAL	0.25GM/ML	A212780	001	Aug 23, 2019	Feb CPOT
AA		1.25GM/5ML	A212780	001	Aug 23, 2019	Feb CDFR
AA	LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26, 2021	Feb CPOT
AA		1.25GM/5ML	A214140	001	Jan 26, 2021	Feb CDFR
AA	TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11, 2020	Feb CPOT
AA		1.25GM/5ML	A212494	001	Aug 11, 2020	Feb CDFR
AA	VISTAPHARM	0.25GM/ML	A212814	001	Feb 26, 2020	Feb CPOT
AA		1.25GM/5ML	A212814	001	Feb 26, 2020	Feb CDFR
SYRUP;ORAL						
AMINOCAPROIC ACID						
AA	LEADING PHARMA LLC	1.25GM/5ML	A214140	001	Jan 26, 2021	Jan NEWA
TABLET;ORAL						
AMINOCAPROIC ACID						
AB	LEADING PHARMA LLC	500MG	A213928	001	Feb 12, 2021	Feb NEWA
AB		1GM	A213928	002	Feb 12, 2021	Feb NEWA

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	RUBICON	100MG	A078578	002	Feb 26, 2021	Feb	NEWA
AB		400MG	A078578	003	Feb 26, 2021	Feb	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB	MANKIND PHARMA	10MG	A213999	001	Feb 19, 2021	Feb	NEWA
AB		25MG	A213999	002	Feb 19, 2021	Feb	NEWA
AB		50MG	A213999	003	Feb 19, 2021	Feb	NEWA
AB		75MG	A213999	004	Feb 19, 2021	Feb	NEWA
AB		100MG	A213999	005	Feb 19, 2021	Feb	NEWA
AB		150MG	A213999	006	Feb 19, 2021	Feb	NEWA

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

@ WOCKHARDT

EQ 2.5MG BASE

A078500 001 Sep 06, 2007 Jan DISC

@

EQ 5MG BASE

A078500 002 Sep 06, 2007 Jan DISC

@

EQ 10MG BASE

A078500 003 Sep 06, 2007 Jan DISC

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Jan	CAHN
----	---------	------------------------------------	---------	-----	--------------	-----	------

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	RHODES PHARMS	2.5MG; 2.5MG; 2.5MG; 2.5MG	A213111	003	Jan 13, 2021	Jan	NEWA
AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A213111	005	Jan 13, 2021	Jan	NEWA
AB		5MG; 5MG; 5MG; 5MG	A213111	006	Jan 13, 2021	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	AB	ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A213709	001	Apr 22, 2021	Apr	NEWA
>A>	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A213709	002	Apr 22, 2021	Apr	NEWA
>A>	AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A213709	003	Apr 22, 2021	Apr	NEWA
>A>	AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A213709	004	Apr 22, 2021	Apr	NEWA
>A>	AB		3.75MG; 3.75MG; 3.75MG; 3.75MG	A213709	005	Apr 22, 2021	Apr	NEWA
>A>	AB		5MG; 5MG; 5MG; 5MG	A213709	006	Apr 22, 2021	Apr	NEWA
>A>	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A213709	007	Apr 22, 2021	Apr	NEWA
	AB	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A213111	001	Jan 13, 2021	Jan	NEWA
	AB		1.875MG; 1.875MG; 1.875MG; 1.875MG	A213111	002	Jan 13, 2021	Jan	NEWA
	AB		3.125MG; 3.125MG; 3.125MG; 3.125MG	A213111	004	Jan 13, 2021	Jan	NEWA
	AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A213111	007	Jan 13, 2021	Jan	NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

AA	GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jan	NEWA
AA		10MG	A212186	002	Jan 27, 2021	Jan	NEWA
	@ MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jan	DISC
	@	10MG	A213898	002	Jul 14, 2020	Jan	DISC
	@ NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Mar	DISC
	@	10MG	A213763	002	Aug 24, 2020	Mar	DISC
AA	SPECGX LLC	5MG	A213583	001	Jan 22, 2021	Jan	NEWA
AA		10MG	A213583	002	Jan 22, 2021	Jan	NEWA
AA	SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Jan	NEWA
AA		10MG	A214574	002	Jan 27, 2021	Jan	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

EVEKEO ODT

>A>	+	ARBOR PHARMS LLC	2.5MG	N209905	005	Apr 16, 2021	Apr	NEWA
>D>	+		20MG	N209905	004	Jan 30, 2019	Apr	CHRS
>A>	+		20MG	N209905	004	Jan 30, 2019	Apr	CHRS

AMPICILLIN SODIUM

INJECTABLE; INJECTION		AMPICILLIN SODIUM							
	@ HQ SPECPLT PHARMA	EQ 125MG BASE/VIAL		A 062772	005	Apr 15, 1993	Mar	CAHN	
AP		EQ 250MG BASE/VIAL		A 062772	006	Apr 15, 1993	Mar	CAHN	
AP		EQ 500MG BASE/VIAL		A 062772	007	Apr 15, 1993	Mar	CAHN	
	@	EQ 500MG BASE/VIAL		A 062772	008	Apr 15, 1993	Mar	CAHN	
AP		EQ 1GM BASE/VIAL		A 062772	001	Apr 15, 1993	Mar	CAHN	
	@	EQ 1GM BASE/VIAL		A 062772	002	Apr 15, 1993	Mar	CAHN	
AP		EQ 2GM BASE/VIAL		A 062772	003	Apr 15, 1993	Mar	CAHN	
	@	EQ 2GM BASE/VIAL		A 062772	004	Apr 15, 1993	Mar	CAHN	
AP		EQ 10GM BASE/VIAL		A 063142	001	Apr 15, 1993	Mar	CAHN	

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION		AMPICILLIN AND SULBACTAM							
AP	HQ SPECPLT PHARMA	EQ 1GM BASE/VIAL; EQ 500MG		A 065176	001	Nov 30, 2005	Mar	CAHN	
		BASE/VIAL							
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL		A 065176	002	Nov 30, 2005	Mar	CAHN	
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL		A 065188	001	Nov 25, 2005	Mar	CAHN	

APREMILAST

TABLET; ORAL		APREMILAST							
AB	UNICHEM	10MG		A 211819	001	Feb 17, 2021	Feb	NFTG	
AB		20MG		A 211819	002	Feb 17, 2021	Feb	NFTG	
AB		30MG		A 211819	003	Feb 17, 2021	Feb	NFTG	

ARGATROBAN

INJECTABLE; INJECTION		ARGATROBAN							
AP	CAPLIN	50MG/50ML (1MG/ML)		A 214235	001	Jan 21, 2021	Jan	NFTG	

ARSENIC TRIOXIDE

INJECTABLE; INJECTION		ARSENIC TRIOXIDE							
AP	AMNEAL	1MG/ML		A 210739	001	Jan 25, 2021	Jan	NEWA	
	@ INGENUS PHARMS LLC	2MG/ML		A 209315	002	Jan 14, 2021	Feb	DISC	
AP		2MG/ML		A 209315	002	Jan 14, 2021	Jan	NEWA	

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; INTRAVENOUS		INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)							
+!	SANDOZ CANADA INC	80MG/VIAL; 0.02MG/VIAL; 400		N 021265	002	Jan 29, 2004	Feb	CAIN	
		IU/VIAL; 0.001MG/VIAL; 5MG/VIAL; 0.14							
		MG/VIAL; 1.7MG/VIAL; 1MG/VIAL; 1.4MG/V							
		IAL; 1.2MG/VIAL; 7 IU/VIAL; 2,300							
		IU/VIAL; 0.2MG/VIAL							

ASENAPINE MALEATE

TABLET; SUBLINGUAL		ASENAPINE MALEATE							
AB	BRECKENRIDGE	EQ 5MG BASE		A 205960	003	Mar 08, 2021	Feb	NEWA	

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL		ASPIRIN AND DIPYRIDAMOLE							
>D>	AB LANNETT CO INC	25MG; 200MG		A 204552	001	Mar 20, 2019	Apr	DISC	
>A>	@	25MG; 200MG		A 204552	001	Mar 20, 2019	Apr	DISC	

ATAZANAVIR SULFATE

CAPSULE; ORAL		ATAZANAVIR SULFATE							
>A>	AB LAURUS LABS LTD	EQ 150MG BASE		A 212579	001	Apr 30, 2021	Apr	NEWA	
>A>	AB	EQ 200MG BASE		A 212579	002	Apr 30, 2021	Apr	NEWA	
>A>	AB	EQ 300MG BASE		A 212579	003	Apr 30, 2021	Apr	NEWA	

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar	NEWA
AB		18MG	A202682	002	Mar 11, 2021	Mar	NEWA
AB		25MG	A202682	003	Mar 11, 2021	Mar	NEWA
AB		40MG	A202682	004	Mar 11, 2021	Mar	NEWA
AB		60MG	A202682	005	Mar 11, 2021	Mar	NEWA
AB		80MG	A202682	006	Mar 11, 2021	Mar	NEWA
AB		100MG	A202682	007	Mar 11, 2021	Mar	NEWA
	@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb	DISC
AB		10MG	A079021	001	Feb 18, 2021	Feb	NEWA
	@	18MG	A079021	002	Feb 18, 2021	Feb	DISC
AB		18MG	A079021	002	Feb 18, 2021	Feb	NEWA
	@	25MG	A079021	003	Feb 18, 2021	Feb	DISC
AB		25MG	A079021	003	Feb 18, 2021	Feb	NEWA
	@	40MG	A079021	004	Feb 18, 2021	Feb	DISC
AB		40MG	A079021	004	Feb 18, 2021	Feb	NEWA
	@	60MG	A079021	005	Feb 18, 2021	Feb	DISC
AB		60MG	A079021	005	Feb 18, 2021	Feb	NEWA
	@	80MG	A079021	006	Feb 18, 2021	Feb	DISC
AB		80MG	A079021	006	Feb 18, 2021	Feb	NEWA
	@	100MG	A079021	007	Feb 18, 2021	Feb	DISC
AB		100MG	A079021	007	Feb 18, 2021	Feb	NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan	CAHN
AB		EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan	CAHN
AB		EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan	CAHN
AB		EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

+ @	ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb	CAHN
+ @		EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb	CAHN
+ @		EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb	CAHN
+ @		EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb	CAHN

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar	NEWA
----	----------------	-----------	---------	-----	--------------	-----	------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP	+! HOSPIRA	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar	CTEC
AP		1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar	CTEC
AP	ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar	NFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	WINDER LABS LLC	0.025MG;2.5MG	A211362	001	Jan 27, 2021	Jan	NEWA
----	-----------------	---------------	---------	-----	--------------	-----	------

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

+ @	MYLAN	0.14MG/ML;10MG/ML	N019678	001	Nov 06, 1991	Jan	CAHN
-----	-------	-------------------	---------	-----	--------------	-----	------

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;INTRAVENOUS

AVYCAZ

+!	ALLERGAN	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Jan	CDFR
----	----------	------------------------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

AB PERRIGO UK FINCO EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A208111 001 Feb 18, 2021 Feb NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB TARO EQ 200MG BASE/5ML A211521 001 Dec 11, 2019 Feb CMFD

INJECTABLE;INJECTION

AZITHROMYCIN

@ MYLAN ASI

EQ 500MG BASE/VIAL

A065506 001 Mar 24, 2009 Feb DISC

TABLET;ORAL

AZITHROMYCIN

AB YUNG SHIN PHARM EQ 500MG BASE A211318 001 Mar 17, 2021 Mar NEWA

AB EQ 600MG BASE A211068 001 May 08, 2020 Feb CMFD

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

AP MAIA PHARMS INC 0.05MG/ML A210777 001 Jan 15, 2021 Jan NEWA

GABLOFEN

AP +! PIRAMAL CRITICAL 0.05MG/ML N022462 001 Nov 19, 2010 Mar CHRS

AP + 0.05MG/ML N022462 001 Nov 19, 2010 Mar CRLD

AP +! 0.5MG/ML N022462 002 Nov 19, 2010 Mar CHRS

AP + 0.5MG/ML N022462 002 Nov 19, 2010 Mar CRLD

AP +! 2MG/ML N022462 003 Nov 19, 2010 Mar CHRS

AP + 2MG/ML N022462 003 Nov 19, 2010 Mar CRLD

TABLET;ORAL

BACLOFEN

>A> AB INNOGENIX 5MG A212378 003 Apr 30, 2021 Apr NEWA

AB KARTHA 5MG A214374 001 Mar 05, 2021 Feb NEWA

AB 10MG A214374 002 Mar 05, 2021 Feb NEWA

AB 20MG A214374 003 Mar 05, 2021 Feb NEWA

BALOXAVIR MARBOXIL

TABLET;ORAL

XOFLUZA

+ GENENTECH INC 80MG N210854 003 Mar 18, 2021 Mar NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

LOTENSIN

AB + VALIDUS PHARMS 5MG N019851 001 Jun 25, 1991 Feb CAHN

AB + 10MG N019851 002 Jun 25, 1991 Feb CAHN

AB + 20MG N019851 003 Jun 25, 1991 Feb CAHN

AB +! 40MG N019851 004 Jun 25, 1991 Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

LOTENSIN HCT

+ @ VALIDUS PHARMS 5MG;6.25MG N020033 001 May 19, 1992 Feb CAHN

AB + 10MG;12.5MG N020033 002 May 19, 1992 Feb CAHN

AB + 20MG;12.5MG N020033 004 May 19, 1992 Feb CAHN

AB +! 20MG;25MG N020033 003 May 19, 1992 Feb CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

>A> AB ENCUBE 5%;1.2% A212433 001 Apr 28, 2021 Apr NEWA

AB ! PERRIGO ISRAEL 5%;1.2% A090979 001 Jun 26, 2012 Jan CHRS

DUAC

AB + STIEFEL 5%;1.2% N050741 001 Aug 26, 2002 Jan CHRS

BETAMETHASONE DIPROPIONATE

SPRAY;TOPICAL

SERNIVO

+! PRIMUS PHARMS EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	!	TARO	EQ 0.05% BASE;1%	A076493	001	Jul 28, 2004	Feb	CHRS
		LOTRISONE						
	+	@ MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Feb	DISC

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ WOCKHARDT

5MG

A040532 001 Sep 29, 2003 Jan DISC

@

50MG

A040518 001 Sep 29, 2003 Jan DISC

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB		TEVA PHARMS USA	75MG	A209931	001	Jan 14, 2021	Jan	NEWA
----	--	-----------------	------	---------	-----	--------------	-----	------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

@ AKORN

0.03%

A203299 001 Nov 08, 2018 Feb CAHN

AT	!	ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Jan	CHRS
----	---	--------------------	-------	---------	-----	--------------	-----	------

AT		LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Jan	CHRS
----	--	-----------	-------	---------	-----	--------------	-----	------

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

>A>	AB		UNICHEM	5MG	A078635	001	Aug 18, 2009	Apr	CAHN
>A>	AB	!		10MG	A078635	002	Aug 18, 2009	Apr	CAHN
>D>	AB		UNICHEM PHARMS (USA)	5MG	A078635	001	Aug 18, 2009	Apr	CAHN
>D>	AB	!		10MG	A078635	002	Aug 18, 2009	Apr	CAHN

BOSENTAN

TABLET; ORAL

TRACLEER

AB	+	ACTELION	62.5MG	N021290	001	Nov 20, 2001	Feb	CAHN
AB	+	!	125MG	N021290	002	Nov 20, 2001	Feb	CAHN

TABLET, FOR SUSPENSION; ORAL

TRACLEER

		+	!	ACTELION	32MG	N209279	001	Sep 05, 2017	Feb	CAHN
--	--	---	---	----------	------	---------	-----	--------------	-----	------

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

PARLODEL

AB	+	VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb	CAHN
----	---	----------------	-------------	---------	-----	--------------	-----	------

TABLET; ORAL

PARLODEL

AB	+	VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb	CAHN
----	---	----------------	---------------	---------	-----	--	-----	------

BUDESONIDE

>D> CAPSULE; ORAL

>D> BUDESONIDE

>D>		@	ALVOGEN	3MG	A206724	001	Nov 23, 2016	Apr	CDFR
-----	--	---	---------	-----	---------	-----	--------------	-----	------

>D>	AB		AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Apr	CDFR
-----	----	--	---------------	-----	---------	-----	--------------	-----	------

>D>		@	BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Apr	CDFR
-----	--	---	--------------------	-----	---------	-----	--------------	-----	------

		@		3MG	A090379	001	Apr 02, 2014	Jan	DISC
--	--	---	--	-----	---------	-----	--------------	-----	------

>D>	AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Apr	CDFR
-----	----	--	--------------	-----	---------	-----	--------------	-----	------

>D>	AB		MYLAN	3MG	A090410	001	May 16, 2011	Apr	CDFR
-----	----	--	-------	-----	---------	-----	--------------	-----	------

>D>	AB		RISING	3MG	A207367	001	Apr 07, 2017	Apr	CDFR
-----	----	--	--------	-----	---------	-----	--------------	-----	------

>D>	AB		SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Apr	CDFR
-----	----	--	---------------------	-----	---------	-----	--------------	-----	------

>D>	AB		ZYDUS PHARMS	3MG	A206134	001	May 04, 2017	Apr	CDFR
-----	----	--	--------------	-----	---------	-----	--------------	-----	------

>D> ENTOCORT EC

>D>	AB	+	!	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	Apr	CDFR
-----	----	---	---	---------------------	-----	---------	-----	--------------	-----	------

>A> CAPSULE, DELAYED RELEASE; ORAL

>A> BUDESONIDE

>A>		@	ALVOGEN	3MG	A206724	001	Nov 23, 2016	Apr	CDFR
-----	--	---	---------	-----	---------	-----	--------------	-----	------

>A>	AB		AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Apr	CDFR
-----	----	--	---------------	-----	---------	-----	--------------	-----	------

>A>		@	BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Apr	CDFR
-----	--	---	--------------------	-----	---------	-----	--------------	-----	------

>A>	AB		MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Apr	CDFR
-----	----	--	--------------	-----	---------	-----	--------------	-----	------

>A>	AB		MYLAN	3MG	A090410	001	May 16, 2011	Apr	CDFR
-----	----	--	-------	-----	---------	-----	--------------	-----	------

>A>	CAPSULE, DELAYED RELEASE;ORAL						
>A>	BUDESONIDE						
>A> AB	RISING	3MG	A207367	001	Apr 07, 2017	Apr	CDFR
>A> AB	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Apr	CDFR
>A> AB	ZYDUS PHARMS	3MG	A206134	001	May 04, 2017	Apr	CDFR
>A>	ENTOCORT EC						
>A> AB	+! PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	Apr	CDFR
	SUSPENSION;INHALATION						
	BUDESONIDE						
>A> AN	SUN PHARM	0.25MG/2ML	A211922	001	Apr 14, 2021	Apr	NEWA
>A> AN		0.5MG/2ML	A211922	002	Apr 14, 2021	Apr	NEWA
>A> AN		1MG/2ML	A211922	003	Apr 14, 2021	Apr	NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE;INFILTRATION

POSIMIR

+ @ DURECT	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Mar	DISC
+!	660MG/5ML (132MG/ML)	N204803	001	Feb 01, 2021	Feb	NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

AP	HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A205141	002	Feb 11, 2021	Feb	NEWA
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE						
AP	HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb	NEWA
AP		0.5%	A204842	002	Feb 11, 2021	Feb	NEWA
AP		0.75%	A204842	003	Feb 11, 2021	Feb	NEWA

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUPRENORPHINE

>A> AB	MYLAN TECHNOLOGIES	5MCG/HR	A210162	001	May 03, 2021	Apr	NEWA
>A> AB		7.5MCG/HR	A210162	002	May 03, 2021	Apr	NEWA
>A> AB		10MCG/HR	A210162	003	May 03, 2021	Apr	NEWA
>A> AB		15MCG/HR	A210162	004	May 03, 2021	Apr	NEWA
>A> AB		20MCG/HR	A210162	005	May 03, 2021	Apr	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

@ MAYNE PHARMA INC	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jan	DISC
@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jan	DISC

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

+ BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
+	348MG	N022108	002	Apr 23, 2008	Feb	CAHN
+!	522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

@ TORRENT	100MG	A203969	001	Oct 31, 2014	Jan	DISC	
@	150MG	A203969	002	Oct 31, 2014	Jan	DISC	
@	200MG	A203969	003	Oct 31, 2014	Jan	DISC	
	WELLBUTRIN XL						
AB3 +	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb	CAHN
AB3 +!		300MG	N021515	002	Aug 28, 2003	Feb	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

BUSPIRONE HYDROCHLORIDE

AB	RUBICON	5MG	A075521	001	Apr 05, 2002	Feb	CMFD
AB		7.5MG	A075521	004	Mar 16, 2021	Mar	NEWA
AB		10MG	A075521	002	Apr 05, 2002	Feb	CMFD
AB		15MG	A075521	003	Apr 05, 2002	Feb	CMFD
AB		30MG	A075521	005	Mar 16, 2021	Mar	NEWA

BUSULFAN

	INJECTABLE; INJECTION						
	BUSULFAN						
AP	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb	CAHN

CABERGOLINE

	TABLET; ORAL						
	DOSTINEX						
	+ @ PFIZER	0.5MG	N020664	001	Dec 23, 1996	Jan	CAHN

CABOTEGRAVIR SODIUM

	TABLET; ORAL						
	VOCABRIA						
	+! VIIV HLTHCARE	EQ 30MG BASE	N212887	001	Jan 21, 2021	Jan	NEWA

CABOTEGRAVIR; RILPIVIRINE

	SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR						
	CABENUVA KIT						
	+! VIIV HLTHCARE	400MG/2ML (200MG/ML); 600MG/2ML (300MG/ML)	N212888	001	Jan 21, 2021	Jan	NEWA
	+!	600MG/3ML (200MG/ML); 900MG/3ML (300MG/ML)	N212888	002	Jan 21, 2021	Jan	NEWA

CALCIUM ACETATE

	TABLET; ORAL							
	CALCIUM ACETATE							
>D>	AB	CHARTWELL MOLECULAR	667MG	A202420	001	Feb 05, 2013	Apr	CHRS
>A>	AB	!	667MG	A202420	001	Feb 05, 2013	Apr	CHRS

CARBAMAZEPINE

	TABLET, EXTENDED RELEASE; ORAL							
	CARBAMAZEPINE							
>A>	AB	CSPC OUYI	100MG	A213311	001	Apr 13, 2021	Apr	NEWA
>A>	AB		200MG	A213311	002	Apr 13, 2021	Apr	NEWA
>A>	AB		400MG	A213311	003	Apr 13, 2021	Apr	NEWA

CARBIDOPA; LEVODOPA

	TABLET; ORAL							
	CARBIDOPA AND LEVODOPA							
>A>	AB	SCIEGEN PHARMS INC	10MG; 100MG	A214092	001	May 07, 2021	Apr	NEWA
>A>	AB		25MG; 100MG	A214092	002	May 07, 2021	Apr	NEWA
>A>	AB		25MG; 250MG	A214092	003	May 07, 2021	Apr	NEWA

CARBOPLATIN

	INJECTABLE; INTRAVENOUS							
	CARBOPLATIN							
AP	!	HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	Mar	CHRS
AP	!		150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	Mar	CHRS
AP	!		450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	Mar	CHRS
AP	!		600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	Mar	CHRS
AP		PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Mar	CHRS
AP			150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Mar	CHRS
AP			450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Mar	CHRS
AP			600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Mar	CHRS

CARBOPROST TROMETHAMINE

	INJECTABLE; INJECTION						
	CARBOPROST TROMETHAMINE						
AP	SUNNY PHARMTECH INC	EQ 0.25MG BASE/ML	A213118	001	Mar 25, 2021	Mar	NEWA

CARMUSTINE

	INJECTABLE; INJECTION						
	CARMUSTINE						
AP	JIANGSU HENGRUI MED	100MG/VIAL	A211202	001	Mar 12, 2021	Mar	NEWA

CASIMERSEN

	SOLUTION; INTRAVENOUS						
	AMONDYS 45						
	+! SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021	Feb	NEWA

CEFAZOLIN SODIUM

SOLUTION;INTRAVENOUS
CEFAZOLIN IN PLASTIC CONTAINER

+!	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	Mar	NEWA
+!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar	CRLD
!		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar	CHRS

CEFDINIR

CAPSULE;ORAL
CEFDINIR

AB	ALKEM LABS LTD	300MG	A210220	001	Feb 19, 2021	Feb	NEWA
	FOR SUSPENSION;ORAL CEFDINIR						
AB	ALKEM LABS LTD	125MG/5ML	A210534	001	Feb 19, 2021	Feb	NEWA
AB		250MG/5ML	A210534	002	Feb 19, 2021	Feb	NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION
CEFEPIME HYDROCHLORIDE

@	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Mar	DISC
@		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Mar	DISC

CEFIXIME

FOR SUSPENSION;ORAL
CEFIXIME

AB	ALKEM LABS LTD	100MG/5ML	A211775	001	Feb 19, 2021	Feb	NEWA
AB		200MG/5ML	A211775	002	Feb 19, 2021	Feb	NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION
CLAFORAN

+ @	VALIDUS PHARMS	EQ 500MG BASE/VIAL	N050547	001		Feb	CAHN
+ @		EQ 1GM BASE/VIAL	N050547	002		Feb	CAHN
+ @		EQ 2GM BASE/VIAL	N050547	003		Feb	CAHN
+ @		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Feb	CAHN
	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Feb	CAHN
@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Feb	CAHN
	CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
@	VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Feb	CAHN
@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Feb	CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION
FORTAZ IN PLASTIC CONTAINER

@	TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Feb	CAHN
+ @		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Feb	CAHN
+ @		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Feb	CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION
ZINACEF

AP	+!	TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb	CAHN
AP	+!		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb	CAHN
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ZINACEF						
AB	+!	TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb	CAHN

CELECOXIB

CAPSULE;ORAL
CELEBREX

>D>	AB	+	GD SEARLE	50MG	N020998	004	Dec 15, 2006	Apr	CAHN
>D>	AB	+		100MG	N020998	001	Dec 31, 1998	Apr	CAHN
>D>	AB	+		200MG	N020998	002	Dec 31, 1998	Apr	CAHN
>D>	AB	+!		400MG	N020998	003	Aug 29, 2002	Apr	CAHN
>A>	AB	+	UPJOHN	50MG	N020998	004	Dec 15, 2006	Apr	CAHN
>A>	AB	+		100MG	N020998	001	Dec 31, 1998	Apr	CAHN
>A>	AB	+		200MG	N020998	002	Dec 31, 1998	Apr	CAHN
>A>	AB	+!		400MG	N020998	003	Aug 29, 2002	Apr	CAHN

CAPSULE;ORAL

CELECOXIB							
AB	UNICHEM	50MG	A213301	001	Jan 12, 2021	Jan	NEWA
AB		100MG	A213301	002	Jan 12, 2021	Jan	NEWA
AB		200MG	A213301	003	Jan 12, 2021	Jan	NEWA
AB		400MG	A213301	004	Jan 12, 2021	Jan	NEWA

CEPHALEXINCAPSULE;ORAL

CEPHALEXIN

@	YUNG SHIN PHARM	EQ 250MG BASE	A065152	001	Feb 24, 2005	Mar	DISC
@		EQ 500MG BASE	A065152	002	Feb 24, 2005	Mar	DISC

CHLORDIAZEPOXIDE HYDROCHLORIDECAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

>A>	@ CHARTWELL RX	5MG	A084678	001		Apr	CAHN
>A>	@	10MG	A084041	001		Apr	CAHN
>A>	@	25MG	A084679	002		Apr	CAHN
>D>	@ UPSHER SMITH LABS	5MG	A084678	001		Apr	CAHN
>D>	@	10MG	A084041	001		Apr	CAHN
>D>	@	25MG	A084679	002		Apr	CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDECAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

>A>	AB	ALKEM LABS LTD	5MG;2.5MG	A214065	001	Apr 26, 2021	Apr	NEWA
>A>	AB	DR REDDYS	5MG;2.5MG	A214698	001	May 10, 2021	Apr	NEWA

CHLORHEXIDINE GLUCONATESOLUTION;DENTAL

CHLORHEXIDINE GLUCONATE

AT	BAJAJ	0.12%	A075561	001	Nov 14, 2000	Feb	CMFD
----	-------	-------	---------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDETABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	10MG	A212144	001	Mar 23, 2021	Mar	NEWA
AB		25MG	A212144	002	Mar 23, 2021	Mar	NEWA
AB		50MG	A212144	003	Mar 23, 2021	Mar	NEWA
AB		100MG	A212144	004	Mar 23, 2021	Mar	NEWA
AB		200MG	A212144	005	Mar 23, 2021	Mar	NEWA
AB	LANNETT CO INC	10MG	A212996	001	Jan 22, 2021	Jan	NEWA
AB		25MG	A212996	002	Jan 22, 2021	Jan	NEWA
AB		50MG	A212996	003	Jan 22, 2021	Jan	NEWA
AB		100MG	A212996	004	Jan 22, 2021	Jan	NEWA
AB		200MG	A212996	005	Jan 22, 2021	Jan	NEWA
	@ MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar	DISC
	@	25MG	A213590	002	Aug 31, 2020	Mar	DISC
	@	50MG	A213590	003	Aug 31, 2020	Mar	DISC
	@	100MG	A213590	004	Aug 31, 2020	Mar	DISC
	@	200MG	A213590	005	Aug 31, 2020	Mar	DISC

CHLORPROPAMIDETABLET;ORAL

CHLORPROPAMIDE

@	RISING	100MG	A088725	001	Aug 31, 1984	Jan	CAHN
@		250MG	A088726	001	Aug 31, 1984	Jan	CAHN

CHLORZOXAZONETABLET;ORAL

CHLORZOXAZONE

>A>	AB	PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr	NEWA
-----	----	---------------	-------	---------	-----	--------------	-----	------

CHOLESTYRAMINEPOWDER;ORAL

CHOLESTYRAMINE

AB	TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb	NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb	NEWA
	LOCHOLEST LIGHT						
>D>	@ ALLIED	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr	CAHN
>D>	@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr	CAHN

		POWDER;ORAL								
		LOCHOLEST LIGHT								
>A>		@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr	CAHN		
>A>		@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr	CAHN		
		<u>CHOLINE C-11</u>								
		INJECTABLE;INTRAVENOUS								
		CHOLINE C-11								
>D>	AP	UCSF RODIOPHARM	4-33.1mCi/ML	A208444	001	Nov 20, 2017	Apr	DISC		
>A>		@	4-33.1mCi/ML	A208444	001	Nov 20, 2017	Apr	DISC		
		<u>CICLOPIROX</u>								
		SOLUTION;TOPICAL								
		CICLOPIROX								
>D>	AT	AKORN	8%	A078975	001	Feb 17, 2010	Apr	DISC		
>A>		@	8%	A078975	001	Feb 17, 2010	Apr	DISC		
		<u>CILOSTAZOL</u>								
		TABLET;ORAL								
		CILOSTAZOL								
		@ EPIC PHARMA LLC	50MG	A077022	002	Mar 11, 2005	Jan	CMS1		
		@ NOSTRUM LABS INC	50MG	A077708	001	Sep 28, 2009	Mar	DISC		
AB		@	50MG	A077708	001	Sep 28, 2009	Jan	CAHN		
		@	100MG	A077708	002	Sep 28, 2009	Mar	DISC		
AB		@	100MG	A077708	002	Sep 28, 2009	Jan	CAHN		
		<u>CIMETIDINE</u>								
		TABLET;ORAL								
		CIMETIDINE								
		@ NOVITIUM PHARMA	300MG	A074340	001	Jun 23, 1995	Feb	CAHN		
		@	400MG	A074340	002	Jun 23, 1995	Feb	CAHN		
		@	800MG	A074339	001	Jun 23, 1995	Feb	CAHN		
		<u>CISATRACURIUM BESYLATE</u>								
		INJECTABLE;INJECTION								
		CISATRACURIUM BESYLATE								
		@ ZYDUS PHARMS	EQ 2MG BASE/ML	A213527	001	Aug 31, 2020	Feb	DISC		
		<u>CLARITHROMYCIN</u>								
		TABLET;ORAL								
		CLARITHROMYCIN								
		@ WOCKHARDT	250MG	A065266	001	May 31, 2006	Jan	DISC		
		@	500MG	A065266	002	May 31, 2006	Jan	DISC		
		<u>CLASCOTERONE</u>								
		CREAM;TOPICAL								
		WINLEVI								
		+ @ CASSIOPEA SPA	1%	N213433	001	Aug 26, 2020	Mar	DISC		
		<u>CLINDAMYCIN HYDROCHLORIDE</u>								
		CAPSULE;ORAL								
		CLEOCIN HYDROCHLORIDE								
AB	+	PFIZER	EQ 75MG BASE	N050162	001			Feb	CAHN	
AB	+		EQ 150MG BASE	N050162	002			Feb	CAHN	
AB	+	!	EQ 300MG BASE	N050162	003	Apr 14, 1988		Feb	CAHN	
		<u>CLINDAMYCIN PALMITATE HYDROCHLORIDE</u>								
		FOR SOLUTION;ORAL								
		CLEOCIN								
AA	!	PFIZER	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986		Feb	CAHN	
		<u>CLINDAMYCIN PHOSPHATE</u>								
		CREAM;VAGINAL								
		CLEOCIN								
		@ PFIZER	EQ 2% BASE	N050680	001	Aug 11, 1992		Feb	CAHN	
AB	+	!	EQ 2% BASE	N050680	002	Mar 02, 1998		Feb	CAHN	
		GEL;TOPICAL								
		CLEOCIN T								
AB	+	!	PFIZER	EQ 1% BASE	N050615	001	Jan 07, 1987		Feb	CAHN
		CLINDAMYCIN PHOSPHATE								
AB		ENCUBE	EQ 1% BASE	A212438	001	Mar 11, 2021		Mar	NEWA	
AB		GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001	Feb 10, 2021		Jan	NEWA	

	GEL;TOPICAL						
	CLINDAMYCIN PHOSPHATE						
AB	PERRIGO UK FINCO	EQ 1% BASE	A212104	001	Dec 31, 2020	Jan CAHN	
	INJECTABLE;INJECTION						
	CLEOCIN PHOSPHATE						
AP	PFIZER	EQ 150MG BASE/ML	A062803	001	Oct 16, 1987	Feb CAHN	
AP	+	EQ 150MG BASE/ML	N050441	001		Feb CAHN	
	CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
	+ @ PFIZER	EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	Feb CAHN	
	+ @	EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	Feb CAHN	
	+ @	EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	Feb CAHN	
	CLINDAMYCIN PHOSPHATE						
	@ MYLAN LABS LTD	EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Jan DISC	
	LOTION;TOPICAL						
	CLEOCIN T						
AB	+	PFIZER	EQ 1% BASE	N050600	001	May 31, 1989	Feb CAHN
	CLINDAMYCIN PHOSPHATE						
AB	GAGE DEVELOPMENT	EQ 1% BASE	A214604	001	Mar 08, 2021	Feb NEWA	
AB	PERRIGO UK FINCO	EQ 1% BASE	A214604	001	Mar 08, 2021	Mar CAHN	
	SOLUTION;TOPICAL						
	CLEOCIN T						
	+ @ PFIZER	EQ 1% BASE	N050537	001		Feb CAHN	
	+ @ PHARMACIA AND UPJOHN	EQ 1% BASE	N050537	001		Jan DISC	
	CLINDAMYCIN PHOSPHATE						
AT	!	PERRIGO NEW YORK	EQ 1% BASE	A064050	001	Nov 30, 1995	Jan CHRS
	SUPPOSITORY;VAGINAL						
	CLEOCIN						
	+	PFIZER	100MG	N050767	001	Aug 13, 1999	Feb CAHN
	SWAB;TOPICAL						
	CLEOCIN						
	+ @ PFIZER	EQ 1% BASE	N050537	002	Feb 22, 1994	Mar DISC	
AT	+	!	EQ 1% BASE	N050537	002	Feb 22, 1994	Feb CAHN
	CLINDAMYCIN PHOSPHATE						
AT	!	PERRIGO NEW YORK	EQ 1% BASE	A065049	001	May 25, 2000	Mar CHRS
	<u>CLOBAZAM</u>						
	SUSPENSION;ORAL						
	CLOBAZAM						
>A>	AB	ALKEM LABS LTD	2.5MG/ML	A213039	001	May 06, 2021	Apr NEWA
	TABLET;ORAL						
	CLOBAZAM						
	@ LANNETT CO INC	10MG	A212092	001	Oct 30, 2019	Mar DISC	
	@	20MG	A212092	002	Oct 30, 2019	Mar DISC	
>A>	AB	MSN	10MG	A213404	001	May 11, 2021	Apr NEWA
>A>	AB		20MG	A213404	002	May 11, 2021	Apr NEWA
	<u>CLOBETASOL PROPIONATE</u>						
	CREAM;TOPICAL						
	CLOBETASOL PROPIONATE						
AB1	GLASSHOUSE PHARMS	0.05%	A211207	001	Mar 26, 2021	Mar NEWA	
	IMPOYZ						
	+	PRIMUS PHARMS	0.025%	N209483	001	Nov 28, 2017	Mar CAHN
	OINTMENT;TOPICAL						
	CLOBETASOL PROPIONATE						
	@ TORRENT	0.05%	A212926	001	Oct 25, 2019	Jan DISC	
	SHAMPOO;TOPICAL						
	CLOBETASOL PROPIONATE						
AB	TARO PHARMS	0.05%	A214867	001	Mar 25, 2021	Mar NEWA	
	SOLUTION;TOPICAL						
	CLOBETASOL PROPIONATE						
AT	PRINSTON INC	0.05%	A213139	001	Feb 08, 2021	Jan NEWA	
	SPRAY;TOPICAL						
	CLOBETASOL PROPIONATE						
>D>	AT	AKORN	0.05%	A207218	001	Apr 28, 2017	Apr DISC
>A>	@		0.05%	A207218	001	Apr 28, 2017	Apr DISC

CLOFARABINESOLUTION; INTRAVENOUS
CLOFARABINE

AP	MEITHEAL	20MG/20ML (1MG/ML)	A213461	001	Oct 23, 2020	Jan	CAHN
	@ NOVAST LABS	20MG/20ML (1MG/ML)	A210270	001	Sep 14, 2018	Mar	DISC

CLONAZEPAMTABLET; ORAL
CLONAZEPAM

>D>	AB	WATSON LABS	0.5MG	A074964	001	Dec 30, 1997	Apr	DISC
>A>		@	0.5MG	A074964	001	Dec 30, 1997	Apr	DISC
>D>	AB		1MG	A074964	002	Dec 30, 1997	Apr	DISC
>A>		@	1MG	A074964	002	Dec 30, 1997	Apr	DISC
>D>	AB		2MG	A074964	003	Dec 30, 1997	Apr	DISC
>A>		@	2MG	A074964	003	Dec 30, 1997	Apr	DISC

CLONIDINESYSTEM; TRANSDERMAL
CATAPRES-TTS-1

AB	+	LAVIPHARM	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN
AB	+	TECHNOMED	0.1MG/24HR	N018891	001	Oct 10, 1984	Jan	CAHN
		CATAPRES-TTS-2						
AB	+	LAVIPHARM	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN
AB	+	TECHNOMED	0.2MG/24HR	N018891	002	Oct 10, 1984	Jan	CAHN
		CATAPRES-TTS-3						
AB	+	LAVIPHARM	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN
AB	+	TECHNOMED	0.3MG/24HR	N018891	003	Oct 10, 1984	Jan	CAHN

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION
CLONIDINE HYDROCHLORIDE

AP	!	HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar	CHRS
		DURACLON						
		+ @ MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar	DISC

CLOPIDOGREL BISULFATETABLET; ORAL
CLOPIDOGREL BISULFATE

AB		POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb	CMFD
AB			EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb	CMFD

CLORAZEPATE DIPOTASSIUMTABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB		AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987	Jan	CAHN
AB			7.5MG	A071858	003	Jul 17, 1987	Jan	CAHN
AB	!		15MG	A071858	001	Jul 17, 1987	Jan	CAHN

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDESYRUP; ORAL
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA		AKORN	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Feb	CAHN
----	--	-------	-------------------------------	---------	-----	--------------	-----	------

COLESEVELAM HYDROCHLORIDEFOR SUSPENSION; ORAL
COLESEVELAM HYDROCHLORIDE

		GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Feb	CTEC
		@ WATSON LABS INC	1.875GM/PACKET	A202178	001	Sep 01, 2020	Feb	DISC
		@	3.75GM/PACKET	A202178	002	Sep 01, 2020	Feb	DISC

TABLET; ORAL
COLESEVELAM HYDROCHLORIDE

		@ WATSON LABS INC	625MG	A200830	001	Sep 02, 2020	Feb	DISC
--	--	-------------------	-------	---------	-----	--------------	-----	------

COLESTIPOL HYDROCHLORIDEGRANULE; ORAL
COLESTID

AB	+	PFIZER	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Feb	CAHN
AB	+	!	5GM/PACKET	N017563	004	Sep 22, 1995	Feb	CAHN
		FLAVORED COLESTID						
		+ PFIZER	5GM/PACKET	N017563	001		Feb	CAHN
		+	5GM/SCOOPFUL	N017563	002		Feb	CAHN

	TABLET; ORAL							
	COLESTID							
AB	+!	PFIZER	1GM	N020222	001	Jul 19, 1994	Feb	CAHN
	<u>CROTAMITON</u>							
	CREAM; TOPICAL							
	EURAX							
	+	@ JOURNEY	10%	N006927	001		Jan	CAHN
	LOTION; TOPICAL							
	EURAX							
AT	+!	JOURNEY	10%	N009112	003		Jan	CAHN
	<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE</u>							
	SOLUTION; INTRAVENOUS							
	TRALEMENT							
	+!	AM REGENT	(1ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	001	Jul 02, 2020	Jan	CPOT
	+!		(5ML) EQ 0.3MG COPPER/ML; EQ 55MCG BASE/ML; EQ 60MCG BASE/ML; EQ 3MG BASE/ML	N209376	002	Dec 02, 2020	Jan	NEWA
	<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	CYCLOBENZAPRINE HYDROCHLORIDE							
>D>	AB	PLIVA	10MG	A074421	001	Sep 29, 1995	Apr	DISC
>A>		@	10MG	A074421	001	Sep 29, 1995	Apr	DISC
	<u>CYPROHEPTADINE HYDROCHLORIDE</u>							
	TABLET; ORAL							
	CYPROHEPTADINE HYDROCHLORIDE							
AA		QUAGEN	4MG	A212491	001	Feb 24, 2021	Feb	NEWA
	<u>DACTINOMYCIN</u>							
	INJECTABLE; INJECTION							
	DACTINOMYCIN							
AP		AUROMEDICS PHARMA	0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CAHN
AP		MEITHEAL	0.5MG/VIAL	A213463	001	Nov 13, 2020	Feb	CAHN
	<u>DAPTOMYCIN</u>							
	POWDER; INTRAVENOUS							
	DAPTOMYCIN							
>A>	AP	HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021	Apr	NEWA
	<u>DASIGLUCAGON HYDROCHLORIDE</u>							
	SOLUTION; SUBCUTANEOUS							
	ZEGALOGUE							
	+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar	NEWA
	+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar	NEWA
	<u>DECITABINE</u>							
	INJECTABLE; INTRAVENOUS							
	DECITABINE							
>A>	AP	QILU	50MG/VIAL	A212826	001	Apr 12, 2021	Apr	NEWA
	<u>DEFERASIROX</u>							
	GRANULE; ORAL							
	DEFERASIROX							
AB		AMNEAL	180MG	A214194	001	Feb 09, 2021	Jan	NEWA
AB			360MG	A214194	002	Feb 09, 2021	Jan	NEWA
AB		AUCTA	90MG	A214559	001	Mar 09, 2021	Feb	NEWA
AB			180MG	A214559	002	Mar 09, 2021	Feb	NEWA
AB			360MG	A214559	003	Mar 09, 2021	Feb	NEWA
AB		MSN	180MG	A214650	001	Mar 17, 2021	Mar	NEWA
AB			360MG	A214650	002	Mar 17, 2021	Mar	NEWA

DEFERIPRONETABLET; ORAL
DEFERIPRONE

AB	HIKMA	500MG	A213239	001	Mar 29, 2021	Mar	NEWA
AB	+! FERRIPROX CHIESI	500MG	N021825	001	Oct 14, 2011	Mar	CTEC

DEOXYCHOLIC ACIDSOLUTION; SUBCUTANEOUS
DEOXYCHOLIC ACID

AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar	NFTG
----	---------------------	--------------------	---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDETABLET; ORAL
NORPRAMIN

AB	+ VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb	CAHN
AB	+	25MG	N014399	001		Feb	CAHN
AB	+	50MG	N014399	003		Feb	CAHN
AB	+	75MG	N014399	004		Feb	CAHN
AB	+!	100MG	N014399	005		Feb	CAHN
AB	+	150MG	N014399	006		Feb	CAHN

DESMOPRESSIN ACETATESPRAY, METERED; NASAL
NOCTIVA

	+ @ ROIVANT	0.00083MG/SPRAY	N201656	001	Mar 03, 2017	Feb	CAHN
	+ @	0.00166MG/SPRAY	N201656	002	Mar 03, 2017	Feb	CAHN

DESONIDEGEL; TOPICAL
DESONATE

	+ @ LEO PHARMA AS	0.05%	N021844	001	Oct 20, 2006	Mar	DISC
	! CINTEX SVCS	0.05%	A202470	001	May 11, 2020	Mar	CHRS
		0.05%	A202470	001	May 11, 2020	Mar	CTEC

DESOXIMETASONECREAM; TOPICAL
DESOXIMETASONE

>D>	AB	AKORN	0.05%	A203787	001	Jan 06, 2017	Apr	DISC
>A>		@	0.05%	A203787	001	Jan 06, 2017	Apr	DISC
>D>	AB		0.25%	A203234	001	Jun 12, 2015	Apr	DISC
>A>		@	0.25%	A203234	001	Jun 12, 2015	Apr	DISC
>D>	AB	GLENMARK GENERICS	0.25%	A202838	001	Sep 20, 2013	Apr	CHRS
>A>	AB	!	0.25%	A202838	001	Sep 20, 2013	Apr	CHRS
>D>		TOPICORT						
>D>	AB	! TARO PHARM INDS LTD	0.25%	A074286	001	Jun 07, 1996	Apr	DISC
>A>		@	0.25%	A074286	001	Jun 07, 1996	Apr	DISC

DEXAMETHASONETABLET; ORAL
DEXAMETHASONE

>D>	BP	HIKMA	1MG	A088306	001	Sep 15, 1983	Apr	CHRS
>A>	BP	!	1MG	A088306	001	Sep 15, 1983	Apr	CHRS
>D>	BP		2MG	A087916	001	Aug 26, 1982	Apr	CHRS
>A>	BP	!	2MG	A087916	001	Aug 26, 1982	Apr	CHRS

DEXMETHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	MYLAN	25MG	A204266	005	May 04, 2021	Apr	NEWA
>A>	AB		35MG	A204266	006	May 04, 2021	Apr	NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION							
DEXRAZOXANE HYDROCHLORIDE							
AP	AUROMEDICS PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Jan	CAHN
AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Jan	CAHN
ZINECARD							
AP	+! PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar	CAHN
AP	+!	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar	CAHN

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE; INJECTION							
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%							
	@ FRESenius KABI USA	5GM/100ML; 75MG/100ML	A212346	001	Sep 10, 2020	Mar	DISC
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%							
	@ FRESenius KABI USA	5GM/100ML; 150MG/100ML	A212346	002	Sep 10, 2020	Mar	DISC
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER							
+	BAXTER HLTHCARE	5GM/100ML; 224MG/100ML	N017634	003		Mar	CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION							
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%							
AP	FRESenius KABI USA	5GM/100ML; 74.5MG/100ML; 450MG/100ML	A213523	001	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%							
AP	FRESenius KABI USA	5GM/100ML; 149MG/100ML; 450MG/100ML	A213523	002	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%							
AP	FRESenius KABI USA	5GM/100ML; 149MG/100ML; 900MG/100ML	A213445	001	Mar 09, 2021	Feb	NFTG
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%							
AP	FRESenius KABI USA	5GM/100ML; 224MG/100ML; 450MG/100ML	A213523	003	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%							
AP	FRESenius KABI USA	5GM/100ML; 298MG/100ML; 450MG/100ML	A213523	004	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%							
AP	FRESenius KABI USA	5GM/100ML; 298MG/100ML; 900MG/100ML	A213445	002	Mar 09, 2021	Feb	NFTG

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION							
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER							
	@ FRESenius KABI USA	5GM/100ML; 300MG/100ML	A211194	001	Aug 26, 2020	Feb	DISC
+	! ICU MEDICAL INC	5GM/100ML; 300MG/100ML	N017799	001		Feb	CTEC
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%							
	@ FRESenius KABI USA	5GM/100ML; 450MG/100ML	A211276	001	Sep 15, 2020	Mar	DISC
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%							
	@ FRESenius KABI USA	5GM/100ML; 900MG/100ML	A211211	001	Sep 14, 2020	Mar	DISC

DIAZEPAM

TABLET; ORAL								
DIAZEPAM								
>D>	AB	BARR	2MG	A070152	001	Nov 01, 1985	Apr	DISC
>A>		@	2MG	A070152	001	Nov 01, 1985	Apr	DISC
>D>	AB		10MG	A070154	001	Nov 01, 1985	Apr	DISC
>A>		@	10MG	A070154	001	Nov 01, 1985	Apr	DISC

DICLOFENAC SODIUM

GEL; TOPICAL								
DICLOFENAC SODIUM								
AB	!	TARO	3%	A206298	001	Apr 28, 2016	Mar	CHRS
SOLARAZE								
+	@	FOUGERA PHARMS	3%	N021005	001	Oct 16, 2000	Mar	DISC
SOLUTION; TOPICAL								
DICLOFENAC SODIUM								
AT		AKORN	1.5%	A206655	001	Jan 28, 2021	Jan	NEWA
TABLET, DELAYED RELEASE; ORAL								
DICLOFENAC SODIUM								
	@	MICRO LABS	50MG	A074986	001	Feb 26, 1999	Feb	CAHN
	@		75MG	A074986	002	Feb 26, 1999	Feb	CAHN

DICLOXACILLIN SODIUM

CAPSULE;ORAL							
DICLOXACILLIN SODIUM							
	@	SANDOZ	EQ 125MG BASE	A 061454	002		Jan DISC
	@		EQ 250MG BASE	A 061454	001		Jan DISC
	@		EQ 500MG BASE	A 061454	003		Jan DISC
		TEVA	EQ 250MG BASE	A 062286	001	Jun 03, 1982	Jan CTEC
	!		EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan CTEC
AB	!		EQ 500MG BASE	A 062286	002	Jun 03, 1982	Jan CHRS

DICYCLOMINE HYDROCHLORIDE

SYRUP;ORAL							
DICYCLOMINE HYDROCHLORIDE							
>A>	AA	NOVITIUM PHARMA	10MG/5ML	A 214721	001	Apr 23, 2021	Apr NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL							
DIDANOSINE							
	@	AUROBINDO PHARMA	125MG	A 090094	001	Sep 24, 2008	Jan DISC
	@		200MG	A 090094	002	Sep 24, 2008	Jan DISC
	@		250MG	A 090094	003	Sep 24, 2008	Jan DISC
	@		400MG	A 090094	004	Sep 24, 2008	Jan DISC

DIFLORASONE DIACETATE

CREAM;TOPICAL								
DIFLORASONE DIACETATE								
>A>	BX	!	ANI PHARMS	0.05%	A 076263	001	Dec 20, 2002	Apr CAHN
>D>	BX	!	FOUGERA PHARMS	0.05%	A 076263	001	Dec 20, 2002	Apr CAHN
OINTMENT;TOPICAL								
DIFLORASONE DIACETATE								
>D>	AB		AKORN	0.05%	A 206572	001	Jul 24, 2015	Apr DISC
>A>		@		0.05%	A 206572	001	Jul 24, 2015	Apr DISC

DIHYDROERGOTAMINE MESYLATE

INJECTABLE;INJECTION							
DIHYDROERGOTAMINE MESYLATE							
AP		PROVEPHARM SAS	1MG/ML	A 212046	001	Jan 07, 2020	Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL							
DILTIAZEM HYDROCHLORIDE							
AB1		GLENMARK PHARMS LTD	60MG	A 212317	001	Mar 22, 2021	Mar NEWA
AB1			90MG	A 212317	002	Mar 22, 2021	Mar NEWA
AB1			120MG	A 212317	003	Mar 22, 2021	Mar NEWA
AB1		MYLAN	60MG	A 074910	001	May 02, 1997	Mar CTEC
AB1			90MG	A 074910	002	May 02, 1997	Mar CTEC
AB1	!		120MG	A 074910	003	May 02, 1997	Mar CTEC
INJECTABLE;INJECTION							
DILTIAZEM HYDROCHLORIDE							
	@	INTL MEDICATION	5MG/ML	A 075749	001	Nov 21, 2001	Jan DISC

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL								
DIMETHYL FUMARATE								
AB		PHARMATHEN	120MG	A 210436	001	Mar 26, 2021	Mar NEWA	
AB			240MG	A 210436	002	Mar 26, 2021	Mar NEWA	
	@	ZYDUS PHARMS	120MG	A 210538	001	Sep 24, 2020	Feb DISC	
	@		240MG	A 210538	002	Sep 24, 2020	Feb DISC	
TECFIDERA								
>D>	AB	+	BIOGEN IDEC INC	120MG	N 204063	001	Mar 27, 2013	Apr CAHN
>D>	AB	+	!	240MG	N 204063	002	Mar 27, 2013	Apr CAHN
>A>	AB	+	BIOGEN INC	120MG	N 204063	001	Mar 27, 2013	Apr CAHN
>A>	AB	+	!	240MG	N 204063	002	Mar 27, 2013	Apr CAHN

DINOPROSTONE

GEL;ENDOCERVICAL								
PREPIDIL								
	+	!	PFIZER	0.5MG/3GM	N 019617	001	Dec 09, 1992	Jan CAHN

SUPPOSITORY;VAGINAL
PROSTIN E2

+!	PFIZER	20MG	N017810	001		Jan	CAHN
----	--------	------	---------	-----	--	-----	------

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

AB	OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006	Jan	CMFD
AB		50MG	A040542	002	Apr 21, 2006	Jan	CMFD
AB		75MG	A040542	003	Apr 21, 2006	Jan	CMFD

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

VUMERITY

>D>	+!	BIOGEN	231MG	N211855	001	Oct 29, 2019	Apr	CAHN
>A>	+!	BIOGEN INC	231MG	N211855	001	Oct 29, 2019	Apr	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

@ MAYNE PHARMA

@

EQ 100MG BASE

EQ 150MG BASE

A070173	001	May 31, 1985	Feb	DISC
A070173	002	May 31, 1985	Feb	DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB	AMTA	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Mar	NEWA
AB		EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Mar	NEWA

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

AP	HIKMA	20MG/ML (20MG/ML)	A204490	001	Jan 14, 2021	Jan	NEWA	
AP		80MG/4ML (20MG/ML)	A204490	002	Jan 14, 2021	Jan	NEWA	
>D>	AP	INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Apr	DISC
>A>	@		20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Apr	DISC
>D>	AP	SHILPA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr	CHRS
>A>	AP	+!	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr	CHRS
	AP		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan	CAHN
>D>	AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr	CHRS
>A>	AP	+!	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr	CHRS
	AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan	CAHN
>D>	AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr	CHRS
>A>	AP	+!	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr	CHRS
	AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan	CAHN

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

@ RICONPHARMA LLC

@

@

0.125MG

0.25MG

0.5MG

A212410	001	Dec 27, 2019	Feb	DISC
A212410	002	Dec 27, 2019	Feb	DISC
A212410	003	Dec 27, 2019	Feb	DISC

DOLASETRON MESYLATE

INJECTABLE;INJECTION

ANZEMET

+ @	VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Feb	CAHN
+ @		100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Feb	CAHN
@		500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Feb	CAHN

TABLET;ORAL

ANZEMET

+ @	VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Feb	CAHN
+ @		100MG	N020623	002	Sep 11, 1997	Feb	CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

>A>	AT	ALEMBIC PHARMS LTD	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	Apr	NEWA
	AT	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Feb	CMFD

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

>A>	AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A215076	001	Apr 21, 2021	Apr	NEWA
>A>	AB		EQ 25MG BASE	A215076	002	Apr 21, 2021	Apr	NEWA
>A>	AB		EQ 50MG BASE	A215076	003	Apr 21, 2021	Apr	NEWA
>A>	AB		EQ 75MG BASE	A215076	004	Apr 21, 2021	Apr	NEWA
>A>	AB		EQ 100MG BASE	A215076	005	Apr 21, 2021	Apr	NEWA
	AB	APPCO	EQ 10MG BASE	A214908	001	Apr 01, 2021	Mar	NEWA
	AB		EQ 25MG BASE	A214908	002	Apr 01, 2021	Mar	NEWA
	AB		EQ 50MG BASE	A214908	003	Apr 01, 2021	Mar	NEWA
	AB		EQ 75MG BASE	A214908	004	Apr 01, 2021	Mar	NEWA
	AB		EQ 100MG BASE	A214908	005	Apr 01, 2021	Mar	NEWA
	AB	LEADING PHARMA LLC	EQ 10MG BASE	A211619	001	Mar 09, 2021	Feb	NEWA
	AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Feb	NEWA
	AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Feb	NEWA
	AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Feb	NEWA
	AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Feb	NEWA
	AB		EQ 150MG BASE	A211618	001	Mar 01, 2021	Feb	NEWA
		@ UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb	DISC
		@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb	DISC
		@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb	DISC
		@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb	DISC
		@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb	DISC

TABLET;ORAL

DOXEPIN HYDROCHLORIDE

		@ PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan	DISC
		@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan	DISC
	AB	RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan	CAHN
	AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan	CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

	AB	@ MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan	DISC
	AB		EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan	NEWA
		@	EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan	DISC
	AB		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan	NEWA
		@	EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan	DISC
	AB		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan	NEWA

DOXYCYCLINE HYCLATE

TABLET;ORAL

DOXYCYCLINE HYCLATE

>D>	AB	ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Apr	DISC
>A>		@	EQ 100MG BASE	A213475	001	Mar 10, 2021	Apr	DISC
	AB		EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb	NEWA

DROSPIRENONE; ESTETROL

>A>		TABLET;ORAL						
>A>		NEXTSTELLIS						
>A>		+! MAYNE PHARMA	3MG;14.2MG	N214154	001	Apr 15, 2021	Apr	NEWA

DROXIDOPA

CAPSULE;ORAL

DROXIDOPA

	AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb	NFTG
	AB		200MG	A214391	002	Feb 18, 2021	Feb	NFTG
	AB		300MG	A214391	003	Feb 18, 2021	Feb	NFTG
	AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb	NFTG
	AB		200MG	A213911	002	Feb 18, 2021	Feb	NFTG
	AB		300MG	A213911	003	Feb 18, 2021	Feb	NFTG
	AB	ANNORA	300MG	A211726	001	Feb 18, 2021	Feb	NFTG
	AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb	NFTG
	AB		200MG	A214387	002	Feb 18, 2021	Feb	NFTG
	AB		300MG	A214387	003	Feb 18, 2021	Feb	NFTG
>A>	AB	BLUEPHARMA	100MG	A214543	001	May 05, 2021	Apr	NEWA
>A>	AB		200MG	A214543	002	May 05, 2021	Apr	NEWA
>A>	AB		300MG	A214543	003	May 05, 2021	Apr	NEWA
	AB	HIKMA	100MG	A212835	001	Feb 18, 2021	Feb	NFTG
	AB		200MG	A212835	002	Feb 18, 2021	Feb	NFTG
	AB		300MG	A212835	003	Feb 18, 2021	Feb	NFTG

CAPSULE;ORAL
DROXIDOPA

AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211652	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211652	003	Feb 18, 2021	Feb	NFTG
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211741	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211741	003	Feb 18, 2021	Feb	NFTG
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214017	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214017	003	Feb 18, 2021	Feb	NFTG
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A214384	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A214384	003	Feb 18, 2021	Feb	NFTG
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213661	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213661	003	Feb 18, 2021	Feb	NFTG
AB	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A213162	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A213162	003	Feb 18, 2021	Feb	NFTG
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb	NFTG
AB		200MG	A211818	002	Feb 18, 2021	Feb	NFTG
AB		300MG	A211818	003	Feb 18, 2021	Feb	NFTG

DULOXETINE HYDROCHLORIDE

>A>	CAPSULE, DELAYED REL PELLETS;ORAL						
>A>	DRIZALMA SPRINKLE						
>A>	+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr CDFR
>A>	+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr CDFR
>A>	+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr CDFR
>A>	+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr CDFR
	DULOXETINE HYDROCHLORIDE						
AB	SUNSHINE		EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb NEWA
AB			EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb NEWA
AB			EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb NEWA

>D>	CAPSULE, DELAYED RELEASE;ORAL						
>D>	DRIZALMA SPRINKLE						
>D>	+	SUN PHARMA GLOBAL	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr CDFR
>D>	+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr CDFR
>D>	+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr CDFR
>D>	+	!	EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr CDFR

DUTASTERIDE

	CAPSULE;ORAL						
	DUTASTERIDE						
>D>	@	BRECKENRIDGE	0.5MG	A204705	001	Nov 20, 2015	Apr CAHN
>A>	@	NOSTRUM LABS INC	0.5MG	A204705	001	Nov 20, 2015	Apr CAHN

ECONAZOLE NITRATE

	AEROSOL, FOAM;TOPICAL						
	ECOZA						
+	!	RESILIA PHARMS	1%	N205175	001	Oct 24, 2013	Feb CAHN

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

	TABLET;ORAL						
	EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE						
+	@	AUROBINDO PHARMA LTD	600MG;300MG;300MG	N022343	001	Aug 15, 2018	Feb DISC

EFINACONAZOLE

	SOLUTION;TOPICAL							
	EFINACONAZOLE							
AB		AUROBINDO PHARMA LTD	10%	A212066	001	Mar 29, 2021	Mar NEWA	
	@	PERRIGO PHARMA INTL	10%	A211851	001	Dec 16, 2020	Jan DISC	
AB		TEVA PHARMS USA	10%	A211827	001	Dec 16, 2020	Feb CTEC	
	JUBLIA							
AB	+	!	BAUSCH	10%	N203567	001	Jun 06, 2014	Feb CTEC

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB	CIPLA	200MG;300MG	A 090958	001	Apr 02, 2021	Mar	NEWA
AB	LAURUS LABS LTD	200MG;300MG	A 212114	001	Jul 26, 2019	Jan	CMFD
AB	MACLEODS PHARMS LTD	200MG;300MG	A 203442	001	May 15, 2020	Feb	CMFD
AB	MYLAN	200MG;300MG	A 206436	001	Apr 09, 2018	Feb	CMFD
AB	STRIDES PHARMA	200MG;300MG	A 091055	001	Jan 13, 2021	Jan	NEWA

EPLERENONE

TABLET; ORAL

EPLERENONE

>A>	AB	CHARTWELL RX	25MG	A 078482	001	Jul 30, 2008	Apr	CAHN
>A>	AB		50MG	A 078482	002	Jul 30, 2008	Apr	CAHN
>D>	AB	COREPHARMA	25MG	A 078482	001	Jul 30, 2008	Apr	CAHN
>D>	AB		50MG	A 078482	002	Jul 30, 2008	Apr	CAHN
		@ PIRAMAL HLTHCARE UK	25MG	A 212765	001	Aug 10, 2020	Feb	DISC
		@	50MG	A 212765	002	Aug 10, 2020	Feb	DISC
		INSPIRA						
>D>	AB	+ GD SEARLE LLC	25MG	N 021437	001	Sep 27, 2002	Apr	CAHN
>D>	AB	+	50MG	N 021437	002	Sep 27, 2002	Apr	CAHN
>D>		@	100MG	N 021437	003	Sep 27, 2002	Apr	CAHN
>A>	AB	+ UPJOHN	25MG	N 021437	001	Sep 27, 2002	Apr	CAHN
>A>	AB	+	50MG	N 021437	002	Sep 27, 2002	Apr	CAHN
>A>		@	100MG	N 021437	003	Sep 27, 2002	Apr	CAHN

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

EPOPROSTENOL SODIUM

AP2	SUN PHARM	EQ 0.5MG BASE/VIAL	A 210473	001	Jan 15, 2021	Feb	CTEC	
AP		EQ 0.5MG BASE/VIAL	A 210473	001	Jan 15, 2021	Jan	NFTG	
AP2		EQ 1.5MG BASE/VIAL	A 210473	002	Jan 15, 2021	Feb	CTEC	
AP		EQ 1.5MG BASE/VIAL	A 210473	002	Jan 15, 2021	Jan	NFTG	
AP1	TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A 078396	001	Apr 23, 2008	Feb	CTEC	
AP1		EQ 1.5MG BASE/VIAL	A 078396	002	Apr 23, 2008	Feb	CTEC	
		FLOLAN						
AP1	+	GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N 020444	001	Sep 20, 1995	Feb	CTEC
AP1	+		EQ 1.5MG BASE/VIAL	N 020444	002	Sep 20, 1995	Feb	CTEC
		VELETRI						
AP2	+	ACTELION	EQ 0.5MG BASE/VIAL	N 022260	002	Jun 28, 2012	Feb	CAHN
AP2	+		EQ 1.5MG BASE/VIAL	N 022260	001	Jun 27, 2008	Feb	CAHN
AP2	+	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N 022260	002	Jun 28, 2012	Feb	CHRS
AP2	+		EQ 0.5MG BASE/VIAL	N 022260	002	Jun 28, 2012	Feb	CTEC
AP2	+		EQ 1.5MG BASE/VIAL	N 022260	001	Jun 27, 2008	Feb	CTEC

EPTIFIBATIDE

INJECTABLE; INJECTION

EPTIFIBATIDE

>D>	AP	MYLAN LABS LTD	2MG/ML	A 203258	001	Jul 20, 2018	Apr	CHRS	
>A>	AP	!	2MG/ML	A 203258	001	Jul 20, 2018	Apr	CHRS	
>D>	AP		75MG/100ML	A 203258	002	Jul 20, 2018	Apr	CHRS	
>A>	AP	!	75MG/100ML	A 203258	002	Jul 20, 2018	Apr	CHRS	
>D>		INTEGRILIN							
>D>	AP	+	SCHERING	2MG/ML	N 020718	001	May 18, 1998	Apr	DISC
>A>		+ @		2MG/ML	N 020718	001	May 18, 1998	Apr	DISC
>D>	AP	+		75MG/100ML	N 020718	002	May 18, 1998	Apr	DISC
>A>		+ @		75MG/100ML	N 020718	002	May 18, 1998	Apr	DISC

ERGOCALCIFEROL

CAPSULE; ORAL

DRISDOL

AA	+	VALIDUS PHARMS	50,000 IU	N 003444	001		Feb	CAHN
----	---	----------------	-----------	----------	-----	--	-----	------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL

ERLOTINIB HYDROCHLORIDE

>A>	AB	MSN	EQ 25MG BASE	A 214366	001	May 10, 2021	Apr	NEWA
>A>	AB		EQ 100MG BASE	A 214366	002	May 10, 2021	Apr	NEWA
>A>	AB		EQ 150MG BASE	A 214366	003	May 10, 2021	Apr	NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS
ERTAPENEM SODIUM

AP GLAND PHARMA LTD EQ 1GM BASE/VIAL A212040 001 Mar 26, 2021 Mar NEWA

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHRA-DERM

>D> @ SAPTALIS PHARMS 2% A062687 001 Feb 05, 1988 Apr CMFD
>A> AT 2% A062687 001 Feb 05, 1988 Apr CMFD

TABLET; ORAL
ERYTHROMYCIN

AB TEVA PHARMS USA INC 250MG A214549 001 Feb 11, 2021 Feb NEWA
AB 500MG A214549 002 Feb 11, 2021 Feb NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL
ESOMEPRAZOLE MAGNESIUM

AB ETHYPHARM EQ 20MG BASE A090841 001 Mar 31, 2021 Mar NEWA
AB EQ 40MG BASE A090841 002 Mar 31, 2021 Mar NEWA
AB GRAVITI PHARMS EQ 20MG BASE A213486 001 Mar 19, 2021 Mar NEWA
AB EQ 40MG BASE A213486 002 Mar 19, 2021 Mar NEWA
AB INDCHEMIE HEALTH EQ 20MG BASE A210559 001 Feb 26, 2021 Feb NEWA
AB EQ 40MG BASE A210559 002 Feb 26, 2021 Feb NEWA

ESTRADIOL

INSERT, EXTENDED RELEASE; VAGINAL
ESTRING

+! PFIZER 0.0075MG/24HR N020472 001 Apr 26, 1996 Jan CAHN

ESTRADIOL CYPIONATE

INJECTABLE; INJECTION
DEPO-ESTRADIOL

@ PFIZER 1MG/ML A085470 001 Mar CAHN
@ 3MG/ML A085470 002 Mar CAHN
! 5MG/ML A085470 003 Mar CAHN

ESTROPIPATE

TABLET; ORAL
OGEN .625

@ PFIZER 0.75MG A083220 001 Jan CAHN
OGEN 1.25
@ PFIZER 1.5MG A083220 002 Jan CAHN
OGEN 2.5
@ PFIZER 3MG A083220 003 Jan CAHN
OGEN 5
PFIZER 6MG A083220 004 Jan CAHN

ESZOPICLONE

TABLET; ORAL
ESZOPICLONE

@ NOSTRUM LABS INC 1MG A203087 001 May 08, 2019 Jan CAHN
@ 2MG A203087 002 May 08, 2019 Jan CAHN
@ 3MG A203087 003 May 08, 2019 Jan CAHN

ETHINYL ESTRADIOL; ETONOGESTREL

RING; VAGINAL

ETHINYL ESTRADIOL; ETONOGESTREL

AB TEVA PHARMS USA INC 0.015MG/24HR; 0.12MG/24HR A204305 001 Jan 13, 2021 Jan NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL

ETHINYL ESTRADIOL AND NORELGESTROMIN

AB AMNEAL 0.035MG/24HR; 0.15MG/24HR A213950 001 Feb 25, 2021 Feb NEWA
XULANE
AB ! MYLAN TECHNOLOGIES 0.035MG/24HR; 0.15MG/24HR A200910 001 Apr 16, 2014 Feb CTEC

ETHINYL ESTRADIOL; NORETHINDRONE ACETATECAPSULE; ORAL
GEMMILY

AB	XIROMED	0.02MG;1MG	A213317	001	Nov 09, 2020	Mar	CAHN
----	---------	------------	---------	-----	--------------	-----	------

EVEROLIMUSTABLET; ORAL
AFINITOR

AB	+ NOVARTIS	10MG	N022334	002	Mar 30, 2009	Feb	CTEC
	EVEROLIMUS						
	@ BIOCON PHARMA	2.5MG	A214182	001	Feb 11, 2021	Feb	DISC
AB		2.5MG	A214182	001	Feb 11, 2021	Feb	NEWA
	@	5MG	A214182	002	Feb 11, 2021	Feb	DISC
AB		5MG	A214182	002	Feb 11, 2021	Feb	NEWA
	@	7.5MG	A214182	003	Feb 11, 2021	Feb	DISC
AB		7.5MG	A214182	003	Feb 11, 2021	Feb	NEWA
	@	10MG	A214182	004	Feb 11, 2021	Feb	DISC
AB		10MG	A214182	004	Feb 11, 2021	Feb	NEWA
AB	BRECKENRIDGE	2.5MG	A205426	001	Mar 05, 2021	Feb	NEWA
AB		5MG	A205426	002	Mar 05, 2021	Feb	NEWA
AB		7.5MG	A205426	003	Mar 05, 2021	Feb	NEWA
AB		10MG	A205426	004	Mar 05, 2021	Feb	NEWA

EXEMESTANETABLET; ORAL
AROMASIN

AB	+! PFIZER	25MG	N020753	001	Oct 21, 1999	Mar	CAHN
----	-----------	------	---------	-----	--------------	-----	------

EXENATIDE SYNTHETICFOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS
BYDUREON

	+ @ ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Feb	DISC
	BYDUREON PEN						
	+ @ ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb	DISC

EZETIMIBETABLET; ORAL
ZETIA

AB	+! ORGANON	10MG	N021445	001	Oct 25, 2002	Feb	CAHN
----	------------	------	---------	-----	--------------	-----	------

EZETIMIBE; ROSUVASTATIN CALCIUMTABLET; ORAL
ROSZET

	+ ALTHERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar	NEWA
		10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar	NEWA
		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar	NEWA
		10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar	NEWA
		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar	NEWA
		10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar	NEWA
	+!	10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar	NEWA
	+!	10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar	NEWA

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

EZETIMIBE AND SIMVASTATIN

	@ MYLAN	10MG;10MG	A200082	001	Dec 17, 2020	Jan	DISC
	@	10MG;20MG	A200082	002	Dec 17, 2020	Jan	DISC
	@	10MG;40MG	A200082	003	Dec 17, 2020	Jan	DISC
	@	10MG;80MG	A200082	004	Dec 17, 2020	Jan	DISC
	VYTORIN						
AB	+ ORGANON	10MG;10MG	N021687	001	Jul 23, 2004	Feb	CAHN
AB		10MG;20MG	N021687	002	Jul 23, 2004	Feb	CAHN
AB		10MG;40MG	N021687	003	Jul 23, 2004	Feb	CAHN
AB	+!	10MG;80MG	N021687	004	Jul 23, 2004	Feb	CAHN

FAMOTIDINEFOR SUSPENSION; ORAL
FAMOTIDINE

AB	AKORN	40MG/5ML	A201995	001	May 30, 2014	Feb	CAHN
>A> AB	NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Apr	NEWA

FENOFIBRATE

TABLET; ORAL

FENOFIBRATE

AB	AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan	NEWA
AB		145MG	A208476	002	Feb 10, 2021	Jan	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

@ RISING

EQ 200MG BASE

A072394 001 Oct 17, 1988 Jan CAHN

@

EQ 300MG BASE

A072395 001 Oct 17, 1988 Jan CAHN

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

@ FRESENIUS KABI USA

EQ 0.05MG BASE/ML

A212086 001 Sep 01, 2020 Mar DISC

FERRIC MALTOL

CAPSULE; ORAL

ACCRUFER

>D> + @ SHIELD TX

30MG IRON

N212320 001 Jul 25, 2019 Apr CMFD

>A>

+!

30MG IRON

N212320 001 Jul 25, 2019 Apr CMFD

FERUMOXYTOL

SOLUTION; INTRAVENOUS

FERAHEME

AB +! COVIS

EQ 510MG IRON/17ML (EQ 30MG IRON/ML)

N022180 001 Jun 30, 2009 Mar CAHN

FERUMOXYTOL

AB SANDOZ INC

EQ 510MG IRON/17ML (EQ 30MG IRON/ML)

A206604 001 Jan 15, 2021 Jan NFTG

FINGOLIMOD HYDROCHLORIDE

CAPSULE; ORAL

FINGOLIMOD HYDROCHLORIDE

AB DR REDDYS

EQ 0.5MG BASE

A208000 001 Mar 05, 2021 Feb NEWA

@ MYLAN

EQ 0.5MG BASE

A208005 001 Jan 19, 2021 Jan DISC

AB

@ ZYDUS PHARMS

EQ 0.5MG BASE

A208005 001 Jan 19, 2021 Jan NEWA

@ ZYDUS PHARMS

EQ 0.5MG BASE

A207994 001 Oct 14, 2020 Mar DISC

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

+ @ CNTY LINE PHARMS

50MG

N018830 004 Aug 23, 1988 Jan DISC

+ @

100MG

N018830 001 Oct 31, 1985 Jan DISC

+ @

150MG

N018830 003 Jun 03, 1988 Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP CARDINAL HEALTH 414

20-500mCi/ML

A203603 002 Sep 27, 2018 Mar NEWA

NUKEMED

4-500mCi/ML

A203911 001 Apr 22, 2015 Jan CAHN

AP PHARMALOGIC HLDGS

20-200mCi/ML

A203664 001 Feb 04, 2014 Jan CAHN

AP PRECISION NUCLEAR

20-500mCi/ML

A204546 001 Apr 07, 2015 Mar CTEC

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP BAXTER HLTHCARE CORP

0.5MG/5ML (0.1MG/ML)

A076755 002 Oct 12, 2004 Mar CMFD

AP

1MG/10ML (0.1MG/ML)

A076755 001 Oct 12, 2004 Mar CMFD

FLUOCINOLONE ACETONIDE

OIL; TOPICAL

FLUOCINOLONE ACETONIDE

AT SOLARIS PHARMA CORP

0.01%

A212760 001 Apr 02, 2021 Mar NEWA

AT

0.01%

A212761 001 Apr 02, 2021 Mar NEWA

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT SOLARIS PHARMA CORP

0.01%

A212762 001 Apr 02, 2021 Mar NEWA

AT

TASMAN PHARMA

0.01%

A213264 001 Feb 05, 2021 Jan NEWA

FLUOROURACIL

INJECTABLE; INJECTION

FLUOROURACIL

@ NOVAST LABS	5GM/100ML (50MG/ML)	A209271	001	Dec 11, 2019	Mar CPOT
---------------	---------------------	---------	-----	--------------	----------

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

@ ACCORD HLTHCARE	EQ 10MG BASE	A202729	001	Aug 27, 2020	Feb DISC
@	EQ 20MG BASE	A202729	002	Aug 27, 2020	Feb DISC
@	EQ 40MG BASE	A202729	003	Aug 27, 2020	Feb DISC

TABLET; ORAL

FLUOXETINE HYDROCHLORIDE

TORRENT	EQ 10MG BASE	A206937	001	Oct 21, 2016	Mar CHRS
!	EQ 20MG BASE	A206937	002	Oct 21, 2016	Mar CHRS
SARAFEM					
+ @ APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Mar DISC
+ @	EQ 20MG BASE	N021860	003	May 19, 2006	Mar DISC

FLUOXYMESTERONE

TABLET; ORAL

FLUOXYMESTERONE

@ UPSHER SMITH LABS	10MG	A088342	001	Oct 21, 1983	Jan DISC
---------------------	------	---------	-----	--------------	----------

FLUPHENAZINE HYDROCHLORIDE

TABLET; ORAL

FLUPHENAZINE HYDROCHLORIDE

AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan NEWA
AB	NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb NEWA
AB		2.5MG	A214674	002	Mar 01, 2021	Feb NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb NEWA
AB		10MG	A214674	004	Mar 01, 2021	Feb NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS; OPHTHALMIC

FLURBIPROFEN SODIUM

!	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995	Jan CHRS
		0.03%	A074447	001	Jan 04, 1995	Jan CTEC
	OCUFEN					
+ @	ALLERGAN	0.03%	N019404	001	Dec 31, 1986	Jan DISC

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

@ CIPLA	125MG	A075780	001	Sep 19, 2001	Mar DISC	
!	PAR PHARM	125MG	A075298	001	Sep 18, 2001	Mar CHRS
	125MG	A075298	001	Sep 18, 2001	Mar CTEC	

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

>A> AB	BEIJING	EQ 80MG BASE	A209397	001	Apr 26, 2021	Apr NEWA
--------	---------	--------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

@ BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb DISC
------------------	-------	---------	-----	--------------	----------

FOSAPREPITANT DIMEGLUMINE

POWDER; INTRAVENOUS

FOSAPREPITANT DIMEGLUMINE

AP	AUROBINDO PHARMA LTD	EQ 150MG BASE/VIAL	A210625	001	Jan 12, 2021	Jan NEWA
AP	CHIA TAI TIANQING	EQ 150MG BASE/VIAL	A212143	001	Mar 03, 2021	Feb NEWA
	@ MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Mar DISC

FOSCARNET SODIUMINJECTABLE; INJECTION
FOSCARNET SODIUM

AP	FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Jan	NEWA
>A>	GLAND PHARMA LTD	2.4GM/100ML	A213001	001	Apr 21, 2021	Apr	NEWA
FOSCAVIR							
AP	+! CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Jan	CTEC

FOSDENOPTERIN HYDROBROMIDEPOWDER; INTRAVENOUS
NULIBRY

+!	ORIGIN	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Feb	NEWA
----	--------	--------------------	---------	-----	--------------	-----	------

FULVESTRANTINJECTABLE; INTRAMUSCULAR
FULVESTRANT

AO	AUROMEDICS PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Jan	CAHN
----	-------------------	---------	---------	-----	--------------	-----	------

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

>D>	@ ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Apr	CMFD
>A>	AP	10MG/ML	A070017	001	Dec 15, 1986	Apr	CMFD
AP	ATHENEX INC	10MG/ML	A214766	001	Jan 27, 2021	Jan	NEWA
TABLET; ORAL							
LASIX							
AB	+ VALIDUS PHARMS	20MG	N016273	002		Feb	CAHN
AB	+	40MG	N016273	001		Feb	CAHN
AB	+!	80MG	N016273	003		Feb	CAHN

GABAPENTINCAPSULE; ORAL
GABAPENTIN

>A>	AB	ASCENT PHARMS INC	100MG	A214956	001	May 10, 2021	Apr	NEWA
>A>	AB		300MG	A214956	002	May 10, 2021	Apr	NEWA
>A>	AB		400MG	A214956	003	May 10, 2021	Apr	NEWA
>D>	@	ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Apr	CMFD
>A>	AB		100MG	A213603	001	Aug 17, 2020	Apr	CMFD
	@		100MG	A213603	001	Aug 17, 2020	Feb	DISC
>D>	@		300MG	A213603	002	Aug 17, 2020	Apr	CMFD
>A>	AB		300MG	A213603	002	Aug 17, 2020	Apr	CMFD
	@		300MG	A213603	002	Aug 17, 2020	Feb	DISC
>D>	@		400MG	A213603	003	Aug 17, 2020	Apr	CMFD
>A>	AB		400MG	A213603	003	Aug 17, 2020	Apr	CMFD
	@		400MG	A213603	003	Aug 17, 2020	Feb	DISC

GATIFLOXACINSOLUTION/DROPS; OPHTHALMIC
GATIFLOXACIN

AT	AKORN	0.5%	A203189	001	Sep 03, 2014	Feb	CAHN
----	-------	------	---------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDEINJECTABLE; INJECTION
GEMCITABINE HYDROCHLORIDE

AP	!	JIANGSU HANSOH PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb	CHRS
AP	!		EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb	CHRS
AP		MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan	CAHN
AP			1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan	CAHN
AP			2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan	CAHN
GEMZAR								
	+	@ LILLY	EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb	DISC
	+	@	EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb	DISC

GEMFIBROZILTABLET; ORAL
GEMFIBROZIL

AB	ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021	Jan	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION

HEPARIN SODIUM PRESERVATIVE FREE

>D>	AP	SHENZHEN TECHDOW	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Apr DISC
>A>		@	1,000 UNITS/ML	A202732	001	Jun 12, 2014	Apr DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

MICROZIDE

AB	+!	TEVA BRANDED PHARM	12.5MG	N020504	001	Dec 27, 1996	Mar CAHN
----	----	--------------------	--------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

ZESTORETIC

AB	+	ALMATICA	12.5MG; 10MG	N019888	003	Nov 18, 1993	Jan CAHN
AB	+!		12.5MG; 20MG	N019888	001	Sep 20, 1990	Jan CAHN
AB	+!		25MG; 20MG	N019888	002	Jul 20, 1989	Jan CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	+	VALIDUS PHARMS	25MG; 50MG	N018303	001	Dec 31, 1984	Feb CAHN
	+ @		25MG; 100MG	N018303	002	Dec 31, 1984	Feb CAHN
	+ @		50MG; 100MG	N018303	003	Dec 31, 1984	Feb CAHN

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

HYDROCODONE BITARTRATE

AB		ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	Feb NFTG
AB			30MG	A208269	002	Mar 01, 2021	Feb NFTG
AB			40MG	A208269	003	Mar 01, 2021	Feb NFTG
AB			60MG	A208269	004	Mar 01, 2021	Feb NFTG
AB			80MG	A208269	005	Mar 01, 2021	Feb NFTG
AB			100MG	A208269	006	Mar 01, 2021	Feb NFTG
AB			120MG	A208269	007	Mar 01, 2021	Feb NFTG

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB		NOSTRUM LABS INC	5MG; 200MG	A077727	001	Nov 06, 2006	Jan CAHN
AB			7.5MG; 200MG	A077723	001	Nov 06, 2006	Jan CAHN
			10MG; 200MG	A077723	002	Nov 06, 2006	Mar CTEC
AB			10MG; 200MG	A077723	002	Nov 06, 2006	Jan CAHN
		REPREXAIN					
	@	AMNEAL PHARMS NY	2.5MG; 200MG	A076642	003	Oct 19, 2007	Mar DISC
	@		10MG; 200MG	A076642	004	Oct 19, 2007	Mar DISC

HYDROCORTISONE

ENEMA; RECTAL

COLOCORT

>A>	AB	CHARTWELL	100MG/60ML	A075172	001	Dec 03, 1999	Apr CAHN
>D>	AB	CP PHARMA	100MG/60ML	A075172	001	Dec 03, 1999	Apr CAHN

HYDROCORTISONE PROBUTATE

CREAM; TOPICAL

PANDEL

>A>	+!	ANI PHARMS	0.1%	N020453	001	Feb 28, 1997	Apr CAHN
>D>	+!	FOUGERA PHARMS	0.1%	N020453	001	Feb 28, 1997	Apr CAHN

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

HYDROCORTONE

	+	@ MERCK	EQ 50MG BASE/ML	N012052	001		Feb CRLD
--	---	---------	-----------------	---------	-----	--	----------

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB		COSETTE	0.2%	A213724	001	Feb 11, 2021	Feb NEWA
----	--	---------	------	---------	-----	--------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ LANNETT CO INC

2MG

A077471 002 Dec 09, 2009 Mar DISC

@

4MG

A077471 003 Dec 09, 2009 Mar DISC

@

8MG

A077471 001 Dec 09, 2009 Mar DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR

MAKENA

AP1 +! COVIS 1250MG/5ML (250MG/ML)

N021945 001 Feb 03, 2011 Mar CAHN

MAKENA PRESERVATIVE FREE

AP +! COVIS 250MG/ML (250MG/ML)

N021945 002 Feb 19, 2016 Mar CAHN

SOLUTION; SUBCUTANEOUS

MAKENA (AUTOINJECTOR)

+! COVIS 275MG/1.1ML (250MG/ML)

N021945 004 Feb 14, 2018 Mar CAHN

HYDROXYUREA

TABLET; ORAL

SIKLOS

+! ADDMEDICA SAS 1GM

N208843 002 Dec 21, 2017 Mar CHRS

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

AB PRINSTON INC 10MG

A040580 003 May 27, 2005 Feb CMS1

AB 25MG

A040580 002 May 27, 2005 Feb CMS1

IBRUTINIB

CAPSULE; ORAL

IBRUTINIB

AB ZYDUS 70MG

A211344 001 Mar 31, 2021 Mar NFTG

AB 140MG

A211344 002 Mar 31, 2021 Mar NFTG

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ VINTAGE PHARMS 400MG

A071644 001 Feb 01, 1988 Feb DISC

IBUTILIDE FUMARATE

INJECTABLE; INJECTION

CORVERT

AP +! PFIZER 0.1MG/ML

N020491 001 Dec 28, 1995 Feb CAHN

ICOSAPENT ETHYL

CAPSULE; ORAL

ICOSAPENT ETHYL

@ TEVA PHARMS USA 500MG

A209525 001 Sep 11, 2020 Mar DISC

@ 1GM

A209525 002 Sep 11, 2020 Mar DISC

VASCEPA

+ AMARIN PHARMS 500MG

N202057 002 Feb 16, 2017 Mar CTEC

ILOPROST

SOLUTION; INHALATION

VENTAVIS

+! ACTELION 10MCG/ML (10MCG/ML)

N021779 002 Dec 08, 2005 Feb CAHN

@ 20MCG/2ML (10MCG/ML)

N021779 001 Dec 29, 2004 Feb CAHN

+! 20MCG/ML (20MCG/ML)

N021779 003 Aug 07, 2009 Feb CAHN

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB TARO 3.75%

A205971 001 Jan 26, 2021 Jan NFTG

INDOMETHACIN

CAPSULE; ORAL

INDOMETHACIN

@ JUBILANT GENERICS 25MG

A205215 001 Aug 25, 2017 Jan DISC

@ 50MG

A205215 002 Aug 25, 2017 Jan DISC

	CAPSULE;ORAL								
>D>	TIVORBEX								
>D>	+	GENUS	20MG	N204768	001	Feb 24, 2014	Apr	DISC	
>A>	+	@	20MG	N204768	001	Feb 24, 2014	Apr	DISC	
>D>	+	!	40MG	N204768	002	Feb 24, 2014	Apr	DISC	
>A>	+	@	40MG	N204768	002	Feb 24, 2014	Apr	DISC	
	CAPSULE, EXTENDED RELEASE;ORAL								
	INDOMETHACIN								
	@	AUROBINDO PHARMA LTD	75MG	A204243	001	Dec 27, 2016	Jan	DISC	
	<u>IOPAMIDOL</u>								
	INJECTABLE;INJECTION								
	ISOVUE-300								
	+	!	BRACCO	61%	N018735	002	Dec 31, 1985	Jan	CTEC
			ISOVUE-370						
	+	!	BRACCO	76%	N018735	003	Dec 31, 1985	Jan	CTEC
			SCANLUX-300						
	@	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Jan	DISC	
		SCANLUX-370							
	@	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Jan	DISC	
	<u>IRINOTECAN HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	IRINOTECAN HYDROCHLORIDE								
	@	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771	001	Feb 14, 2012	Mar	DISC	
	@		100MG/5ML (20MG/ML)	A200771	002	Feb 14, 2012	Mar	DISC	
	<u>ISOPROTERENOL HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	ISOPROTERENOL HYDROCHLORIDE								
AP		AUROBINDO PHARMA LTD	0.2MG/ML	A211864	001	Feb 09, 2021	Jan	NEWA	
AP		MICRO LABS	0.2MG/ML	A210845	001	Feb 16, 2021	Feb	NEWA	
	<u>ISOTRETINOIN</u>								
	CAPSULE;ORAL								
	AMNESTEEM								
AB1		MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002	Mar	CTEC	
AB1			20MG	A075945	002	Nov 08, 2002	Mar	CTEC	
AB1			40MG	A075945	003	Nov 08, 2002	Mar	CTEC	
	CLARAVIS								
AB1		TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	Mar	CTEC	
AB1			20MG	A076135	002	Apr 11, 2003	Mar	CTEC	
AB1			30MG	A076135	003	May 11, 2006	Mar	CTEC	
AB1	!		40MG	A076135	001	Apr 11, 2003	Mar	CTEC	
	ISOTRETINOIN								
AB2		ACTAVIS LABS FL	10MG	A205063	001	Mar 31, 2021	Mar	NFTG	
AB2			20MG	A205063	002	Mar 31, 2021	Mar	NFTG	
AB2			25MG	A205063	003	Mar 31, 2021	Mar	NFTG	
AB2			30MG	A205063	004	Mar 31, 2021	Mar	NFTG	
AB2			35MG	A205063	005	Mar 31, 2021	Mar	NFTG	
AB2			40MG	A205063	006	Mar 31, 2021	Mar	NFTG	
AB1		AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Mar	CTEC	
AB1			20MG	A207792	002	Sep 29, 2017	Mar	CTEC	
AB1			30MG	A207792	003	Sep 29, 2017	Mar	CTEC	
AB1			40MG	A207792	004	Sep 29, 2017	Mar	CTEC	
>A>	AB2	UPSHER SMITH LABS	40MG	A213571	001	Apr 12, 2021	Apr	NEWA	
	MYORISAN								
AB1		DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Mar	CTEC	
AB1			20MG	A076485	002	Jan 19, 2012	Mar	CTEC	
AB1			30MG	A076485	004	Aug 25, 2015	Mar	CTEC	
AB1			40MG	A076485	003	Jan 19, 2012	Mar	CTEC	
	ZENATANE								
AB1		DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar	CTEC	
AB1			20MG	A202099	002	Mar 25, 2013	Mar	CTEC	
AB1			30MG	A202099	004	Feb 23, 2015	Mar	CTEC	
AB1			40MG	A202099	003	Mar 25, 2013	Mar	CTEC	

>D>	<u>ITRACONAZOLE</u>							
>D>	TABLET;ORAL							
>D>	ONMEL							
>D>	+!	SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010	Apr	DISC
>A>	+	@	200MG	N022484	001	Apr 29, 2010	Apr	DISC
	<u>IVERMECTIN</u>							
	TABLET;ORAL							
	STROMEKTOL							
	+	@ MERCK SHARP DOHME	6MG	N050742	001	Nov 22, 1996	Feb	CRLD
	<u>IVOSIDENIB</u>							
	TABLET;ORAL							
	TIBSOVO							
>D>	+!	AGIOS PHARMS INC	250MG	N211192	001	Jul 20, 2018	Apr	CAHN
>A>	+!	SERVIER	250MG	N211192	001	Jul 20, 2018	Apr	CAHN
	<u>KETAMINE HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	KETAMINE HYDROCHLORIDE							
AP		AUROMEDICS PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Jan	CAHN
AP			EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Jan	CAHN
AP			EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Jan	CAHN
	<u>KETOCONAZOLE</u>							
	TABLET;ORAL							
	KETOCONAZOLE							
	@	MYLAN	200MG	A075597	001	Dec 23, 1999	Mar	DISC
	<u>KETOPROFEN</u>							
	CAPSULE;ORAL							
	KETOPROFEN							
	@	RISING	50MG	A074024	001	Dec 29, 1995	Jan	CAHN
	@		75MG	A074024	002	Dec 29, 1995	Jan	CAHN
	<u>KETOROLAC TROMETHAMINE</u>							
	INJECTABLE;INJECTION							
	KETOROLAC TROMETHAMINE							
>D>	AP	AUROBINDO PHARMA LTD	15MG/ML	A212939	001	Oct 20, 2020	Apr	DISC
>A>		@	15MG/ML	A212939	001	Oct 20, 2020	Apr	DISC
>D>	AP		30MG/ML	A212939	002	Oct 20, 2020	Apr	DISC
>A>		@	30MG/ML	A212939	002	Oct 20, 2020	Apr	DISC
		@ HOSPIRA	15MG/ML	A074993	001	Jan 27, 1999	Mar	DISC
	<u>LABETALOL HYDROCHLORIDE</u>							
	INJECTABLE;INJECTION							
	LABETALOL HYDROCHLORIDE							
AP		BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Mar	CMFD
	TABLET;ORAL							
	TRANDATE							
>D>	AB	+ CNTY LINE PHARMS	200MG	N018716	002	Aug 01, 1984	Apr	CHRS
>A>	AB	+!	200MG	N018716	002	Aug 01, 1984	Apr	CHRS
	<u>LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE</u>							
	TABLET;ORAL							
	LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE							
	+	@ AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Feb	DISC
	<u>LAMOTRIGINE</u>							
	TABLET, ORALLY DISINTEGRATING;ORAL							
	LAMOTRIGINE							
AB		AJANTA PHARMA LTD	25MG	A213271	001	Jan 19, 2021	Jan	NEWA
AB			50MG	A213271	002	Jan 19, 2021	Jan	NEWA
AB			100MG	A213271	003	Jan 19, 2021	Jan	NEWA
AB			200MG	A213271	004	Jan 19, 2021	Jan	NEWA

LANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

AB	DR REDDYS LABS LTD	15MG	A210465	001	Feb 01, 2021	Jan	NEWA
AB		30MG	A210465	002	Feb 01, 2021	Jan	NEWA

LEFLUNOMIDE

TABLET;ORAL
LEFLUNOMIDE

AB	AUROBINDO PHARMA LTD	10MG	A213652	001	Mar 29, 2021	Mar	NEWA
AB		20MG	A213652	002	Mar 29, 2021	Mar	NEWA
>A>	AB	AXUNIO	A213497	001	May 10, 2021	Apr	NEWA
>A>	AB		A213497	002	May 10, 2021	Apr	NEWA

LETROZOLE

TABLET;ORAL
LETROZOLE
@ APOTEX INC

2.5MG

A091303 001 Apr 19, 2012 Jan DISC

LEVETIRACETAM

INJECTABLE;INTRAVENOUS
LEVETIRACETAM IN SODIUM CHLORIDE

AP	AUROBINDO PHARMA LTD	1GM/100ML (10MG/ML)	A207160	002	Jan 04, 2017	Feb	CPOT
AP		1.5GM/100ML (15MG/ML)	A207160	003	Jan 04, 2017	Feb	CPOT
AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A206880	002	Oct 25, 2017	Feb	CPOT
AP		1.5GM/100ML (15MG/ML)	A206880	003	Oct 25, 2017	Feb	CDFR
AP	+!	HQ SPECIALITY PHARMA	N202543	002	Nov 09, 2011	Feb	CPOT
AP	+!		N202543	003	Nov 09, 2011	Feb	CPOT
AP	NEXUS PHARMS	1GM/100ML (10MG/ML)	A213532	002	Jul 06, 2020	Feb	CPOT
AP		1.5GM/100ML (15MG/ML)	A213532	003	Jul 06, 2020	Feb	CPOT

SOLUTION;ORAL
LEVETIRACETAM

AA	AKORN	100MG/ML	A090601	001	Feb 28, 2012	Feb	CAHN
----	-------	----------	---------	-----	--------------	-----	------

TABLET;ORAL
LEVETIRACETAM

	@ NOSTRUM LABS INC	250MG	A090511	001	Aug 18, 2011	Mar	DISC
AB		250MG	A090511	001	Aug 18, 2011	Jan	CAHN
	@	500MG	A090511	002	Aug 18, 2011	Mar	DISC
AB		500MG	A090511	002	Aug 18, 2011	Jan	CAHN
	@	750MG	A090511	003	Aug 18, 2011	Mar	DISC
AB		750MG	A090511	003	Aug 18, 2011	Jan	CAHN
	@	1GM	A090511	004	Aug 18, 2011	Mar	DISC
AB		1GM	A090511	004	Aug 18, 2011	Jan	CAHN

TABLET, EXTENDED RELEASE;ORAL
ELEPSIA XR

	+ TRIPOINT	1GM	N204417	001	Dec 20, 2018	Jan	CAHN
	+!	1.5GM	N204417	002	Dec 20, 2018	Jan	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL
XYZAL

>D>							
>D>	AA	+ SANOFI AVENTIS US	2.5MG/5ML	N022157	001	Jan 28, 2008	Apr DISC
>A>		+ @	2.5MG/5ML	N022157	001	Jan 28, 2008	Apr DISC

TABLET;ORAL
LEVOCETIRIZINE DIHYDROCHLORIDE

>D>		@ FOSUN PHARMA	5MG	A090486	001	Mar 26, 2013	Apr CAHN
>D>	AB	GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Apr CHRS
>A>	AB	!	5MG	A090385	001	Feb 24, 2011	Apr CHRS
>A>		@ GRANULES	5MG	A090486	001	Mar 26, 2013	Apr CAHN
>D>		XYZAL					
>D>	AB	+! SANOFI AVENTIS US	5MG	N022064	001	May 25, 2007	Apr DISC
>A>		+ @	5MG	N022064	001	May 25, 2007	Apr DISC

LEVORPHANOL TARTRATE

TABLET;ORAL
LEVORPHANOL TARTRATE

AB	NOVITIUM PHARMA	3MG	A213479	002	Jan 12, 2021	Jan	NEWA
AB	! SENTYNL THERAPS INC	3MG	A074278	003	Jun 18, 2018	Jan	CTEC

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

LEVOTHYROXINE SODIUM

>D>	AB	TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020	Apr	DISC
>A>		@	0.075MG	A211369	001	Oct 28, 2020	Apr	DISC
>A>	AB		0.112MG	A211369	003	Apr 16, 2021	Apr	NFTG
>D>	AB		0.15MG	A211369	002	Oct 28, 2020	Apr	DISC
>A>		@	0.15MG	A211369	002	Oct 28, 2020	Apr	DISC
		TIROSINT						
>D>	AB	+ INSTITUT BIOCHIMIQUE	0.075MG	N021924	004	Oct 13, 2006	Apr	CTEC
>A>		+	0.075MG	N021924	004	Oct 13, 2006	Apr	CTEC
>D>	AB	+	0.15MG	N021924	007	Oct 13, 2006	Apr	CTEC
>A>		+	0.15MG	N021924	007	Oct 13, 2006	Apr	CTEC

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

@ DR REDDYS

100MCG/VIAL

A208837 001 Mar 27, 2020 Feb DISC

SOLUTION;ORAL

THYQUIDITY

>D>		+! EMP	100MCG/5ML	N214047	001	Nov 30, 2020	Apr	CAHN
>A>		+! VISTAPHARM	100MCG/5ML	N214047	001	Nov 30, 2020	Apr	CAHN
		TIROSINT-SOL						
		+ INSTITUT BIOCHIMIQUE	37.5MCG/ML	N206977	013	Jan 13, 2021	Jan	NEWA
		+	44MCG/ML	N206977	014	Jan 13, 2021	Jan	NEWA
		+	62.5MCG/ML	N206977	015	Jan 13, 2021	Jan	NEWA

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

>A>	AT	QUAGEN	5%	A212695	001	Apr 20, 2021	Apr	NEWA
		PATCH;TOPICAL						
		LIDOCAINE						
>A>	AB	NAL PHARM	5%	A205882	001	Apr 29, 2021	Apr	NEWA

LIDOCAINE HYDROCHLORIDE

JELLY;TOPICAL

XYLOCAINE

+ @ AKORN

2%

N008816 001 Jan DISC

SOLUTION;ORAL

LIDOCAINE HYDROCHLORIDE VISCOUS

AT		LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Jan	CMFD
----	--	----------------	----	---------	-----	--------------	-----	------

LINACLOTIDE

CAPSULE;ORAL

LINACLOTIDE

		@ MYLAN	145MCG	A209564	001	Feb 09, 2021	Feb	DISC
AB			145MCG	A209564	001	Feb 09, 2021	Jan	NFTG
		@	290MCG	A209564	002	Feb 09, 2021	Feb	DISC
AB			290MCG	A209564	002	Feb 09, 2021	Jan	NFTG
		LINZESS						
		+! ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Feb	CTEC
		+	290MCG	N202811	002	Aug 30, 2012	Feb	CTEC

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOCIN

AP		+! PFIZER	EQ 300MG BASE/ML	N050317	001		Feb	CAHN
		LINCOMYCIN HYDROCHLORIDE						
AP		PRAXGEN	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	Mar	NEWA

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB		ZYDUS	EQ 0.005MG BASE	A214803	001	Jan 22, 2021	Jan	NEWA
AB			EQ 0.025MG BASE	A214803	002	Jan 22, 2021	Jan	NEWA
AB			EQ 0.05MG BASE	A214803	003	Jan 22, 2021	Jan	NEWA

LISINOPRIL

TABLET; ORAL
LISINOPRIL

AB	YILING	20MG	A208920	001	Mar 04, 2021	Feb NEWA
AB		30MG	A208920	002	Mar 04, 2021	Feb NEWA
AB		40MG	A208920	003	Mar 04, 2021	Feb NEWA

LORAZEPAM

CONCENTRATE; ORAL
LORAZEPAM

AA	AKORN	2MG/ML	A200169	001	Jan 30, 2012	Feb CAHN
----	-------	--------	---------	-----	--------------	----------

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC
LOTEPREDNOL ETABONATE

AB	AKORN	0.5%	A212080	001	Feb 10, 2021	Jan NFTG
----	-------	------	---------	-----	--------------	----------

SUSPENSION/DROPS; OPHTHALMIC
LOTEPREDNOL ETABONATE

AB	SUN PHARM	0.5%	A212450	001	Feb 26, 2021	Feb NEWA
----	-----------	------	---------	-----	--------------	----------

LURASIDONE HYDROCHLORIDE

TABLET; ORAL
LURASIDONE HYDROCHLORIDE

AB	WATSON LABS TEVA	20MG	A208016	001	Feb 02, 2021	Jan NEWA
AB		40MG	A208016	002	Feb 02, 2021	Jan NEWA
AB		60MG	A208016	003	Feb 02, 2021	Jan NEWA
AB		80MG	A208016	004	Feb 02, 2021	Jan NEWA
AB		120MG	A208016	005	Feb 02, 2021	Jan NEWA

MACITENTAN

TABLET; ORAL
MACITENTAN

AB	ZYDUS	10MG	A211224	001	Apr 06, 2021	Mar NFTG
----	-------	------	---------	-----	--------------	----------

MAGNESIUM SULFATE

INJECTABLE; INJECTION
MAGNESIUM SULFATE

>A>	AP	B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26, 2021	Apr NEWA
>A>	AP		4GM/100ML (40MG/ML)	A207967	002	Apr 26, 2021	Apr NEWA
>A>	AP		4GM/50ML (80MG/ML)	A207967	003	Apr 26, 2021	Apr NEWA

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11, 2020	Feb CMFD
----	----------------------	-----------	---------	-----	--------------	----------

MAGNESIUM SULFATE IN PLASTIC CONTAINER

AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01, 2020	Feb CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01, 2020	Feb CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01, 2020	Feb CMFD

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION
DEPO-PROVERA

AB	+ @ PFIZER	100MG/ML	N012541	002		Mar CAHN
	+!	150MG/ML	N020246	001	Oct 29, 1992	Mar CAHN
	+!	400MG/ML	N012541	003		Mar CAHN

INJECTABLE; SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

	+! PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar CAHN
--	-----------	--------------	---------	-----	--------------	----------

TABLET; ORAL
PROVERA

AB	+ PFIZER	2.5MG	N011839	001		Mar CAHN
AB	+	5MG	N011839	003		Mar CAHN
AB	+!	10MG	N011839	004		Mar CAHN

MEFENAMIC ACID

CAPSULE; ORAL
MEFENAMIC ACID

	@ STRIDES PHARMA	250MG	A209209	001	Sep 18, 2020	Mar DISC
--	------------------	-------	---------	-----	--------------	----------

MELOXICAM

	CAPSULE; ORAL						
	MELOXICAM						
AB	LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb	CTEC
AB	!	10MG	A209487	002	Jun 01, 2020	Feb	CTEC
AB	NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb	NEWA
AB		10MG	A211398	002	Mar 09, 2021	Feb	NEWA

MELPHALAN

TABLET; ORAL
MELPHALAN

! ALVOGEN 2MG A207809 001 Mar 22, 2017 Jan CAHN

MELPHALAN FLUFENAMIDE

POWDER; INTRAVENOUS
PEPAXTO

+! ONCOPEPTIDES AB 20MG/VIAL N214383 001 Feb 26, 2021 Feb NEWA

MELPHALAN FLUFENAMIDE HYDROCHLORIDE

POWDER; INTRAVENOUS
PEPAXTO

+! ONCOPEPTIDES AB EQ 20MG BASE/VIAL N214383 001 Feb 26, 2021 Mar CPOT
+! 20MG/VIAL N214383 001 Feb 26, 2021 Mar CAIN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION
ALKERAN

+ @ APOTEX EQ 50MG BASE/VIAL N020207 001 Nov 18, 1992 Jan DISC

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
MEMANTINE HYDROCHLORIDE

AB	YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021	Mar	NEWA
AB		14MG	A211100	002	Apr 02, 2021	Mar	NEWA
AB		21MG	A211100	003	Apr 02, 2021	Mar	NEWA
AB		28MG	A211100	004	Apr 02, 2021	Mar	NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
DEMEROL

@ VALIDUS PHARMS 25MG/ML N005010 007 Feb CAHN
@ 50MG/ML N005010 002 Feb CAHN
@ 75MG/ML N005010 009 Feb CAHN
@ 100MG/ML N005010 003 Feb CAHN

SYRUP; ORAL

DEMEROL

@ VALIDUS PHARMS 50MG/5ML N005010 005 Feb CAHN

TABLET; ORAL

DEMEROL

+ @ VALIDUS PHARMS 50MG N005010 001 Feb CAHN
+ @ 100MG N005010 004 Feb CAHN

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

AA	! ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	Mar	CHRS
AA	!	400MG	A090122	002	Feb 18, 2009	Mar	CHRS
	@ WATSON LABS	200MG	A083304	001		Mar	DISC
	@	400MG	A083308	001		Mar	DISC

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS
VABOMERE

+! REMPEX 1GM/VIAL; 1GM/VIAL N209776 001 Aug 29, 2017 Feb CAHN

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

METFORMIN HYDROCHLORIDE

AB3	AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb	NEWA
AB3		1GM	A213962	002	Mar 09, 2021	Feb	NEWA
>D>	AB1	APOTEX	500MG	A076706	001	Dec 14, 2004	Apr DISC
>A>	@		500MG	A076706	001	Dec 14, 2004	Apr DISC
AB3	GRANULES	500MG	A213344	001	Jan 12, 2021	Jan	NEWA
AB3		1GM	A213344	002	Jan 12, 2021	Jan	NEWA
>A>	AB3	SCIEGEN PHARMS INC	500MG	A213334	001	Apr 16, 2021	Apr NEWA
>A>	AB3		1GM	A213334	002	Apr 16, 2021	Apr NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

@ TORRENT PHARMS LTD 500MG;EQ 15MG BASE

A202001 001 Feb 13, 2013 Jan DISC

@ 850MG;EQ 15MG BASE

A202001 002 Feb 13, 2013 Jan DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

METHADONE HYDROCHLORIDE

AA	LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Feb	NEWA
----	----------------	---------	---------	-----	--------------	-----	------

METHENAMINE HIPURATE

TABLET;ORAL

HIPREX

AB	+ @ VALIDUS PHARMS	1GM	N017681	001		Mar	DISC
----	--------------------	-----	---------	-----	--	-----	------

AB	+!	1GM	N017681	001		Feb	CAHN
----	----	-----	---------	-----	--	-----	------

METHENAMINE HIPPURATE

AB	! AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Mar	CHRS
----	------------------------	-----	---------	-----	--------------	-----	------

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

>A>	AA	@ AUROBINDO PHARMA LTD	750MG	A213967	001	Aug 12, 2020	Feb DISC
-----	----	------------------------	-------	---------	-----	--------------	----------

>A>	AA	GRANULATION TECH	500MG	A212623	001	Apr 30, 2021	Apr NEWA
-----	----	------------------	-------	---------	-----	--------------	----------

>A>	AA		750MG	A212623	002	Apr 30, 2021	Apr NEWA
-----	----	--	-------	---------	-----	--------------	----------

METHOTREXATE SODIUM

TABLET;ORAL

METHOTREXATE SODIUM

>A>	AB	LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr NEWA
-----	----	--------------------	---------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHYLERGONOVINE MALEATE

AB	RISING	0.2MG	A211919	001	Jan 15, 2021	Jan	NEWA
----	--------	-------	---------	-----	--------------	-----	------

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	ASCENT PHARMS INC	5MG/5ML	A207417	001	Jan 29, 2021	Jan	NEWA
----	-------------------	---------	---------	-----	--------------	-----	------

AA		10MG/5ML	A207417	002	Jan 29, 2021	Jan	NEWA
----	--	----------	---------	-----	--------------	-----	------

	@ LANNETT CO INC	5MG/5ML	A207414	001	Dec 16, 2020	Jan	DISC
--	------------------	---------	---------	-----	--------------	-----	------

	@	10MG/5ML	A207414	002	Dec 16, 2020	Jan	DISC
--	---	----------	---------	-----	--------------	-----	------

METHYLPREDNISOLONE

TABLET;ORAL

METHYLPREDNISOLONE

AB	PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	CAHN
----	---------	-----	---------	-----	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

>A>	AP	GENEYORK PHARMS	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Apr NEWA
-----	----	-----------------	-------------------	---------	-----	--------------	----------

>A>	AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Apr NEWA
-----	----	--	--------------------	---------	-----	--------------	----------

>A>	AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Apr NEWA
-----	----	--	--------------------	---------	-----	--------------	----------

>A>	AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Apr NEWA
-----	----	--	------------------	---------	-----	--------------	----------

>A>	AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Apr NEWA
-----	----	--	------------------	---------	-----	--------------	----------

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	BAYSHORE PHARMS LLC	2.5MG	A214799	001	Mar 30, 2021	Mar	NEWA
AB		5MG	A214799	002	Mar 30, 2021	Mar	NEWA
AB		10MG	A214799	003	Mar 30, 2021	Mar	NEWA
AB	INNOGENIX	2.5MG	A213827	001	Mar 30, 2021	Mar	NEWA
AB		5MG	A213827	002	Mar 30, 2021	Mar	NEWA
AB		10MG	A213827	003	Mar 30, 2021	Mar	NEWA

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	YICHANG HUMANWELL	EQ 100MG TARTRATE	A213854	001	Feb 12, 2021	Feb	NEWA
AB		EQ 200MG TARTRATE	A213854	002	Feb 12, 2021	Feb	NEWA

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	+ VALIDUS PHARMS	50MG	N017963	001		Feb	CAHN
AB	+	100MG	N017963	002		Feb	CAHN

MEXILETINE HYDROCHLORIDE

CAPSULE; ORAL

MEXILETINE HYDROCHLORIDE

AB	RICONPHARMA LLC	150MG	A214352	001	Jan 25, 2021	Jan	NEWA
AB		200MG	A214352	002	Jan 25, 2021	Jan	NEWA
AB		250MG	A214352	003	Jan 25, 2021	Jan	NEWA

MIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

+	!	INFORLIFE	50MG/50ML (1MG/ML)	N211844	001	Mar 22, 2021	Mar	NEWA
+	!		100MG/100ML (1MG/ML)	N211844	002	Mar 22, 2021	Mar	NEWA

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	2.5MG	A214734	001	Jan 21, 2021	Jan	NEWA
AB		5MG	A214734	002	Jan 21, 2021	Jan	NEWA
AB		10MG	A214734	003	Jan 21, 2021	Jan	NEWA

MIGLITOL

TABLET; ORAL

GLYSET

AB	+	!	PFIZER	25MG	N020682	001	Dec 18, 1996	Feb	CAHN
AB	+			50MG	N020682	002	Dec 18, 1996	Feb	CAHN
AB	+			100MG	N020682	003	Dec 18, 1996	Feb	CAHN

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

>A>	AP	CAPLIN	EQ 1MG BASE/ML	A214380	001	Apr 16, 2021	Apr	NEWA
-----	----	--------	----------------	---------	-----	--------------	-----	------

MINOCYCLINE HYDROCHLORIDE

AEROSOL, FOAM; TOPICAL

AMZEEQ

+	!	VYNE	EQ 4% BASE	N212379	001	Oct 18, 2019	Mar	CAHN
+	!	ZILXI						
+	!	VYNE	EQ 1.5% BASE	N213690	001	May 28, 2020	Mar	CAHN

MINOXIDIL

TABLET; ORAL

LONITEN

+	@	PFIZER	2.5MG	N018154	001		Feb	CAHN
+	@		10MG	N018154	003		Feb	CAHN

MIRABEGRONFOR SUSPENSION, EXTENDED RELEASE;ORAL
MYRBETRIQ GRANULES

+! APGDI 8MG/ML N213801 001 Mar 25, 2021 Mar NEWA

MOMETASONE FUROATEOINTMENT;TOPICAL
MOMETASONE FUROATE

@ TORRENT 0.1% A207899 001 Jul 13, 2018 Jan DISC

MORPHINE SULFATEINJECTABLE;INJECTION
MORPHINE SULFATE

>A> +! HOSPIRA INC 50MG/ML N202515 006 Apr 29, 2021 Apr NEWA

>A> INTL MEDICATION SYS 1MG/ML A202861 001 Apr 29, 2021 Apr NFTG

SOLUTION;ORAL

MORPHINE SULFATE

@ ANI PHARMS 10MG/5ML A205509 001 Apr 17, 2018 Jan DISC

@ 20MG/5ML A205509 002 Apr 17, 2018 Jan DISC

@ 100MG/5ML A205509 003 Apr 17, 2018 Jan DISC

AA WINDER LABS LLC 10MG/5ML A211454 001 Feb 12, 2021 Feb NEWA

AA 20MG/5ML A211454 002 Feb 12, 2021 Feb NEWA

AA 100MG/5ML A211454 003 Feb 12, 2021 Feb NEWA

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
MOXIFLOXACIN HYDROCHLORIDE

AT1 UPSHER SMITH LABS EQ 0.5% BASE A212616 001 Feb 10, 2021 Jan NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDEINJECTABLE;INJECTION
MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP AMNEAL 500MG/VIAL A211374 001 Mar 05, 2021 Feb NEWA

AP MEITHEAL 500MG/VIAL A212130 001 Jan 15, 2021 Jan CAHN

AP NANJING KING-FRIEND 500MG/VIAL A212130 001 Jan 15, 2021 Jan NEWA

MYCOPHENOLIC ACIDTABLET, DELAYED RELEASE;ORAL
MYCOPHENOLIC ACID

AB AMTA 180MG A214376 001 Feb 10, 2021 Jan NEWA

AB 360MG A214376 002 Feb 10, 2021 Jan NEWA

NABUMETONETABLET;ORAL
NABUMETONE

AB ANNORA PHARMA 500MG A090445 001 Jan 12, 2011 Mar CAHN

AB 750MG A090445 002 Jan 12, 2011 Mar CAHN

NALOXONE HYDROCHLORIDEINJECTABLE;INJECTION
NALOXONE HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 1MG/ML A213279 001 Jan 14, 2021 Jan NEWA

AP BAXTER HLTHCARE CORP 0.4MG/ML A214785 001 Jan 29, 2021 Jan NEWA

SPRAY;NASAL

>A> KLOXXADO

>A> +! HIKMA 8MG/SPRAY N212045 001 Apr 29, 2021 Apr NEWA

NAPROXENSUSPENSION;ORAL
NAPROXEN

AB NOVITIUM PHARMA 25MG/ML A211910 001 Mar 10, 2021 Feb NEWA

TABLET;ORAL

NAPROXEN

AB GRANULES 250MG A074140 001 Dec 21, 1993 Feb CMFD

AB 375MG A074140 002 Dec 21, 1993 Feb CMFD

AB 500MG A074140 003 Dec 21, 1993 Feb CMFD

NEOSTIGMINE METHYLSULFATESOLUTION; INTRAVENOUS
NEOSTIGMINE METHYLSULFATE

>A>	AP	CAPLIN	5MG/10ML (0.5MG/ML)	A213074	001	Apr 20, 2021	Apr	NEWA
>A>	AP		10MG/10ML (1MG/ML)	A213074	002	Apr 20, 2021	Apr	NEWA
>D>	AP	HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr	CAHN
	AP		5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar	NEWA
>D>	AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr	CAHN
	AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar	NEWA
>A>	AP	MEITHEAL	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr	CAHN
>A>	AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr	CAHN

NICARDIPINE HYDROCHLORIDEINJECTABLE; INJECTION
NICARDIPINE HYDROCHLORIDE

>D>	!	AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Apr	CTEC
>A>	AP	!	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Apr	CTEC
	!		25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Feb	CHRS
>A>	AP	AUROBINDO PHARMA LTD	25MG/10ML (2.5MG/ML)	A211121	001	Apr 08, 2021	Apr	NEWA

NIFEDIPINETABLET, EXTENDED RELEASE; ORAL
NIFEDIPINE

>D>	AB1	PAR PHARM	30MG	A077899	001	Dec 13, 2006	Apr	DISC
>A>	@		30MG	A077899	001	Dec 13, 2006	Apr	DISC
>D>	AB1		60MG	A077899	002	Dec 13, 2006	Apr	DISC
>A>	@		60MG	A077899	002	Dec 13, 2006	Apr	DISC
>D>	AB1		90MG	A077899	003	May 25, 2012	Apr	DISC
>A>	@		90MG	A077899	003	May 25, 2012	Apr	DISC

NISOLDIPINETABLET, EXTENDED RELEASE; ORAL
NISOLDIPINE

!	MYLAN	20MG	A079051	001	Jul 25, 2008	Jan	CHRS
		30MG	A079051	002	Jul 25, 2008	Jan	CHRS

NITROGLYCERINTABLET; SUBLINGUAL
NITROGLYCERIN

>A>	AB	RUBICON	0.3MG	A209779	001	May 03, 2021	Apr	NEWA
>A>	AB		0.4MG	A209779	002	May 03, 2021	Apr	NEWA
>A>	AB		0.6MG	A209779	003	May 03, 2021	Apr	NEWA

NOREPINEPHRINE BITARTRATEINJECTABLE; INJECTION
NOREPINEPHRINE BITARTRATE

AP	ANDERSEN GLOBAL	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Jan	NEWA	
AP	BRECKENRIDGE	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Mar	CAHN	
>A>	AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A214323	001	May 06, 2021	Apr	NEWA
AP	SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Jan	NEWA	

SOLUTION; INTRAVENOUS

NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE

+	!	BAXTER HLTHCARE CORP	EQ 4MG BASE/250ML (EQ 16MCG BASE/ML)	N214313	001	Jan 15, 2021	Jan	NEWA
+	!		EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214313	002	Jan 15, 2021	Jan	NEWA

NORTRIPTYLINE HYDROCHLORIDECAPSULE; ORAL
NORTRIPTYLINE HYDROCHLORIDE

AB	ZYDUS	EQ 10MG BASE	A213441	001	Feb 24, 2021	Feb	NEWA
AB		EQ 25MG BASE	A213441	002	Feb 24, 2021	Feb	NEWA
AB		EQ 50MG BASE	A213441	003	Feb 24, 2021	Feb	NEWA
AB		EQ 75MG BASE	A213441	004	Feb 24, 2021	Feb	NEWA

NYSTATINOINTMENT; TOPICAL
NYSTATIN

AT	MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021	Jan	NEWA
----	---------------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	ALEOR DERMA	CEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar	NEWA
----	-------------	-----------	-----------------------	---------	-----	--------------	-----	------

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

@ ALVOGEN 0.3%

A076830	001	Aug 31, 2004	Jan	DISC
---------	-----	--------------	-----	------

TABLET; ORAL

FLOXIN

+ @	JANSSEN PHARMS	200MG
+ @		300MG
+ @		400MG

N019735	001	Dec 28, 1990	Jan	CRLD
N019735	002	Dec 28, 1990	Jan	CRLD
N019735	003	Dec 28, 1990	Jan	CRLD

OLANZAPINE

TABLET; ORAL

OLANZAPINE

AB	HISUN PHARM	HANGZHOU	2.5MG
AB			5MG
AB			7.5MG
AB			10MG
AB			15MG
AB			20MG

A206924	001	Dec 31, 2020	Feb	CAHN
A206924	002	Dec 31, 2020	Feb	CAHN
A206924	003	Dec 31, 2020	Feb	CAHN
A206924	004	Dec 31, 2020	Feb	CAHN
A206924	005	Dec 31, 2020	Feb	CAHN
A206924	006	Dec 31, 2020	Feb	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	HISUN PHARM	HANGZHOU	5MG
AB			10MG
AB			15MG
AB			20MG

A206892	001	Dec 31, 2020	Feb	CAHN
A206892	002	Dec 31, 2020	Feb	CAHN
A206892	003	Dec 31, 2020	Feb	CAHN
A206892	004	Dec 31, 2020	Feb	CAHN

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN	EQ 0.2% BASE
USV	EQ 0.1% BASE

A204723	001	Dec 05, 2017	Mar	CTEC
A203152	001	Dec 07, 2015	Apr	CMKT

>D> AT

SPRAY, METERED; NASAL

OLOPATADINE HYDROCHLORIDE

AB	AMNEAL	0.665MG/SPRAY
	@	0.665MG/SPRAY

A210901	001	Jan 28, 2020	Mar	CMFD
A210901	001	Jan 28, 2020	Jan	DISC

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

AB	+!	WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS
----	----	----------	--

N021654	001	Nov 10, 2004	Feb	CAHN
---------	-----	--------------	-----	------

ONDANSETRON

FILM; ORAL

ZUPLENZ

+ @	AQUESTIVE	4MG
+ @		8MG

N022524	001	Jul 02, 2010	Feb	CAHN
N022524	002	Jul 02, 2010	Feb	CAHN

ORITAVANCIN DIPHOSPHATE

POWDER; INTRAVENOUS

KIMYRSA

+! MELINTA THERAP EQ 1.2GM BASE/VIAL

N214155	001	Mar 12, 2021	Mar	NEWA
---------	-----	--------------	-----	------

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

@ IMPAX PHARMS 100MG

A040368	001	Jun 23, 2000	Jan	DISC
---------	-----	--------------	-----	------

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL

OSELTAMIVIR PHOSPHATE

AB	@	MYLAN	EQ 30MG BASE
			EQ 30MG BASE
	@		EQ 45MG BASE
AB			EQ 45MG BASE

A210157	001	Jan 21, 2021	Jan	DISC
A210157	001	Jan 21, 2021	Jan	NEWA
A210157	002	Jan 21, 2021	Jan	DISC
A210157	002	Jan 21, 2021	Jan	NEWA

		CAPSULE;ORAL							
		OSELTAMIVIR PHOSPHATE							
	@	EQ 75MG BASE		A210157	003	Jan 21, 2021	Jan	DISC	
AB		EQ 75MG BASE		A210157	003	Jan 21, 2021	Jan	NEWA	
<u>OXICONAZOLE NITRATE</u>									
		LOTION;TOPICAL							
		OXISTAT							
>A>	+	ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	CAHN	
>D>	+	FOUGERA PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr	CAHN	
<u>OXYBUTYNIN CHLORIDE</u>									
		TABLET;ORAL							
		OXYBUTYNIN CHLORIDE							
AB	APPCO		5MG	A209025	001	Dec 21, 2017	Jan	CAHN	
<u>OXYCODONE HYDROCHLORIDE</u>									
		CAPSULE;ORAL							
		OXYCODONE HYDROCHLORIDE							
>D>	AB	LANNETT CO INC	5MG	A203823	001	Aug 01, 2014	Apr	DISC	
>A>	@		5MG	A203823	001	Aug 01, 2014	Apr	DISC	
		TABLET;ORAL							
		OXAYDO							
	+	ZYLA	5MG	N202080	001	Jun 17, 2011	Mar	CRLD	
	+		7.5MG	N202080	002	Jun 17, 2011	Mar	CRLD	
		OXYCODONE HYDROCHLORIDE							
>D>	AB	ALVOGEN	5MG	A202116	001	Dec 30, 2011	Apr	CAHN	
>A>	AB		5MG	A202116	001	Dec 30, 2011	Apr	CAHN	
>D>	AB		15MG	A202116	002	Dec 30, 2011	Apr	CAHN	
>A>	AB		15MG	A202116	002	Dec 30, 2011	Apr	CAHN	
>D>	AB		30MG	A202116	003	Dec 30, 2011	Apr	CAHN	
>A>	AB		30MG	A202116	003	Dec 30, 2011	Apr	CAHN	
>D>	<u>OXYMETHOLONE</u>								
>D>	TABLET;ORAL								
>D>	ANADROL-50								
>D>	+	MYLAN SPECIALITY LP	50MG	N016848	001		Apr	DISC	
>A>	+	@	50MG	N016848	001		Apr	DISC	
<u>PACLITAXEL</u>									
		INJECTABLE;INJECTION							
		PACLITAXEL							
	@	MYLAN LABS LTD	6MG/ML	A091540	001	Sep 29, 2011	Mar	DISC	
<u>PALONOSETRON HYDROCHLORIDE</u>									
		INJECTABLE;INTRAVENOUS							
>D>	ALOXI								
>D>	AP	+	HEL SINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Apr	DISC
>A>		+	@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N021372	002	Feb 29, 2008	Apr	DISC
>D>	AP	+		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Apr	DISC
>A>		+	@	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N021372	001	Jul 25, 2003	Apr	DISC
		PALONOSETRON HYDROCHLORIDE							
AP	ACCORD HLTHCARE		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Mar	NEWA	
>D>	AP	DR REDDYS LABS LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	CHRS	
>A>	AP	!	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	CHRS	
>D>	AP	HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Apr	DISC	
>A>		@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Apr	DISC	
>D>	AP	QILU	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Apr	DISC	
>A>		@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Apr	DISC	
>D>	AP	TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Apr	DISC	
>A>		@	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Apr	DISC	

PAROXETINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PAROXETINE HYDROCHLORIDE

AB	CSPC OUYI	EQ 12.5MG BASE	A213485	001	Feb 16, 2021	Feb	NEWA
AB		EQ 25MG BASE	A213485	002	Feb 16, 2021	Feb	NEWA
AB		EQ 37.5MG BASE	A213485	003	Feb 16, 2021	Feb	NEWA

PEMETREXED

SOLUTION;INTRAVENOUS
PEMETREXED

	+ @ ACTAVIS LLC	100MG/4ML (25MG/ML)	N208419	001	Aug 21, 2020	Jan	DISC
	+ @	500MG/20ML (25MG/ML)	N208419	002	Aug 21, 2020	Jan	DISC
	+ @	1GM/40ML (25MG/ML)	N208419	003	Aug 21, 2020	Jan	DISC

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION
PENICILLIN G POTASSIUM

	HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A065149	001	Jul 23, 2009	Mar	CAHN
AP		5,000,000 UNITS/VIAL	A065149	002	Jul 23, 2009	Mar	CAHN
AP		20,000,000 UNITS/VIAL	A065149	003	Jul 23, 2009	Mar	CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL
PENICILLIN V POTASSIUM

	@ DAVA PHARMS INC	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar	DISC
	@	EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar	DISC
	PENICILLIN-VK						
	TEVA	EQ 125MG BASE/5ML	A060456	001		Mar	CTEC
	!	EQ 250MG BASE/5ML	A060456	002		Mar	CTEC

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION
PENTAMIDINE ISETHIONATE

AP	EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan	NEWA
----	-------------------	------------	---------	-----	--------------	-----	------

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL
TRENAL

	+ @ VALIDUS PHARMS	400MG	N018631	001	Aug 30, 1984	Feb	CAHN
--	--------------------	-------	---------	-----	--------------	-----	------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS
BIORPHEN

	+!	ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb	CPOT
>D>	+!		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Apr	DISC
>A>	+ @		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Apr	DISC
	+!		10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Mar	NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AUROBINDO PHARMA LTD	10MG/ML (10MG/ML)	A210696	001	Jan 07, 2021	Jan	NEWA	
>A>	AP1	GLAND PHARMA LTD	10MG/ML (10MG/ML)	A211920	003	Apr 08, 2021	Apr	NEWA
	AP2	HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jan	CAHN
	AP2	+	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jan	CAHN
	AP2	+	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jan	CAHN
	AP1	PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jan	CAHN
	AP1		50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jan	CAHN
	AP1		100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jan	CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	AKORN	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Feb	CAHN
----	-------	---------------------	---------	-----	--------------	-----	------

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL
PIOGLITAZONE HYDROCHLORIDE

AB	ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014	Jan	CAHN
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Jan	CAHN
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Jan	CAHN
AB	SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jan	NEWA
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jan	NEWA
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jan	NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

>D>	AP	MYLAN LABS LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Apr	DISC
>A>	@		EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Apr	DISC
	@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar	DISC
	AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan	CAHN
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan	CAHN
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan	CAHN
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan	CAHN
	AP		EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Jan	CAHN
	AP	SAGENT PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021	Feb	NEWA
	AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021	Feb	NEWA
	AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021	Feb	NEWA
	AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021	Feb	NEWA
	AP	! WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Jan	CHRS
	AP	!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan	CHRS
	AP	!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan	CHRS
	AP	!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan	CHRS
		ZOSYN						
	+	@ WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Jan	DISC
	+	@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Jan	DISC
	+	@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Jan	DISC
	+	@	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Jan	DISC

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB		NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan	CMS1
----	--	------------------	------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE; ORAL

POMALIDOMIDE

	@	BRECKENRIDGE	1MG	A210111	001	Oct 30, 2020	Feb	DISC
	@		2MG	A210111	002	Oct 30, 2020	Feb	DISC
	@		3MG	A210111	003	Oct 30, 2020	Feb	DISC
	@		4MG	A210111	004	Oct 30, 2020	Feb	DISC
>D>	AB	EUGIA PHARMA	1MG	A210249	001	Oct 30, 2020	Apr	DISC
>A>	@		1MG	A210249	001	Oct 30, 2020	Apr	DISC
>D>	AB		2MG	A210249	002	Oct 30, 2020	Apr	DISC
>A>	@		2MG	A210249	002	Oct 30, 2020	Apr	DISC
>D>	AB		3MG	A210249	003	Oct 30, 2020	Apr	DISC
>A>	@		3MG	A210249	003	Oct 30, 2020	Apr	DISC
>D>	AB		4MG	A210249	004	Oct 30, 2020	Apr	DISC
>A>	@		4MG	A210249	004	Oct 30, 2020	Apr	DISC
		POMALYST						
>D>	AB	+ CELGENE	1MG	N204026	001	Feb 08, 2013	Apr	CTEC
>A>	+		1MG	N204026	001	Feb 08, 2013	Apr	CTEC
>D>	AB	+	2MG	N204026	002	Feb 08, 2013	Apr	CTEC
>A>	+		2MG	N204026	002	Feb 08, 2013	Apr	CTEC
>D>	AB	+	3MG	N204026	003	Feb 08, 2013	Apr	CTEC
>A>	+		3MG	N204026	003	Feb 08, 2013	Apr	CTEC
>D>	AB	+	4MG	N204026	004	Feb 08, 2013	Apr	CTEC
>A>	+		4MG	N204026	004	Feb 08, 2013	Apr	CTEC

PONESIMODTABLET; ORAL
PONVORY

+	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	Mar	NEWA
+		3MG	N213498	002	Mar 18, 2021	Mar	NEWA
+		4MG	N213498	003	Mar 18, 2021	Mar	NEWA
+		5MG	N213498	004	Mar 18, 2021	Mar	NEWA
+		6MG	N213498	005	Mar 18, 2021	Mar	NEWA
+		7MG	N213498	006	Mar 18, 2021	Mar	NEWA
+		8MG	N213498	007	Mar 18, 2021	Mar	NEWA
+		9MG	N213498	008	Mar 18, 2021	Mar	NEWA
+		10MG	N213498	009	Mar 18, 2021	Mar	NEWA
+		20MG	N213498	010	Mar 18, 2021	Mar	NEWA

POSACONAZOLETABLET, DELAYED RELEASE; ORAL
POSACONAZOLE

AB	AET PHARMA	100MG	A213454	001	Feb 01, 2021	Jan	NEWA
----	------------	-------	---------	-----	--------------	-----	------

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

AB	GRANULES	8MEQ	A214686	001	Feb 16, 2021	Feb	NEWA
AB		10MEQ	A214686	002	Feb 16, 2021	Feb	NEWA

FOR SOLUTION; ORAL
POTASSIUM CHLORIDE

AA	STRIDES PHARMA	20MEQ	A211667	001	Mar 11, 2021	Mar	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION
POTASSIUM CHLORIDE 10MEQ

	@ FRESENIUS KABI USA	14.9MG/ML	A211087	001	Sep 09, 2020	Mar	DISC
	@	746MG/100ML	A211087	002	Sep 09, 2020	Mar	DISC
AP	NEXUS PHARMS	14.9MG/ML	A214727	001	Mar 18, 2021	Mar	NFTG
AP		745MG/100ML	A214727	002	Mar 18, 2021	Mar	NFTG

POTASSIUM CHLORIDE 20MEQ

>A>	AP	@ FRESENIUS KABI USA	29.8MG/ML	A211087	003	Sep 09, 2020	Mar	DISC
	AP		1.49GM/100ML	A211087	005	May 07, 2021	Apr	NEWA
	AP	NEXUS PHARMS	29.8MG/ML	A214727	003	Mar 18, 2021	Mar	NFTG
	AP		1.49GM/100ML	A214727	004	Mar 18, 2021	Mar	NFTG

POTASSIUM CHLORIDE 40MEQ

	@ FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar	DISC
AP	NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021	Mar	NFTG

SOLUTION; ORAL

POTASSIUM CHLORIDE

AA	GRANULES	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan	NEWA
AA		40MEQ/15ML	A213392	002	Jan 29, 2021	Jan	NEWA

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

AB1	AMTA	10MEQ	A214395	001	Jan 28, 2021	Jan	NEWA
AB1		20MEQ	A214395	002	Jan 28, 2021	Jan	NEWA
AB1	AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021	Mar	NEWA
AB1		15MEQ	A214728	002	Mar 31, 2021	Mar	NEWA
AB1		20MEQ	A214728	003	Mar 31, 2021	Mar	NEWA
	@ CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Mar	DISC
	@	20MEQ	A213588	002	Aug 21, 2020	Mar	DISC

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE; INJECTION

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

+	BAXTER HLTHCARE	150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTNA
+		150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar	CTEC
	@ FRESENIUS KABI USA	150MG/100ML; 450MG/100ML	A212347	001	Sep 17, 2020	Mar	DISC

POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%

AP	+	BAXTER HLTHCARE	150MG/100ML; 900MG/100ML	N017648	001		Mar	CTNA
AP	+		150MG/100ML; 900MG/100ML	N017648	001		Mar	CHRS

POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%

+	BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648	002		Mar	CTNA
+		300MG/100ML; 900MG/100ML	N017648	002		Mar	CHRS
+		300MG/100ML; 900MG/100ML	N017648	002		Mar	CTEC
	@ FRESENIUS KABI USA	300MG/100ML; 900MG/100ML	A212347	002	Sep 17, 2020	Mar	DISC
	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%						
	@ BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004		Mar	CTNA

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL
POTASSIUM CITRATE

AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan	NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan	NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan	NEWA
>D>	@ BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Apr	CMFD
>A>	AB	10MEQ	A212799	001	Jun 29, 2020	Apr	CMFD
	@	10MEQ	A212799	001	Jun 29, 2020	Feb	DISC
>D>	@	15MEQ	A212799	002	Jun 29, 2020	Apr	CMFD
>A>	AB	15MEQ	A212799	002	Jun 29, 2020	Apr	CMFD
	@	15MEQ	A212799	002	Jun 29, 2020	Feb	DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb	NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb	NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb	NEWA

PRALSETINIB

CAPSULE;ORAL
GAVRETO

+!	GENENTECH INC	100MG	N213721	001	Sep 04, 2020	Mar	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

>D>	AB	BRECKENRIDGE PHARM	0.125MG	A091450	001	Oct 08, 2010	Apr	CAHN
>D>	AB		0.25MG	A091450	002	Oct 08, 2010	Apr	CAHN
>D>	AB		0.5MG	A091450	003	Oct 08, 2010	Apr	CAHN
>D>	AB		1MG	A091450	004	Oct 08, 2010	Apr	CAHN
>D>	AB		1.5MG	A091450	005	Oct 08, 2010	Apr	CAHN
>A>	AB	NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Apr	CAHN
>A>	AB		0.25MG	A091450	002	Oct 08, 2010	Apr	CAHN
>A>	AB		0.5MG	A091450	003	Oct 08, 2010	Apr	CAHN
>A>	AB		1MG	A091450	004	Oct 08, 2010	Apr	CAHN
>A>	AB		1.5MG	A091450	005	Oct 08, 2010	Apr	CAHN

PRASUGREL HYDROCHLORIDE

TABLET;ORAL
PRASUGREL

@	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan	DISC
@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan	DISC

PRAVASTATIN SODIUM

TABLET;ORAL
PRAVASTATIN SODIUM

AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan	CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jan	CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan	CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan	CAHN
	@ HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan	DISC
	@	40MG	A206061	002	Nov 23, 2018	Jan	DISC
	@	80MG	A206061	003	Nov 23, 2018	Jan	DISC

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL
PRAZOSIN HYDROCHLORIDE

AB	ANI PHARMS	EQ 1MG BASE	A072577	002	May 16, 1989	Feb	CMFD
AB		EQ 2MG BASE	A072577	001	May 16, 1989	Feb	CMFD
AB		EQ 5MG BASE	A072577	003	May 16, 1989	Feb	CMFD

PREDNISOLONE

SYRUP;ORAL
PREDNISOLONE

AA	CHARTWELL RX	15MG/5ML	A040323	001	May 13, 1999	Mar	CMFD
----	--------------	----------	---------	-----	--------------	-----	------

TABLET;ORAL
PREDNISOLONE

@	RISING	5MG	A084773	001		Jan	CAHN
---	--------	-----	---------	-----	--	-----	------

PREDNISONETABLET; ORAL
PREDNISONE

	@	RISING	10MG	A089983	001	Jan 12, 1989	Jan	CAHN
	@		20MG	A085813	001		Jan	CAHN
	@		50MG	A089984	001	Jan 12, 1989	Jan	CAHN
AB		STRIDES PHARMA	10MG	A208412	001	Feb 11, 2021	Feb	NEWA
AB			20MG	A208412	002	Feb 11, 2021	Feb	NEWA

TABLET, DELAYED RELEASE; ORAL
RAYOS

>A>	+	HORIZON	1MG	N202020	001	Jul 26, 2012	Apr	CAHN
>A>	+		2MG	N202020	002	Jul 26, 2012	Apr	CAHN
>A>	+	!	5MG	N202020	003	Jul 26, 2012	Apr	CAHN
>D>	+	HORIZON PHARMA USA	1MG	N202020	001	Jul 26, 2012	Apr	CAHN
>D>	+		2MG	N202020	002	Jul 26, 2012	Apr	CAHN
>D>	+	!	5MG	N202020	003	Jul 26, 2012	Apr	CAHN

PREGABALINCAPSULE; ORAL
LYRICA

>D>	AB	+	PFIZER	25MG	N021446	001	Dec 30, 2004	Apr	CAHN
>D>	AB	+		50MG	N021446	002	Dec 30, 2004	Apr	CAHN
>D>	AB	+		75MG	N021446	003	Dec 30, 2004	Apr	CAHN
>D>	AB	+		100MG	N021446	004	Dec 30, 2004	Apr	CAHN
>D>	AB	+		150MG	N021446	005	Dec 30, 2004	Apr	CAHN
>D>	AB	+		200MG	N021446	006	Dec 30, 2004	Apr	CAHN
>D>	AB	+		225MG	N021446	007	Dec 30, 2004	Apr	CAHN
>D>	AB	+	!	300MG	N021446	008	Dec 30, 2004	Apr	CAHN
>A>	AB	+	UPJOHN	25MG	N021446	001	Dec 30, 2004	Apr	CAHN
>A>	AB	+		50MG	N021446	002	Dec 30, 2004	Apr	CAHN
>A>	AB	+		75MG	N021446	003	Dec 30, 2004	Apr	CAHN
>A>	AB	+		100MG	N021446	004	Dec 30, 2004	Apr	CAHN
>A>	AB	+		150MG	N021446	005	Dec 30, 2004	Apr	CAHN
>A>	AB	+		200MG	N021446	006	Dec 30, 2004	Apr	CAHN
>A>	AB	+		225MG	N021446	007	Dec 30, 2004	Apr	CAHN
>A>	AB	+	!	300MG	N021446	008	Dec 30, 2004	Apr	CAHN

PREGABALIN

AB		ALKEM LABS LTD	25MG	A207799	007	Sep 30, 2019	Feb	CMS1
AB			50MG	A207799	008	Sep 30, 2019	Feb	CMS1

SOLUTION; ORAL
LYRICA

>D>	AA	+	PFIZER	20MG/ML	N022488	001	Jan 04, 2010	Apr	CAHN
>A>	AA	+	UPJOHN	20MG/ML	N022488	001	Jan 04, 2010	Apr	CAHN

TABLET, EXTENDED RELEASE; ORAL

LYRICA CR

>D>		+	PFIZER	82.5MG	N209501	001	Oct 11, 2017	Apr	CAHN
>D>		+		165MG	N209501	002	Oct 11, 2017	Apr	CAHN
>D>		+	!	330MG	N209501	003	Oct 11, 2017	Apr	CAHN
>A>	AB	+	UPJOHN	82.5MG	N209501	001	Oct 11, 2017	Apr	CAHN
>A>	AB	+		165MG	N209501	002	Oct 11, 2017	Apr	CAHN
>A>	AB	+	!	330MG	N209501	003	Oct 11, 2017	Apr	CAHN

PREGABALIN

>A>	AB		ALVOGEN PINE BROOK	82.5MG	A211593	001	Apr 13, 2021	Apr	NFTG
>A>	AB			165MG	A211593	002	Apr 13, 2021	Apr	NFTG
>A>	AB			330MG	A211593	003	Apr 13, 2021	Apr	NFTG
>A>	AB		APOTEX	165MG	A213313	001	Apr 13, 2021	Apr	NFTG
>A>	AB			330MG	A213313	002	Apr 13, 2021	Apr	NFTG
>A>	AB		MSN	82.5MG	A213226	001	Apr 13, 2021	Apr	NFTG
>A>	AB			165MG	A213226	002	Apr 13, 2021	Apr	NFTG
>A>	AB			330MG	A213226	003	Apr 13, 2021	Apr	NFTG
>A>	AB		MYLAN	82.5MG	A211948	001	Apr 13, 2021	Apr	NFTG
>A>	AB		SUN PHARM	82.5MG	A211889	001	Apr 13, 2021	Apr	NFTG
>A>	AB			165MG	A211889	002	Apr 13, 2021	Apr	NFTG
>A>	AB			330MG	A211889	003	Apr 13, 2021	Apr	NFTG

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

>A>	AP		CAPLIN	EQ 5MG BASE/ML	A214379	001	Apr 22, 2021	Apr	NEWA
-----	----	--	--------	----------------	---------	-----	--------------	-----	------

PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

@	AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Feb	DISC
---	---------------	------------	---------	-----	--------------	-----	------

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

>A>	AB	ZYDUS	225MG	A214184	001	Apr 21, 2021	Apr	NEWA
>A>	AB		325MG	A214184	002	Apr 21, 2021	Apr	NEWA
>A>	AB		425MG	A214184	003	Apr 21, 2021	Apr	NEWA

>D> PROPANTHELINE BROMIDE

>D> TABLET;ORAL

>D> PROPANTHELINE BROMIDE

>D>	!	HIKMA	15MG	A080927	002		Apr	DISC
>A>	@		15MG	A080927	002		Apr	DISC

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

>D>	AB	WATSON LABS	60MG	A070178	002	Apr 23, 2018	Apr	DISC
>A>	@		60MG	A070178	002	Apr 23, 2018	Apr	DISC

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD		QUAGEN	50MG	A080154	001		Mar	CMFD
----	--	--------	------	---------	-----	--	-----	------

PYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

>D>	@	NOVITIUM PHARMA	500MG	A080157	001		Apr	CMFD
>A>	AB		500MG	A080157	001		Apr	CMFD

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

	@	MYLAN	EQ 50MG BASE	A202228	001	Feb 02, 2021	Feb	DISC
AB			EQ 50MG BASE	A202228	001	Feb 02, 2021	Jan	NEWA
	@		EQ 150MG BASE	A202228	002	Feb 02, 2021	Feb	DISC
AB			EQ 150MG BASE	A202228	002	Feb 02, 2021	Jan	NEWA
	@		EQ 200MG BASE	A202228	003	Feb 02, 2021	Feb	DISC
AB			EQ 200MG BASE	A202228	003	Feb 02, 2021	Jan	NEWA
	@		EQ 300MG BASE	A202228	004	Feb 02, 2021	Feb	DISC
AB			EQ 300MG BASE	A202228	004	Feb 02, 2021	Jan	NEWA
	@		EQ 400MG BASE	A202228	005	Feb 02, 2021	Feb	DISC
AB			EQ 400MG BASE	A202228	005	Feb 02, 2021	Jan	NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@	RISING	324MG	A089894	001	Dec 15, 1988	Jan	CAHN
---	--------	-------	---------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	WOCKHARDT LTD	EQ 150MG BASE	A075208	001	Dec 17, 1998	Jan	DISC
@		EQ 300MG BASE	A075208	002	Dec 17, 1998	Jan	DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

>D>	AB	AMNEAL	500MG	A207690	001	Mar 11, 2021	Apr	DISC
>A>	@		500MG	A207690	001	Mar 11, 2021	Apr	DISC
	AB		500MG	A207690	001	Mar 11, 2021	Mar	NEWA
>D>	AB		1GM	A207690	002	Mar 11, 2021	Apr	DISC
>A>	@		1GM	A207690	002	Mar 11, 2021	Apr	DISC
	AB		1GM	A207690	002	Mar 11, 2021	Mar	NEWA
	AB	GRAVITI PHARMS	500MG	A212889	001	Jan 28, 2021	Jan	NEWA
	AB		1GM	A212889	002	Jan 28, 2021	Jan	NEWA

TABLET, EXTENDED RELEASE;ORAL
RANOLAZINE

AB	PRAXGEN	500MG	A212781	001	Mar 23, 2020	Feb CAHN
AB		1GM	A212781	002	Mar 23, 2020	Feb CAHN

RILUZOLE

FILM;ORAL
EXSERVAN

+	!	MITSUBISHI HOLDINGS	50MG	N212640	001	Nov 22, 2019	Feb CAHN
---	---	---------------------	------	---------	-----	--------------	----------

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL
RISPERDAL

+	@	JANSSEN PHARMS	0.5MG	N021444	001	Apr 02, 2003	Feb DISC
+	@		1MG	N021444	002	Apr 02, 2003	Feb DISC
+	@		2MG	N021444	003	Apr 02, 2003	Feb DISC
+	@		3MG	N021444	004	Dec 23, 2004	Feb DISC
+	@		4MG	N021444	005	Dec 23, 2004	Feb DISC

AB	!	JUBILANT GENERICS	1MG	A090839	002	Nov 04, 2011	Feb CHRS
----	---	-------------------	-----	---------	-----	--------------	----------

RITONAVIR

CAPSULE;ORAL
RITONAVIR

@	HIKMA	100MG	A205801	001	Dec 03, 2020	Mar DISC
---	-------	-------	---------	-----	--------------	----------

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION
NAROPIN

+	@	FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	Mar CRLD
+	@		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Mar CRLD

ROPIVACAINE HYDROCHLORIDE

@	MYLAN ASI	150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Jan DISC
@		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Jan DISC

ROSUVASTATIN CALCIUM

TABLET;ORAL
CRESTOR

>D>	AB	+	IPR	5MG	N021366	002	Aug 12, 2003	Apr CPOT
>A>	AB	+		EQ 5MG BASE	N021366	002	Aug 12, 2003	Apr CPOT
>D>	AB	+		10MG	N021366	003	Aug 12, 2003	Apr CPOT
>A>	AB	+		EQ 10MG BASE	N021366	003	Aug 12, 2003	Apr CPOT
>D>	AB	+		20MG	N021366	004	Aug 12, 2003	Apr CPOT
>A>	AB	+		EQ 20MG BASE	N021366	004	Aug 12, 2003	Apr CPOT
>D>	AB	+	!	40MG	N021366	005	Aug 12, 2003	Apr CPOT
>A>	AB	+	!	EQ 40MG BASE	N021366	005	Aug 12, 2003	Apr CPOT

ROSUVASTATIN CALCIUM

>D>	AB		ACCORD HLTHCARE	5MG	A206434	001	Oct 31, 2016	Apr CPOT
>A>	AB			EQ 5MG BASE	A206434	001	Oct 31, 2016	Apr CPOT
>D>	AB			10MG	A206434	002	Oct 31, 2016	Apr CPOT
>A>	AB			EQ 10MG BASE	A206434	002	Oct 31, 2016	Apr CPOT
>D>	AB			20MG	A206434	003	Oct 31, 2016	Apr CPOT
>A>	AB			EQ 20MG BASE	A206434	003	Oct 31, 2016	Apr CPOT
>D>	AB			40MG	A206434	004	Oct 31, 2016	Apr CPOT
>A>	AB			EQ 40MG BASE	A206434	004	Oct 31, 2016	Apr CPOT
>D>	AB		ALKEM LABS LTD	5MG	A206465	001	Mar 21, 2017	Apr CPOT
>A>	AB			EQ 5MG BASE	A206465	001	Mar 21, 2017	Apr CPOT
>D>	AB			10MG	A206465	002	Mar 21, 2017	Apr CPOT
>A>	AB			EQ 10MG BASE	A206465	002	Mar 21, 2017	Apr CPOT
>D>	AB			20MG	A206465	003	Mar 21, 2017	Apr CPOT
>A>	AB			EQ 20MG BASE	A206465	003	Mar 21, 2017	Apr CPOT
>D>	AB			40MG	A206465	004	Mar 21, 2017	Apr CPOT
>A>	AB			EQ 40MG BASE	A206465	004	Mar 21, 2017	Apr CPOT
>D>	AB		ALLIED	5MG	A079168	001	Jul 19, 2016	Apr CPOT
>A>	AB			EQ 5MG BASE	A079168	001	Jul 19, 2016	Apr CPOT
>D>	AB			10MG	A079168	002	Jul 19, 2016	Apr CPOT
>A>	AB			EQ 10MG BASE	A079168	002	Jul 19, 2016	Apr CPOT
>D>	AB			20MG	A079168	003	Jul 19, 2016	Apr CPOT
>A>	AB			EQ 20MG BASE	A079168	003	Jul 19, 2016	Apr CPOT
>D>	AB			40MG	A079168	004	Jul 19, 2016	Apr CPOT
>A>	AB			EQ 40MG BASE	A079168	004	Jul 19, 2016	Apr CPOT
>D>		@	AMNEAL PHARMS CO	5MG	A208850	001	Oct 16, 2018	Apr CPOT
>A>		@		EQ 5MG BASE	A208850	001	Oct 16, 2018	Apr CPOT

TABLET;ORAL

ROSUVASTATIN CALCIUM

>D>	@	10MG	A208850	002	Oct 16, 2018	Apr	CPOT
>A>	@	EQ 10MG BASE	A208850	002	Oct 16, 2018	Apr	CPOT
>D>	@	20MG	A208850	003	Oct 16, 2018	Apr	CPOT
>A>	@	EQ 20MG BASE	A208850	003	Oct 16, 2018	Apr	CPOT
>D>	@	40MG	A208850	004	Oct 16, 2018	Apr	CPOT
>A>	@	EQ 40MG BASE	A208850	004	Oct 16, 2018	Apr	CPOT
>D>	@ APOTEX INC	5MG	A079145	001	Jul 19, 2016	Apr	CPOT
>A>	@	EQ 5MG BASE	A079145	001	Jul 19, 2016	Apr	CPOT
>D>	@	10MG	A079145	002	Jul 19, 2016	Apr	CPOT
>A>	@	EQ 10MG BASE	A079145	002	Jul 19, 2016	Apr	CPOT
>D>	@	20MG	A079145	003	Jul 19, 2016	Apr	CPOT
>A>	@	EQ 20MG BASE	A079145	003	Jul 19, 2016	Apr	CPOT
>D>	@	40MG	A079145	004	Jul 19, 2016	Apr	CPOT
>A>	@	EQ 40MG BASE	A079145	004	Jul 19, 2016	Apr	CPOT
>D> AB	AUROBINDO PHARMA LTD	5MG	A079170	001	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 5MG BASE	A079170	001	Jul 19, 2016	Apr	CPOT
>D> AB		10MG	A079170	002	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 10MG BASE	A079170	002	Jul 19, 2016	Apr	CPOT
>D> AB		20MG	A079170	003	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 20MG BASE	A079170	003	Jul 19, 2016	Apr	CPOT
>D> AB		40MG	A079170	004	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 40MG BASE	A079170	004	Jul 19, 2016	Apr	CPOT
>D> AB	BIOCON LTD	5MG	A207752	001	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 5MG BASE	A207752	001	Oct 31, 2016	Apr	CPOT
>D> AB		10MG	A207752	002	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Apr	CPOT
>D> AB		20MG	A207752	003	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Apr	CPOT
>D> AB		40MG	A207752	004	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Apr	CPOT
>D> AB	CADILA PHARMS LTD	5MG	A207453	001	Nov 23, 2016	Apr	CPOT
>A> AB		EQ 5MG BASE	A207453	001	Nov 23, 2016	Apr	CPOT
>D> AB		10MG	A207453	002	Nov 23, 2016	Apr	CPOT
>A> AB		EQ 10MG BASE	A207453	002	Nov 23, 2016	Apr	CPOT
>D> AB		20MG	A207453	003	Nov 23, 2016	Apr	CPOT
>A> AB		EQ 20MG BASE	A207453	003	Nov 23, 2016	Apr	CPOT
>D> AB		40MG	A207453	004	Nov 23, 2016	Apr	CPOT
>A> AB		EQ 40MG BASE	A207453	004	Nov 23, 2016	Apr	CPOT
>D> AB	CHANGZHOU PHARM	5MG	A207408	001	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 5MG BASE	A207408	001	Oct 31, 2016	Apr	CPOT
>D> AB		10MG	A207408	002	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 10MG BASE	A207408	002	Oct 31, 2016	Apr	CPOT
>D> AB		20MG	A207408	003	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 20MG BASE	A207408	003	Oct 31, 2016	Apr	CPOT
>D> AB		40MG	A207408	004	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 40MG BASE	A207408	004	Oct 31, 2016	Apr	CPOT
>D> AB	GLENMARK PHARMS	5MG	A079172	001	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 5MG BASE	A079172	001	Jul 19, 2016	Apr	CPOT
>D> AB		10MG	A079172	002	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 10MG BASE	A079172	002	Jul 19, 2016	Apr	CPOT
>D> AB		20MG	A079172	003	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 20MG BASE	A079172	003	Jul 19, 2016	Apr	CPOT
>D> AB		40MG	A079172	004	Jul 19, 2016	Apr	CPOT
>A> AB		EQ 40MG BASE	A079172	004	Jul 19, 2016	Apr	CPOT
>D> AB	HETERO LABS LTD V	5MG	A207616	001	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 5MG BASE	A207616	001	Oct 31, 2016	Apr	CPOT
>D> AB		10MG	A207616	002	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 10MG BASE	A207616	002	Oct 31, 2016	Apr	CPOT
>D> AB		20MG	A207616	003	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 20MG BASE	A207616	003	Oct 31, 2016	Apr	CPOT
>D> AB		40MG	A207616	004	Oct 31, 2016	Apr	CPOT
>A> AB		EQ 40MG BASE	A207616	004	Oct 31, 2016	Apr	CPOT
>D> AB	INVENTIA	5MG	A207653	001	Feb 05, 2021	Apr	CPOT
>A> AB		EQ 5MG BASE	A207653	001	Feb 05, 2021	Apr	CPOT
AB		5MG	A207653	001	Feb 05, 2021	Jan	NEWA
>D> AB		10MG	A207653	002	Feb 05, 2021	Apr	CPOT
>A> AB		EQ 10MG BASE	A207653	002	Feb 05, 2021	Apr	CPOT
AB		10MG	A207653	002	Feb 05, 2021	Jan	NEWA
>D> AB		20MG	A207653	003	Feb 05, 2021	Apr	CPOT
>A> AB		EQ 20MG BASE	A207653	003	Feb 05, 2021	Apr	CPOT
AB		20MG	A207653	003	Feb 05, 2021	Jan	NEWA
>D> AB		40MG	A207653	004	Feb 05, 2021	Apr	CPOT

TABLET;ORAL
ROSUVASTATIN CALCIUM

>A>	AB		EQ 40MG BASE	A207653	004	Feb 05,	2021	Apr	CPOT
	AB		40MG	A207653	004	Feb 05,	2021	Jan	NEWA
>D>	AB	LUPIN	5MG	A205587	001	Jul 31,	2017	Apr	CPOT
>A>	AB		EQ 5MG BASE	A205587	001	Jul 31,	2017	Apr	CPOT
>D>	AB		10MG	A205587	002	Jul 31,	2017	Apr	CPOT
>A>	AB		EQ 10MG BASE	A205587	002	Jul 31,	2017	Apr	CPOT
>D>	AB		20MG	A205587	003	Jul 31,	2017	Apr	CPOT
>A>	AB		EQ 20MG BASE	A205587	003	Jul 31,	2017	Apr	CPOT
>D>	AB		40MG	A205587	004	Jul 31,	2017	Apr	CPOT
>A>	AB		EQ 40MG BASE	A205587	004	Jul 31,	2017	Apr	CPOT
>D>	AB	MSN	5MG	A208898	001	Nov 22,	2017	Apr	CPOT
>A>	AB		EQ 5MG BASE	A208898	001	Nov 22,	2017	Apr	CPOT
>D>	AB		10MG	A208898	002	Nov 22,	2017	Apr	CPOT
>A>	AB		EQ 10MG BASE	A208898	002	Nov 22,	2017	Apr	CPOT
>D>	AB		20MG	A208898	003	Nov 22,	2017	Apr	CPOT
>A>	AB		EQ 20MG BASE	A208898	003	Nov 22,	2017	Apr	CPOT
>D>	AB		40MG	A208898	004	Nov 22,	2017	Apr	CPOT
>A>	AB		EQ 40MG BASE	A208898	004	Nov 22,	2017	Apr	CPOT
>D>		@ MYLAN	5MG	A079161	001	Jul 19,	2016	Apr	CPOT
>A>		@	EQ 5MG BASE	A079161	001	Jul 19,	2016	Apr	CPOT
>D>		@	10MG	A079161	002	Jul 19,	2016	Apr	CPOT
>A>		@	EQ 10MG BASE	A079161	002	Jul 19,	2016	Apr	CPOT
>D>		@	20MG	A079161	003	Jul 19,	2016	Apr	CPOT
>A>		@	EQ 20MG BASE	A079161	003	Jul 19,	2016	Apr	CPOT
>D>		@	40MG	A079161	004	Jul 19,	2016	Apr	CPOT
>A>		@	EQ 40MG BASE	A079161	004	Jul 19,	2016	Apr	CPOT
>D>	AB	RENATA	5MG	A207062	001	Oct 31,	2016	Apr	CPOT
>A>	AB		EQ 5MG BASE	A207062	001	Oct 31,	2016	Apr	CPOT
>D>	AB		10MG	A207062	002	Oct 31,	2016	Apr	CPOT
>A>	AB		EQ 10MG BASE	A207062	002	Oct 31,	2016	Apr	CPOT
>D>	AB		20MG	A207062	003	Oct 31,	2016	Apr	CPOT
>A>	AB		EQ 20MG BASE	A207062	003	Oct 31,	2016	Apr	CPOT
>D>	AB		40MG	A207062	004	Oct 31,	2016	Apr	CPOT
>A>	AB		EQ 40MG BASE	A207062	004	Oct 31,	2016	Apr	CPOT
>D>	AB	SANDOZ INC	5MG	A079171	001	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 5MG BASE	A079171	001	Jul 19,	2016	Apr	CPOT
>D>	AB		10MG	A079171	002	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 10MG BASE	A079171	002	Jul 19,	2016	Apr	CPOT
>D>	AB		20MG	A079171	003	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 20MG BASE	A079171	003	Jul 19,	2016	Apr	CPOT
>D>	AB		40MG	A079171	004	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 40MG BASE	A079171	004	Jul 19,	2016	Apr	CPOT
>D>		@ SCIEGEN PHARMS INC	5MG	A206381	001	Apr 24,	2019	Apr	CPOT
>A>		@	EQ 5MG BASE	A206381	001	Apr 24,	2019	Apr	CPOT
>D>		@	10MG	A206381	002	Apr 24,	2019	Apr	CPOT
>A>		@	EQ 10MG BASE	A206381	002	Apr 24,	2019	Apr	CPOT
>D>		@	20MG	A206381	003	Apr 24,	2019	Apr	CPOT
>A>		@	EQ 20MG BASE	A206381	003	Apr 24,	2019	Apr	CPOT
>D>		@	40MG	A206381	004	Apr 24,	2019	Apr	CPOT
>A>		@	EQ 40MG BASE	A206381	004	Apr 24,	2019	Apr	CPOT
>D>	AB	SHANDONG	5MG	A207375	001	May 07,	2019	Apr	CPOT
>A>	AB		EQ 5MG BASE	A207375	001	May 07,	2019	Apr	CPOT
>D>	AB		10MG	A207375	002	May 07,	2019	Apr	CPOT
>A>	AB		EQ 10MG BASE	A207375	002	May 07,	2019	Apr	CPOT
>D>	AB		20MG	A207375	003	May 07,	2019	Apr	CPOT
>A>	AB		EQ 20MG BASE	A207375	003	May 07,	2019	Apr	CPOT
>D>	AB		40MG	A207375	004	May 07,	2019	Apr	CPOT
>A>	AB		EQ 40MG BASE	A207375	004	May 07,	2019	Apr	CPOT
>D>	AB	SUN PHARM	5MG	A079169	001	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 5MG BASE	A079169	001	Jul 19,	2016	Apr	CPOT
>D>	AB		10MG	A079169	002	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 10MG BASE	A079169	002	Jul 19,	2016	Apr	CPOT
>D>	AB		20MG	A079169	003	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 20MG BASE	A079169	003	Jul 19,	2016	Apr	CPOT
>D>	AB		40MG	A079169	004	Jul 19,	2016	Apr	CPOT
>A>	AB		EQ 40MG BASE	A079169	004	Jul 19,	2016	Apr	CPOT
>D>		@ SUNSHINE	5MG	A210667	001	Apr 01,	2020	Apr	CPOT
>A>		@	EQ 5MG BASE	A210667	001	Apr 01,	2020	Apr	CPOT
>D>		@	10MG	A210667	002	Apr 01,	2020	Apr	CPOT
>A>		@	EQ 10MG BASE	A210667	002	Apr 01,	2020	Apr	CPOT
>D>		@	20MG	A210667	003	Apr 01,	2020	Apr	CPOT
>A>		@	EQ 20MG BASE	A210667	003	Apr 01,	2020	Apr	CPOT

TABLET;ORAL

ROSUVASTATIN CALCIUM

>D>	@		40MG	A210667	004	Apr 01, 2020	Apr	CPOT
>A>	@		EQ 40MG BASE	A210667	004	Apr 01, 2020	Apr	CPOT
>D>	@	TEVA PHARMS USA	5MG	A079166	001	Jul 19, 2016	Apr	CPOT
>A>	@		EQ 5MG BASE	A079166	001	Jul 19, 2016	Apr	CPOT
>D>	@		10MG	A079166	002	Jul 19, 2016	Apr	CPOT
>A>	@		EQ 10MG BASE	A079166	002	Jul 19, 2016	Apr	CPOT
>D>	@		20MG	A079166	003	Jul 19, 2016	Apr	CPOT
>A>	@		EQ 20MG BASE	A079166	003	Jul 19, 2016	Apr	CPOT
>D>	@		40MG	A079166	004	Jul 19, 2016	Apr	CPOT
>A>	@		EQ 40MG BASE	A079166	004	Jul 19, 2016	Apr	CPOT
>D>	AB	TORRENT	5MG	A201619	001	Oct 31, 2016	Apr	CPOT
>A>	AB		EQ 5MG BASE	A201619	001	Oct 31, 2016	Apr	CPOT
>D>	AB		10MG	A201619	002	Oct 31, 2016	Apr	CPOT
>A>	AB		EQ 10MG BASE	A201619	002	Oct 31, 2016	Apr	CPOT
>D>	AB		20MG	A201619	003	Oct 31, 2016	Apr	CPOT
>A>	AB		EQ 20MG BASE	A201619	003	Oct 31, 2016	Apr	CPOT
>D>	AB		40MG	A201619	004	Oct 31, 2016	Apr	CPOT
>A>	AB		EQ 40MG BASE	A201619	004	Oct 31, 2016	Apr	CPOT
>D>	@	UMEDICA LABS PVT LTD	5MG	A207626	001	Apr 09, 2019	Apr	CPOT
>A>	@		EQ 5MG BASE	A207626	001	Apr 09, 2019	Apr	CPOT
>D>	@		10MG	A207626	002	Apr 09, 2019	Apr	CPOT
>A>	@		EQ 10MG BASE	A207626	002	Apr 09, 2019	Apr	CPOT
>D>	@		20MG	A207626	003	Apr 09, 2019	Apr	CPOT
>A>	@		EQ 20MG BASE	A207626	003	Apr 09, 2019	Apr	CPOT
>D>	@		40MG	A207626	004	Apr 09, 2019	Apr	CPOT
>A>	@		EQ 40MG BASE	A207626	004	Apr 09, 2019	Apr	CPOT
>D>	AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	CPOT
>A>	AB		EQ 5MG BASE	A079167	001	Apr 29, 2016	Apr	CPOT
>D>	AB		10MG	A079167	002	Apr 29, 2016	Apr	CPOT
>A>	AB		EQ 10MG BASE	A079167	002	Apr 29, 2016	Apr	CPOT
>D>	AB		20MG	A079167	003	Apr 29, 2016	Apr	CPOT
>A>	AB		EQ 20MG BASE	A079167	003	Apr 29, 2016	Apr	CPOT
>D>	AB		40MG	A079167	004	Apr 29, 2016	Apr	CPOT
>A>	AB		EQ 40MG BASE	A079167	004	Apr 29, 2016	Apr	CPOT
>D>	AB	ZHEJIANG YONGTAI	5MG	A212059	001	Nov 04, 2019	Apr	CPOT
>A>	AB		EQ 5MG BASE	A212059	001	Nov 04, 2019	Apr	CPOT
	AB		5MG	A212059	001	Nov 04, 2019	Feb	CMFD
>D>	AB		10MG	A212059	002	Nov 04, 2019	Apr	CPOT
>A>	AB		EQ 10MG BASE	A212059	002	Nov 04, 2019	Apr	CPOT
	AB		10MG	A212059	002	Nov 04, 2019	Feb	CMFD
>D>	AB		20MG	A212059	003	Nov 04, 2019	Apr	CPOT
>A>	AB		EQ 20MG BASE	A212059	003	Nov 04, 2019	Apr	CPOT
	AB		20MG	A212059	003	Nov 04, 2019	Feb	CMFD
>D>	AB		40MG	A212059	004	Nov 04, 2019	Apr	CPOT
>A>	AB		EQ 40MG BASE	A212059	004	Nov 04, 2019	Apr	CPOT
	AB		40MG	A212059	004	Nov 04, 2019	Feb	CMFD
>D>	@	ZYDUS PHARMS	5MG	A206513	001	Mar 01, 2019	Apr	CPOT
>A>	@		EQ 5MG BASE	A206513	001	Mar 01, 2019	Apr	CPOT
>D>	@		10MG	A206513	002	Mar 01, 2019	Apr	CPOT
>A>	@		EQ 10MG BASE	A206513	002	Mar 01, 2019	Apr	CPOT
>D>	@		20MG	A206513	003	Mar 01, 2019	Apr	CPOT
>A>	@		EQ 20MG BASE	A206513	003	Mar 01, 2019	Apr	CPOT
>D>	@		40MG	A206513	004	Mar 01, 2019	Apr	CPOT
>A>	@		EQ 40MG BASE	A206513	004	Mar 01, 2019	Apr	CPOT

RUFINAMIDE

SUSPENSION;ORAL

RUFINAMIDE

AB		ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb	NEWA
----	--	----------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

RUFINAMIDE

>A>	AB	HETERO LABS LTD III	200MG	A204993	001	May 11, 2021	Apr	NEWA
>A>	AB		400MG	A204993	002	May 11, 2021	Apr	NEWA

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

SAPROPTERIN DIHYDROCHLORIDE

AB		DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar	NEWA
----	--	-----------	--------------	---------	-----	--------------	-----	------

SCOPOLAMINESYSTEM; TRANSDERMAL
TRANSDERM SCOP

AB +! BAXTER HLTHCARE CORP 1MG/72HR N017874 001 Mar CAHN

SELEGILINE HYDROCHLORIDECAPSULE; ORAL
SELEGILINE HYDROCHLORIDE>D> @ NOVITIUM PHARMA 5MG A075352 001 Nov 30, 1998 Apr CMFD
>A> AB 5MG A075352 001 Nov 30, 1998 Apr CMFDSELENIOS ACIDSOLUTION; INTRAVENOUS
SELENIOS ACID+! AM REGENT EQ 60MCG BASE/ML (EQ 60MCG
BASE/ML) N209379 002 Jan 25, 2021 Jan NEWASELEXIPAGTABLET; ORAL
UPTRAVI+ ACTELION 0.2MG N207947 001 Dec 21, 2015 Feb CAHN
+! 0.4MG N207947 002 Dec 21, 2015 Feb CAHN
+ 0.6MG N207947 003 Dec 21, 2015 Feb CAHN
+ 0.8MG N207947 004 Dec 21, 2015 Feb CAHN
+ 1MG N207947 005 Dec 21, 2015 Feb CAHN
+ 1.2MG N207947 006 Dec 21, 2015 Feb CAHN
+ 1.4MG N207947 007 Dec 21, 2015 Feb CAHN
+ 1.6MG N207947 008 Dec 21, 2015 Feb CAHNSELINEXORTABLET; ORAL
XPOVIO>A> + KARYOPHARM THERAPS 40MG N212306 002 Apr 15, 2021 Apr NEWA
>A> + 50MG N212306 003 Apr 15, 2021 Apr NEWA
>A> + 60MG N212306 004 Apr 15, 2021 Apr NEWASERTRALINE HYDROCHLORIDETABLET; ORAL
SERTRALINE HYDROCHLORIDEAB ACI HEALTHCARE LTD EQ 25MG BASE A076881 001 Feb 06, 2007 Jan CMFD
AB EQ 50MG BASE A076881 002 Feb 06, 2007 Jan CMFD
AB EQ 100MG BASE A076881 003 Feb 06, 2007 Jan CMFD
>A> AB ASCENT PHARMS INC EQ 25MG BASE A214790 001 May 03, 2021 Apr NEWA
>A> AB EQ 50MG BASE A214790 002 May 03, 2021 Apr NEWA
>A> AB EQ 100MG BASE A214790 003 May 03, 2021 Apr NEWA
>D> @ SCIEGEN PHARMS INC EQ 25MG BASE A076442 001 Apr 30, 2007 Apr CMFD
>A> AB EQ 25MG BASE A076442 001 Apr 30, 2007 Apr CMFD
>D> @ EQ 50MG BASE A076442 002 Apr 30, 2007 Apr CMFD
>A> AB EQ 50MG BASE A076442 002 Apr 30, 2007 Apr CMFD
>D> @ EQ 100MG BASE A076442 003 Apr 30, 2007 Apr CMFD
>A> AB EQ 100MG BASE A076442 003 Apr 30, 2007 Apr CMFDSEVELAMER CARBONATEFOR SUSPENSION; ORAL
SEVELAMER CARBONATE@ IMPAX 800MG/PACKET A211316 001 Nov 20, 2020 Mar DISC
@ 2.4GM/PACKET A211316 002 Nov 20, 2020 Mar DISCTABLET; ORAL
SEVELAMER CARBONATEAB ANXIN 800MG A212970 001 Apr 09, 2020 Mar CMFD
AB LUPIN LTD 800MG A204600 001 Jan 14, 2021 Jan NEWASILDENAFIL CITRATEFOR SUSPENSION; ORAL
SILDENAFIL CITRATE>A> AB APPCO EQ 10MG BASE/ML A213814 001 Apr 29, 2021 Apr NEWA
>A> AB HETERO LABS LTD V EQ 10MG BASE/ML A213014 001 May 11, 2021 Apr NEWATABLET; ORAL
SILDENAFIL CITRATEAB REYOUNG EQ 25MG BASE A208494 001 Jun 12, 2020 Mar CAHN
AB EQ 50MG BASE A208494 002 Jun 12, 2020 Mar CAHN

TABLET;ORAL
SILDENAFIL CITRATE

AB EQ 100MG BASE A208494 003 Jun 12, 2020 Mar CAHN

SIMVASTATIN

TABLET;ORAL
SIMVASTATIN

AB BIOCON PHARMA 5MG A078034 001 Dec 20, 2006 Mar CAHN
 AB 10MG A078034 002 Dec 20, 2006 Mar CAHN
 AB 20MG A078034 003 Dec 20, 2006 Mar CAHN
 AB 40MG A078034 004 Dec 20, 2006 Mar CAHN
 AB 80MG A078034 005 Dec 20, 2006 Mar CAHN
 >D> @ HISUN PHARM HANGZHOU 10MG A206557 001 Nov 13, 2017 Apr CMFD
 >A> AB 10MG A206557 001 Nov 13, 2017 Apr CMFD
 >D> @ 20MG A206557 002 Nov 13, 2017 Apr CMFD
 >A> AB 20MG A206557 002 Nov 13, 2017 Apr CMFD
 >D> @ 40MG A206557 003 Nov 13, 2017 Apr CMFD
 >A> AB 40MG A206557 003 Nov 13, 2017 Apr CMFD
 >D> @ 80MG A206557 004 Nov 13, 2017 Apr CMFD
 >A> AB 80MG A206557 004 Nov 13, 2017 Apr CMFD
 ZOCOR
 AB + ORGANON 5MG N019766 001 Dec 23, 1991 Feb CAHN
 AB + 10MG N019766 002 Dec 23, 1991 Feb CAHN
 AB + 20MG N019766 003 Dec 23, 1991 Feb CAHN
 AB + 40MG N019766 004 Dec 23, 1991 Feb CAHN
 AB +! 80MG N019766 005 Jul 10, 1998 Feb CAHN

SINECATECHINS

OINTMENT;TOPICAL
VEREGEN

>A> +! ANI PHARMS 15% N021902 001 Oct 31, 2006 Apr CAHN
 >D> +! FOUGERA PHARMS INC 15% N021902 001 Oct 31, 2006 Apr CAHN

SIROLIMUS

TABLET;ORAL
SIROLIMUS

AB ALKEM LABS LTD 0.5MG A214753 001 Mar 12, 2021 Mar NEWA
 AB 1MG A214753 002 Mar 12, 2021 Mar NEWA
 AB 2MG A214753 003 Mar 12, 2021 Mar NEWA

SODIUM ACETATE

INJECTABLE;INJECTION
SODIUM ACETATE

>A> AP MILLA PHARMS 2MEQ/ML A214805 001 May 04, 2021 Apr NFTG

SODIUM CHLORIDE

INJECTABLE;INJECTION
SODIUM CHLORIDE 23.4%

>A> FRESENIUS KABI USA 234MG/ML A212248 001 Apr 28, 2021 Apr NFTG

SOLUTION;INTRAVENOUS
SODIUM CHLORIDE 14.6%

>A> FRESENIUS KABI USA 50MEQ/20ML (2.5MEQ/ML) A212070 001 Apr 28, 2021 Apr NFTG
 >A> AP 100MEQ/40ML (2.5MEQ/ML) A212070 002 Apr 28, 2021 Apr NFTG

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

AP NUKEMED 10-200mCi/ML A203912 001 Apr 22, 2015 Jan CAHN
 >D> AP UCSF RODIOPHARM 10-200mCi/ML A204437 001 Mar 13, 2014 Apr DISC
 >A> @ 10-200mCi/ML A204437 001 Mar 13, 2014 Apr DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB NOVEL LABS INC 0.398GM;1.102GM A079247 001 Dec 30, 2011 Jan CMFD
 OSMOPREP
 AB +! SALIX PHARMS 0.398GM;1.102GM N021892 001 Mar 16, 2006 Jan CTEC

SODIUM POLYSTYRENE SULFONATE

	POWDER;ORAL, RECTAL							
	KIONEX							
AA	ANI PHARMS	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN	
AA	L PERRIGO CO	454GM/BOT	A040029	001	Feb 06, 1998	Mar	CAHN	
	SUSPENSION;ORAL, RECTAL							
	KIONEX							
	@ ANI PHARMS	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN	
	@ L PERRIGO CO	15GM/60ML	A040028	001	Sep 17, 2007	Mar	CAHN	
	SODIUM POLYSTYRENE SULFONATE							
	@ ANI PHARMS	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN	
	@ L PERRIGO CO	15GM/60ML	A090590	001	May 13, 2011	Mar	CAHN	

SOLIFENACIN SUCCINATE

	TABLET;ORAL							
	SOLIFENACIN SUCCINATE							
	@ ZYDUS PHARMS	5MG	A207721	001	Oct 19, 2020	Mar	DISC	
	@	10MG	A207721	002	Oct 19, 2020	Mar	DISC	

SOTALOL HYDROCHLORIDE

	TABLET;ORAL							
	SOTALOL HYDROCHLORIDE							
	@ MYLAN	80MG	A077616	001	Feb 07, 2007	Feb	DISC	
	@	120MG	A077616	002	Feb 07, 2007	Feb	DISC	
	@	160MG	A077616	003	Feb 07, 2007	Feb	DISC	

STERILE WATER FOR INJECTION

	LIQUID;N/A							
	STERILE WATER FOR INJECTION							
!	NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Jan	NEWA	

SUCCINYLCHOLINE CHLORIDE

	INJECTABLE;INJECTION							
	SUCCINYLCHOLINE CHLORIDE							
AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	Mar	CMFD	
>D>	@ HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Apr	CMFD	
>A>	AP	20MG/ML	A213229	001	Jun 12, 2020	Apr	CMFD	
	@	20MG/ML	A213229	001	Jun 12, 2020	Feb	DISC	
AP	SAGENT PHARMS INC	20MG/ML	A215022	001	Mar 29, 2021	Mar	NEWA	

SULFAMETHOXAZOLE

	TABLET;ORAL							
	SULFAMETHOXAZOLE							
	@ RISING	500MG	A085844	001		Jan	CAHN	

SULFASALAZINE

	TABLET;ORAL							
	AZULFIDINE							
AB	+! PFIZER	500MG	N007073	001		Mar	CAHN	
	TABLET, DELAYED RELEASE;ORAL							
	AZULFIDINE EN-TABS							
AB	+! PFIZER	500MG	N007073	002	Apr 06, 1983	Mar	CAHN	

SULFISOXAZOLE

	TABLET;ORAL							
	SULFISOXAZOLE							
	@ RISING	500MG	A085628	001		Jan	CAHN	

SUMATRIPTAN

	SPRAY;NASAL							
	SUMATRIPTAN							
AB	CIPLA	20MG/SPRAY	A214209	001	Feb 22, 2021	Feb	NEWA	
AB	FLORIDA	20MG/SPRAY	A208967	001	Feb 17, 2021	Mar	CAHN	
AB	PHARMASERVE NW	20MG/SPRAY	A208967	001	Feb 17, 2021	Feb	NEWA	

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

@ MYLAN ASI

EQ 6MG BASE/0.5ML (EQ 12MG
BASE/ML)

A090641 001 Jul 28, 2010 Jan DISC

SPRAY;NASAL
SUMATRIPTAN

AB PERRIGO UK FINCO

5MG/SPRAY

A213465 002 Sep 21, 2020 Feb CMS1

TACROLIMUSCAPSULE;ORAL
TACROLIMUS

>D> AB CONCORD BIOTECH LTD

EQ 0.5MG BASE

A213112 001 Nov 10, 2020 Apr DISC

>A>

@

EQ 0.5MG BASE

A213112 001 Nov 10, 2020 Apr DISC

TADALAFILTABLET;ORAL
CIALIS

AB1 + LILLY

2.5MG

N021368 004 Jan 07, 2008 Feb CTEC

AB1 +

5MG

N021368 001 Nov 21, 2003 Feb CTEC

AB1 +

10MG

N021368 002 Nov 21, 2003 Feb CTEC

TADALAFIL

AB1 ACCORD HLTHCARE

2.5MG

A209167 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209167 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209167 003 Oct 23, 2019 Feb CTEC

AB1 AJANTA PHARMA LTD

2.5MG

A209654 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209654 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209654 003 Mar 26, 2019 Feb CTEC

AB1 ALEMBIC PHARMS LTD

2.5MG

A204809 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A204809 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A204809 003 Mar 26, 2019 Feb CTEC

AB1 AMNEAL PHARMS CO

2.5MG

A209744 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209744 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209744 003 Mar 26, 2019 Feb CTEC

AB1 AUROBINDO PHARMA LTD

2.5MG

A206285 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A206285 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A206285 003 Mar 26, 2019 Feb CTEC

AB1 CIPLA

2.5MG

A209539 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209539 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209539 003 Mar 26, 2019 Feb CTEC

AB1 DR REDDYS LABS LTD

2.5MG

A210069 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A210069 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A210069 003 Mar 26, 2019 Feb CTEC

@ GLENMARK PHARMS LTD

2.5MG

A210716 001 Dec 29, 2020 Feb DISC

@

5MG

A210716 002 Dec 29, 2020 Feb DISC

@

10MG

A210716 003 Dec 29, 2020 Feb DISC

@

20MG

A210716 004 Dec 29, 2020 Feb DISC

AB1 HETERO LABS LTD III

2.5MG

A209908 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A209908 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A209908 003 Mar 26, 2019 Feb CTEC

AB1 LUPIN LTD

2.5MG

A210567 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A210567 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A210567 003 Mar 26, 2019 Feb CTEC

AB1 MACLEODS PHARMS LTD

2.5MG

A207244 001 Oct 07, 2019 Feb CTEC

AB1

5MG

A207244 002 Oct 07, 2019 Feb CTEC

AB1

10MG

A207244 003 Oct 07, 2019 Feb CTEC

AB1 MYLAN

2.5MG

A206956 001 Apr 29, 2019 Feb CTEC

AB1

5MG

A206957 001 Apr 29, 2019 Feb CTEC

AB1

10MG

A206956 002 Apr 29, 2019 Feb CTEC

AB1 QILU

2.5MG

A210420 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A210420 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A210420 003 Mar 26, 2019 Feb CTEC

AB1 SUN PHARM

2.5MG

A208934 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A208934 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A208934 003 Mar 26, 2019 Feb CTEC

AB1 SUNSHINE

2.5MG

A211335 001 Mar 26, 2019 Feb CTEC

AB1

5MG

A211335 002 Mar 26, 2019 Feb CTEC

AB1

10MG

A211335 003 Mar 26, 2019 Feb CTEC

AB1 TEVA PHARMS USA

2.5MG

A090141 001 May 22, 2018 Feb CTEC

AB1

5MG

A090141 002 May 22, 2018 Feb CTEC

AB1

10MG

A090141 003 May 22, 2018 Feb CTEC

AB1 TORRENT

2.5MG

A211839 001 Mar 26, 2019 Feb CTEC

TABLET;ORAL
TADALAFIL

AB1		5MG	A211839	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A211839	003	Mar 26, 2019	Feb CTEC
AB1	UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
AB1		5MG	A211298	002	Oct 23, 2020	Feb CTEC
AB1		10MG	A211298	003	Oct 23, 2020	Feb CTEC
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Feb CTEC
AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
AB1		5MG	A208824	002	Oct 27, 2020	Feb CTEC
AB1		10MG	A208824	003	Oct 27, 2020	Feb CTEC
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206693	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206693	003	Mar 26, 2019	Feb CTEC

TAVABOROLE

SOLUTION;TOPICAL
TAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan NEWA
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Feb CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan NEWA
>A> AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr NEWA

TELMISARTAN

TABLET;ORAL
TELMISARTAN

AB	CELLTRION	20MG	A078710	001	Jan 08, 2014	Feb CMFD
AB		40MG	A078710	002	Jan 08, 2014	Feb CMFD
AB		80MG	A078710	003	Jan 08, 2014	Feb CMFD

TEMOZOLOMIDE

CAPSULE;ORAL
TEMOZOLOMIDE

@	HERITAGE	5MG	A078879	001	Mar 01, 2010	Feb CAHN
@		20MG	A078879	002	Mar 01, 2010	Feb CAHN
@		100MG	A078879	003	Mar 01, 2010	Feb CAHN
@		140MG	A078879	005	Mar 01, 2010	Feb CAHN
@		180MG	A078879	006	Mar 01, 2010	Feb CAHN
@		250MG	A078879	004	Mar 01, 2010	Feb CAHN
@	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Jan DISC
@		20MG	A203959	002	Apr 18, 2017	Jan DISC
@		100MG	A203959	003	Apr 18, 2017	Jan DISC
@		140MG	A203959	004	Apr 18, 2017	Jan DISC
@		250MG	A203959	005	Apr 18, 2017	Jan DISC

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL
TEPMETKO

+!	EMD SERONO INC	EQ 225MG BASE	N214096	001	Feb 03, 2021	Feb NEWA
----	----------------	---------------	---------	-----	--------------	----------

TERIFLUNOMIDE

TABLET;ORAL
TERIFLUNOMIDE

@	IMPAX	14MG	A209677	001	Jun 17, 2020	Feb DISC
---	-------	------	---------	-----	--------------	----------

TESTOSTERONE

GEL;TRANSDERMAL
TESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A204570	002	Jul 17, 2020	Feb NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A204570	003	Jul 17, 2020	Feb NEWA

GEL, METERED;TRANSDERMAL
TESTOSTERONE

AB	ALBOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Feb NEWA
----	----------------------	----------------------------------	---------	-----	--------------	----------

TESTOSTERONE CYPIONATE

	INJECTABLE; INJECTION					
	DEPO-TESTOSTERONE					
	@ PFIZER	50MG/ML	A 085635	001		Mar CAHN
AO	!	100MG/ML	A 085635	002		Mar CAHN
AO	!	200MG/ML	A 085635	003		Mar CAHN

THIAMINE HYDROCHLORIDE

	INJECTABLE; INJECTION					
	THIAMINE HYDROCHLORIDE					
>D>	@ WEST-WARD PHARMS INT	100MG/ML	A 080575	001		Apr CMFD
>A>	AP	100MG/ML	A 080575	001		Apr CMFD

THIORIDAZINE HYDROCHLORIDE

	TABLET; ORAL					
	THIORIDAZINE HYDROCHLORIDE					
	MYLAN	10MG	A 088004	002	Mar 15, 1983	Jan CTEC
		25MG	A 088004	003	Mar 15, 1983	Jan CTEC
		50MG	A 088004	004	Mar 15, 1983	Jan CTEC
	!	100MG	A 088004	001	Nov 18, 1983	Jan CTEC
	@ SUN PHARM INDUSTRIES	10MG	A 089953	004	Aug 01, 1986	Jan DISC
	@	25MG	A 089953	003	Aug 01, 1986	Jan DISC
	@	50MG	A 089953	002	Aug 01, 1986	Jan DISC
	@	100MG	A 089953	001	Oct 07, 1988	Jan DISC

THIOTEPA

	POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL					
	THIOTEPA					
AP	GLAND PHARMA LTD	15MG/VIAL	A 214222	001	Mar 08, 2021	Feb NEWA

TIAGABINE HYDROCHLORIDE

	TABLET; ORAL					
	TIAGABINE HYDROCHLORIDE					
	@ WILSHIRE PHARMS INC	2MG	A 206857	001	Oct 13, 2017	Jan DISC
	@	4MG	A 206857	002	Oct 13, 2017	Jan DISC
	@	12MG	A 206857	003	Oct 13, 2017	Jan DISC
	@	16MG	A 206857	004	Oct 13, 2017	Jan DISC

TIMOLOL MALEATE

	SOLUTION, GEL FORMING/DROPS; OPHTHALMIC							
	TIMOLOL MALEATE							
>D>	AB	ALEMbic PHARMS LTD	EQ 0.25% BASE	A 212942	001	Oct 22, 2020	Apr CHRS	
>A>	AB	!	EQ 0.25% BASE	A 212942	001	Oct 22, 2020	Apr CHRS	
>D>	AB		EQ 0.5% BASE	A 212942	002	Oct 22, 2020	Apr CHRS	
>A>	AB	!	EQ 0.5% BASE	A 212942	002	Oct 22, 2020	Apr CHRS	
	TIMOPTIC-XE							
>D>	AB	+!	VALEANT PHARMS LLC	EQ 0.25% BASE	N 020330	001	Nov 04, 1993	Apr CHRS
>A>	AB	+		EQ 0.25% BASE	N 020330	001	Nov 04, 1993	Apr CHRS
>D>	AB	+!		EQ 0.5% BASE	N 020330	002	Nov 04, 1993	Apr CHRS
>A>	AB	+		EQ 0.5% BASE	N 020330	002	Nov 04, 1993	Apr CHRS
	SOLUTION/DROPS; OPHTHALMIC							
	TIMOLOL MALEATE							
>A>	AT	MANKIND PHARMA	EQ 0.25% BASE	A 078771	001	Sep 28, 2009	Apr CAHN	
>A>	AT1		EQ 0.5% BASE	A 078771	002	Sep 28, 2009	Apr CAHN	
>D>	AT	WOCKHARDT	EQ 0.25% BASE	A 078771	001	Sep 28, 2009	Apr CAHN	
>D>	AT1		EQ 0.5% BASE	A 078771	002	Sep 28, 2009	Apr CAHN	

TIOPRONIN

	TABLET; ORAL						
	TIOPRONIN						
>A>	AB	TEVA PHARMS USA INC	100MG	A 214326	001	Apr 26, 2021	Apr NFTG

TIOTROPIUM BROMIDE

	SPRAY, METERED; INHALATION						
	SPIRIVA RESPIMAT						
	+!	BOEHRINGER INGELHEIM	EQ 0.00125MG BASE/INH	N 021936	002	Sep 15, 2015	Mar CHRS

TIROFIBAN HYDROCHLORIDE

>D>	INJECTABLE; INJECTION							
>D>	AGGRASTAT							
>D>	+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr	CDFR	
>D>	@	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr	CDFR	
>A>	SOLUTION; INTRAVENOUS							
>A>	AGGRASTAT							
>A>	+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr	CDFR	
>A>	@	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr	CDFR	
>A>	TIROFIBAN HYDROCHLORIDE							
>A> AP	GLAND PHARMA LTD	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A206888	001	Apr 08, 2021	Apr	NFTG	

TIVOZANIB HYDROCHLORIDECAPSULE; ORAL
FOTIVDA

+ AVEO PHARMS	EQ 0.89MG BASE	N212904	001	Mar 10, 2021	Mar	NEWA	
+!	EQ 1.34MG BASE	N212904	002	Mar 10, 2021	Mar	NEWA	

TIZANIDINE HYDROCHLORIDE

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	CADILA	EQ 2MG BASE	A208187	001	Mar 09, 2018	Feb	CAHN	
AB		EQ 4MG BASE	A208187	002	Mar 09, 2018	Feb	CAHN	
	@ MYLAN	EQ 2MG BASE	A076354	001	Mar 28, 2003	Jan	DISC	
	@	EQ 4MG BASE	A076354	002	Mar 28, 2003	Feb	DISC	

TOBRAMYCINSOLUTION; INHALATION
TOBRAMYCIN

AN	ALKEM LABS LTD	300MG/5ML	A212848	001	Apr 01, 2021	Mar	NEWA	
AN	AUROBINDO PHARMA LTD	300MG/5ML	A210871	001	Jan 22, 2021	Jan	NEWA	
	SOLUTION/DROPS; OPHTHALMIC							
	TOBRAMYCIN							
AT	GLAND PHARMA LTD	0.3%	A212628	001	Mar 09, 2021	Feb	NEWA	

TOBRAMYCIN SULFATEINJECTABLE; INJECTION
TOBRAMYCIN SULFATE

AP	GLAND PHARMA LTD	EQ 10MG BASE/ML	A209621	001	Feb 11, 2021	Feb	NEWA	
AP		EQ 40MG BASE/ML	A209621	002	Feb 11, 2021	Feb	NEWA	
	TOBRAMYCIN SULFATE (PHARMACY BULK)							
AP	! FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jan	CTEC	
AP	GLAND PHARMA LTD	EQ 40MG BASE/ML	A209346	001	Feb 09, 2021	Jan	NEWA	

TOFACITINIB CITRATESOLUTION; ORAL
XELJANZ

+!	PFIZER	EQ 1MG/ML BASE	N213082	001	Sep 25, 2020	Feb	CMS1	
----	--------	----------------	---------	-----	--------------	-----	------	--

TOLCAPONETABLET; ORAL
TOLCAPONE

@ ALVOGEN	100MG	A207729	001	Jul 29, 2020	Jan	DISC	
-----------	-------	---------	-----	--------------	-----	------	--

TOLTERODINE TARTRATECAPSULE, EXTENDED RELEASE; ORAL
TOLTERODINE TARTRATE

AB	AJANTA PHARMA LTD	2MG	A213397	001	May 19, 2020	Jan	CMFD	
AB		4MG	A213397	002	May 19, 2020	Jan	CMFD	
AB	AMTA	2MG	A213858	001	Feb 02, 2021	Jan	NEWA	
AB		4MG	A213858	002	Feb 02, 2021	Jan	NEWA	

TOLVAPTAN

	TABLET; ORAL						
	SAMSCA						
	+	OTSUKA	15MG	N022275	001	May 19, 2009	Feb CAHN
AB	+	!	30MG	N022275	002	May 19, 2009	Feb CAHN
	+	@	60MG	N022275	003	May 19, 2009	Feb CAHN

TOPIRAMATE

	CAPSULE, EXTENDED RELEASE; ORAL						
	TOPIRAMATE						
AB2		GLENMARK PHARMS LTD	25MG	A210278	001	Feb 01, 2021	Jan NFTG
AB2			50MG	A210278	002	Feb 01, 2021	Jan NFTG
AB2			100MG	A210278	003	Feb 01, 2021	Jan NFTG
AB2			150MG	A210278	004	Feb 01, 2021	Jan NFTG
AB2			200MG	A210278	005	Feb 01, 2021	Jan NFTG
AB1		ZYDUS PHARMS	25MG	A207382	001	Nov 24, 2017	Jan CTEC
AB1			50MG	A207382	002	Nov 24, 2017	Jan CTEC
AB1			100MG	A207382	003	Nov 24, 2017	Jan CTEC
	TROKENDI XR						
AB1	+	SUPERNUS PHARMS	25MG	N201635	001	Aug 16, 2013	Jan CTEC
AB1	+		50MG	N201635	002	Aug 16, 2013	Jan CTEC
AB1	+		100MG	N201635	003	Aug 16, 2013	Jan CTEC

TRAMADOL HYDROCHLORIDE

	TABLET; ORAL						
	TRAMADOL HYDROCHLORIDE						
>D>	@	FOSUN PHARMA	50MG	A075968	001	Jun 25, 2002	Apr CAHN
>A>	@	GRAVITI PHARMS	50MG	A075968	001	Jun 25, 2002	Apr CAHN
AB		POLYGEN PHARMS	50MG	A206706	001	Jul 02, 2019	Feb CMFD
	TABLET, EXTENDED RELEASE; ORAL						
	TRAMADOL HYDROCHLORIDE						
>D>	AB2	ANCHEN PHARMS	100MG	A200491	001	Jun 27, 2012	Apr DISC
>A>		@	100MG	A200491	001	Jun 27, 2012	Apr DISC
>D>	AB2		200MG	A200491	002	Jun 27, 2012	Apr DISC
>A>		@	200MG	A200491	002	Jun 27, 2012	Apr DISC
>D>	AB2		300MG	A200491	003	Jun 27, 2012	Apr DISC
>A>		@	300MG	A200491	003	Jun 27, 2012	Apr DISC

TRANEXAMIC ACID

	INJECTABLE; INJECTION						
	CYKLOKAPRON						
AP	+	PFIZER	100MG/ML	N019281	001	Dec 30, 1986	Mar CAHN
	TRANEXAMIC ACID						
AP		PROVEPHARM SAS	100MG/ML	A212676	001	Jul 17, 2019	Jan CAHN
>D>	AP	ZYDUS PHARMS	100MG/ML	A205228	001	Jul 17, 2017	Apr DISC
>A>		@	100MG/ML	A205228	001	Jul 17, 2017	Apr DISC
	TABLET; ORAL						
	TRANEXAMIC ACID						
		@ APOTEX INC	650MG	A202286	001	Jan 27, 2014	Mar DISC

TRANLYCYPROMINE SULFATE

	TABLET; ORAL						
	TRANLYCYPROMINE SULFATE						
>D>	AB	KINEDEXE	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr CAHN
>A>	AB	NOVITIUM PHARMA	EQ 10MG BASE	A206856	001	Apr 17, 2018	Apr CAHN

TRAVOPROST

	SOLUTION/DROPS; OPHTHALMIC						
	TRAVOPROST						
AT		MICRO LABS	0.004%	A203767	001	Mar 19, 2021	Mar NEWA

TRAZODONE HYDROCHLORIDE

	TABLET; ORAL						
	TRAZODONE HYDROCHLORIDE						
AB		AUROLIFE PHARMA LLC	50MG	A204852	001	Feb 05, 2020	Feb CMFD
AB			100MG	A204852	002	Feb 05, 2020	Feb CMFD
AB			150MG	A204852	003	Feb 05, 2020	Feb CMFD
AB			300MG	A204852	004	Feb 05, 2020	Feb CMFD
		@ RISING	50MG	A072484	001	Apr 30, 1990	Jan CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS
TREPROSTINIL

AP	ALEMBIC GLOBAL	1MG/ML	A211574	001	Feb 11, 2021	Feb	NEWA
AP		2.5MG/ML	A211574	002	Feb 11, 2021	Feb	NEWA
AP		5MG/ML	A211574	003	Feb 11, 2021	Feb	NEWA
AP		10MG/ML	A211574	004	Feb 11, 2021	Feb	NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL
TRIAMCINOLONE ACETONIDE

AT	SAPTALIS PHARMS	0.025%	A040671	001	Jun 09, 2006	Jan	CAHN
AT		0.1%	A040671	002	Jun 09, 2006	Jan	CAHN

OINTMENT;TOPICAL
TRIAMCINOLONE ACETONIDE

AT	PERRIGO ISRAEL	0.05%	A212460	001	Feb 05, 2021	Jan	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

TRIAZOLAM

TABLET;ORAL
HALCION

AB	+ PFIZER	0.125MG	N017892	003	Apr 26, 1985	Feb	CAHN
AB	+!	0.25MG	N017892	001	Nov 15, 1982	Feb	CAHN
	@	0.5MG	N017892	002	Nov 15, 1982	Feb	CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL
CLOVIQUE

AB	CHARTWELL RX	250MG	A209731	001	Oct 21, 2019	Mar	CAHN
AB	CHARTWELL RX	250MG	A209415	001	Sep 16, 2019	Mar	CAHN

TRILACICLIB DIHYDROCHLORIDE

POWDER;INTRAVENOUS
COSELA

+!	G1 THERAP	EQ 300MG BASE/VIAL	N214200	001	Feb 12, 2021	Feb	NEWA
----	-----------	--------------------	---------	-----	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL
TIGAN

>D>	AB	+!	KING PHARMS LLC	300MG	N017531	006	Dec 13, 2001	Apr	DISC
>A>		+ @		300MG	N017531	006	Dec 13, 2001	Apr	DISC
			TRIMETHOBENZAMIDE HYDROCHLORIDE						
>D>	AB		SUN PHARM INDUSTRIES	300MG	A076570	001	Aug 28, 2003	Apr	CHRS
>A>	AB	!		300MG	A076570	001	Aug 28, 2003	Apr	CHRS

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
TROSPIUM CHLORIDE

>A>	AB		AMTA	60MG	A214760	001	Apr 30, 2021	Apr	NEWA
-----	----	--	------	------	---------	-----	--------------	-----	------

UMBRALISIB TOSYLATE

TABLET;ORAL
UKONIQ

+!	TG THERAPS	EQ 200MG BASE	N213176	001	Feb 05, 2021	Feb	NEWA
----	------------	---------------	---------	-----	--------------	-----	------

URSODIOL

CAPSULE;ORAL
URSODIOL

AB	STRIDES PHARMA	300MG	A210344	001	Jan 22, 2021	Jan	NEWA
----	----------------	-------	---------	-----	--------------	-----	------

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL
VALGANCICLOVIR HYDROCHLORIDE

AB	MYLAN	EQ 450MG BASE	A205151	001	Mar 03, 2021	Feb	NEWA
----	-------	---------------	---------	-----	--------------	-----	------

VALPROIC ACID

SYRUP;ORAL
VALPROIC ACID

AA CHARTWELL RX 250MG/5ML A075782 001 Dec 22, 2000 Mar CMFD

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

@ HIKMA EQ 500MG BASE/VIAL A203300 001 Aug 11, 2020 Feb DISC
@ EQ 1GM BASE/VIAL A203300 002 Aug 11, 2020 Feb DISC

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL
LEVITRA

>D> AB + BAYER HLTHCARE EQ 5MG BASE N021400 001 Aug 19, 2003 Apr DISC
>A> + @ EQ 5MG BASE N021400 001 Aug 19, 2003 Apr DISC
>D> AB + EQ 10MG BASE N021400 002 Aug 19, 2003 Apr DISC
>A> + @ EQ 10MG BASE N021400 002 Aug 19, 2003 Apr DISC

VASOPRESSIN

SOLUTION; INTRAVENOUS
VASOSTRICT

>A> +! PAR STERILE PRODUCTS 20UNITS/100ML (0.2UNITS/ML) N204485 005 Apr 21, 2021 Apr NEWA

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL
VENLAFAXINE HYDROCHLORIDE

@ MYLAN EQ 25MG BASE A077166 001 Jun 13, 2008 Jan DISC
@ EQ 37.5MG BASE A077166 002 Jun 13, 2008 Jan DISC
@ EQ 50MG BASE A077166 003 Jun 13, 2008 Jan DISC
@ EQ 75MG BASE A077166 004 Jun 13, 2008 Jan DISC
@ EQ 100MG BASE A077166 005 Jun 13, 2008 Jan DISC

TABLET, EXTENDED RELEASE;ORAL
VENLAFAXINE HYDROCHLORIDE

AB DEXCEL PHARMA EQ 75MG BASE A213927 001 Jan 21, 2021 Jan NEWA

VERICIGUAT

TABLET;ORAL
VERQUVO

+ MERCK SHARP DOHME 2.5MG N214377 001 Jan 19, 2021 Jan NEWA
+ 5MG N214377 002 Jan 19, 2021 Jan NEWA
+! 10MG N214377 003 Jan 19, 2021 Jan NEWA

VIGABATRIN

FOR SOLUTION;ORAL
VIGABATRIN

AA ANNORA PHARMA 500MG/PACKET A213519 001 Jan 26, 2021 Jan NEWA

TABLET;ORAL
VIGABATRIN

AB DR REDDYS 500MG A211539 001 Jan 29, 2021 Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL
VILAZODONE HYDROCHLORIDE

>A> AB ACCORD HLTHCARE 10MG A208209 001 Apr 27, 2021 Apr NEWA
>A> AB 20MG A208209 002 Apr 27, 2021 Apr NEWA
>A> AB 40MG A208209 003 Apr 27, 2021 Apr NEWA
AB INVAGEN PHARMS 10MG A208200 001 Apr 07, 2021 Mar NEWA
AB 40MG A208200 002 Apr 07, 2021 Mar NEWA

VILOXAZINE HYDROCHLORIDE

>A> CAPSULE, EXTENDED RELEASE;ORAL
>A> QELBREE

>A> + SUPERNUS PHARMS EQ 100MG BASE N211964 001 Apr 02, 2021 Apr NEWA
>A> + EQ 150MG BASE N211964 002 Apr 02, 2021 Apr NEWA
>A> +! EQ 200MG BASE N211964 003 Apr 02, 2021 Apr NEWA

VINORELBINE TARTRATE

INJECTABLE; INJECTION
VINORELBINE TARTRATE
@ FRESenius KABI USA

EQ 10MG BASE/ML

A076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN

CAPSULE; ORAL
LUPKYNIS

+! AURINIA

7.9MG

N213716 001 Jan 22, 2021 Jan NEWA

VORICONAZOLE

INJECTABLE; INTRAVENOUS
VORICONAZOLE

AP ALMAJECT

200MG/VIAL

A206398 001 Mar 23, 2016 Feb CAHN

ZOLPIDEM TARTRATE

TABLET, ORALLY DISINTEGRATING; ORAL
TOVALT ODT

>D> @ BIOVAIL LABS INTL

5MG

N021412 001 Apr 25, 2007 Apr CRLD

>A> + @

5MG

N021412 001 Apr 25, 2007 Apr CRLD

>D> @

10MG

N021412 002 Apr 25, 2007 Apr CRLD

>A> + @

10MG

N021412 002 Apr 25, 2007 Apr CRLD

ZONISAMIDE

CAPSULE; ORAL
ZONEGRAN

AB + CONCORDIA

25MG

N020789 003 Aug 22, 2003 Mar CAHN

+ @

50MG

N020789 002 Aug 22, 2003 Mar CAHN

AB +!

100MG

N020789 001 Mar 27, 2000 Mar CAHN

ZONISAMIDE

AB UNICHEM

25MG

A214492 001 Jan 26, 2021 Jan NEWA

AB

50MG

A214492 002 Jan 26, 2021 Jan NEWA

AB

100MG

A214492 003 Jan 26, 2021 Jan NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

ACETAMINOPHEN, ASPIRIN AND CAFFEINE

GRANULES

250MG;250MG;65MG

A214039 001 Feb 23, 2021 Feb NEWA

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

+! J AND J CONSUMER INC 0.032MG/SPRAY

N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

APOTEX

10MG

A207235 001 Aug 12, 2016 Mar CMFD

@

10MG

A207235 001 Aug 12, 2016 Jan DISC

>D> TABLET, CHEWABLE;ORAL

CHILDREN'S ZYRTEC ALLERGY

>D> + J AND J CONSUMER INC 2.5MG

N021621 007 Nov 30, 2020 Apr DISC

>A> + @ 2.5MG

N021621 007 Nov 30, 2020 Apr DISC

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

>D> +! GLAXOSMITHKLINE CONS 0.05MG/SPRAY

N205434 001 Jul 23, 2014 Apr CHRS

>A> + 0.05MG/SPRAY

N205434 001 Jul 23, 2014 Apr CHRS

FLUTICASONE PROPIONATE

>D> HIKMA 0.05MG/SPRAY

A207957 001 May 26, 2016 Apr CHRS

>A> ! 0.05MG/SPRAY

A207957 001 May 26, 2016 Apr CHRS

IBUPROFEN

SUSPENSION;ORAL

IBUPROFEN

GUARDIAN DRUG

100MG/5ML

A210149 001 Aug 17, 2018 Jan CMFD

STRIDES PHARMA

100MG/5ML

A211666 001 Feb 22, 2021 Feb NEWA

TABLET;ORAL

IBUPROFEN

>D> MERRO PHARM 200MG

A070985 001 Oct 02, 1987 Apr DISC

>A> @ 200MG

A070985 001 Oct 02, 1987 Apr DISC

>D> YICHANG HUMANWELL 200MG

A214003 001 Oct 19, 2020 Apr DISC

>A> @ 200MG

A214003 001 Oct 19, 2020 Apr DISC

KETOCONAZOLE

SHAMPOO;TOPICAL

NIZORAL ANTI-DANDRUFF

+! KRAMER 1%

N020310 001 Oct 10, 1997 Feb CTNA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

>A> APOTEX 5MG

A211443 001 Apr 21, 2021 Apr NEWA

LORATADINE

SYRUP;ORAL

LORATADINE

>A> HETERO LABS LTD III 1MG/ML

A210409 001 May 07, 2021 Apr NEWA

TABLET;ORAL

LORATADINE

UNIQUE PHARM

10MG

A214684 001 Jan 07, 2021 Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

@ GLAXOSMITHKLINE

10MG

A075822 001 Feb 10, 2003 Jan DISC

@ TENSHI

5MG

A212795 001 Sep 18, 2020 Mar DISC

@

10MG

A213294 001 Oct 30, 2020 Mar DISC

NICOTINE POLACRILEXTROCHE/LOZENGE; ORAL
NICORETTE

+	GLAXOSMITHKLINE	EQ 2MG BASE	N022360	001	May 18, 2009	Mar	CAHN
+!		EQ 4MG BASE	N022360	002	May 18, 2009	Mar	CAHN

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

	ALEMBIC PHARMS LTD	EQ 0.1% BASE	A209919	001	Dec 07, 2018	Feb	CMKT
		EQ 0.2% BASE	A209420	001	Apr 29, 2019	Jan	CMKT
	APOTEX INC	EQ 0.2% BASE	A090918	001	Dec 05, 2017	Jan	CMKT
	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Feb	CMKT
	@ CIPLA	EQ 0.2% BASE	A206087	001	Dec 05, 2017	Mar	CMKT
	FDC LTD	EQ 0.1% BASE	A209282	001	Sep 26, 2019	Feb	CMKT
	MYLAN	EQ 0.1% BASE	A204392	001	Mar 21, 2018	Feb	CMKT
>A>	USV	EQ 0.1% BASE	A203152	001	Dec 07, 2015	Apr	CMKT

POLYETHYLENE GLYCOL 3350FOR SOLUTION; ORAL
POLYETHYLENE GLYCOL 3350

>A>	ANNORA PHARMA	17GM/SCOOPFUL	A214990	001	Apr 14, 2021	Apr	NEWA
-----	---------------	---------------	---------	-----	--------------	-----	------

RANITIDINE HYDROCHLORIDETABLET; ORAL
RANITIDINE HYDROCHLORIDE

	@ WOCKHARDT	EQ 75MG BASE	A076760	001	Feb 24, 2006	Jan	DISC
>D>	ZANTAC 150						
>D>	+! SANOFI US	EQ 150MG BASE	N021698	001	Aug 31, 2004	Apr	DISC
>A>	+ @	EQ 150MG BASE	N021698	001	Aug 31, 2004	Apr	DISC
>D>	+	EQ 150MG BASE	N021698	002	Mar 13, 2007	Apr	DISC
>A>	+ @	EQ 150MG BASE	N021698	002	Mar 13, 2007	Apr	DISC
>D>	ZANTAC 75						
>D>	+ SANOFI US	EQ 75MG BASE	N020520	001	Dec 19, 1995	Apr	DISC
>A>	+ @	EQ 75MG BASE	N020520	001	Dec 19, 1995	Apr	DISC

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND
RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2021

NO APRIL 2021 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2021 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALBUTEROL SULFATE - PROAIR DIGIHALER</u>						
N 205636 002	10918816	Dec 14, 2035	DP			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025		U-219		
	8895615	Nov 23, 2025		U-3054		
	8895616	Nov 23, 2025		U-219		
	8895616	Nov 23, 2025		U-3054		
	8895617	Nov 23, 2025		U-219		
	8895617	Nov 23, 2025		U-3054		
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037		U-185		
	10894039	Oct 06, 2037		U-3		
	10952998	Oct 06, 2037	DP			
	>A> 10959991	Oct 06, 2037		U-158		
	>A> 10959991	Oct 06, 2037		U-39		
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 001	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 002	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u>						
N 210045 003	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
<u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u>						
N 210875 005	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
<u>APREPITANT - CINVANTI</u>						
N 209296 001	>A> 10953018	Sep 18, 2035		U-2161		
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU</u>						
N 209381 001	10918723	Sep 10, 2033		U-2310		
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001					CGT	Sep 21, 2021
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036	U-3044			
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036	U-3044			
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 210854 003					I-811 NCE	Oct 16, 2022 Oct 24, 2023
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001					NCE	Oct 24, 2023
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	10941095	Dec 23, 2023	U-2747			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10941095	Dec 23, 2023	U-2746			
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 001					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u>						
N 214094 002					NCE ODE-333	Dec 03, 2025 Dec 03, 2027
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					M-82	Feb 24, 2024
<u>BREXANOLONE - ZULRESSO</u>						
N 211371 001	10940156	Mar 08, 2037	U-2552			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	RE48059	Dec 23, 2028	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005					NPP	May 10, 2021
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001					NPP	May 10, 2021
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001					>A> NPP	Mar 22, 2024
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002					>A> NPP	Mar 22, 2024
<u>BUPIVACAINE - POSIMIR</u>						
N 204803 001	8153149	Sep 15, 2025	DP		NP	Feb 01, 2024
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			
	8846072	Sep 15, 2025	DP U-3074			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001					M-128	Dec 18, 2023
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3061			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001					I-854	Jan 22, 2024
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002					I-854	Jan 22, 2024
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003					I-854	Jan 22, 2024
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017			
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	>A> 8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 14, 2035	U-3071		ODE-326	Jul 31, 2027
	10918608	Oct 14, 2035	U-3072		ODE-332	Jul 31, 2027
	10918608	Oct 14, 2035	U-3073			
	>A> 10966939	Jun 17, 2035	DP U-2780			
	>A> 10966939	Jun 17, 2035	DP U-2781			
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10533174	May 04, 2021	DP		>A> ODE-347	Feb 25, 2028
	10781450	Nov 12, 2030	U-3089			
	8524880	Apr 02, 2026	DS DP U-3087			
	8524880	Apr 02, 2026	DS DP U-3088			
	9228187	Nov 12, 2030	DS DP			
	9416361	May 04, 2021	DS			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 003					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 004					CGT	Sep 20, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144	005				CGT	Sep 20, 2021
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352	001	6706276	Mar 06, 2022	DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIO</u>						
N 209589	001				NPP	Aug 15, 2021
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455	001	10786518	Jul 19, 2038	U-2978		
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575	001				>A> NCE >A> NP	Dec 14, 2022 Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963	001	10894012	Feb 07, 2037	U-3014		
		10933060	Feb 07, 2037	U-3014		
<u>CRIZOTINIB - XALKORI</u>						
N 202570	001				I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570	002				I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501	001	>A> 10993952	Feb 15, 2036	DP		
<u>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</u>						
N 212501	002	>A> 10993952	Feb 15, 2036	DP		
<u>CYCLOSPORINE - CEQUA</u>						
N 210913	001	10918694	Feb 28, 2037	DP		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	001	10905662	Aug 16, 2036	U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389	002	10905662	Aug 16, 2036	U-1399		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491	001	10905662	Aug 16, 2036	U-1399	ODE*	Aug 14, 2022
		>A> 8026284	Sep 22, 2027	U-1399	ODE*	Dec 22, 2024
		>A> 8026284*PED	Mar 22, 2028		PED	Feb 14, 2023
		>A> 9173851	Jun 17, 2034	DP		
		>A> 9173851*PED	Dec 17, 2034			
		>A> 9192590	Jan 26, 2027	U-1399		
		>A> 9192590*PED	Jul 26, 2027			
		>A> 9198882	Jan 26, 2027	U-1399		
		>A> 9198882*PED	Jul 26, 2027			
		>A> 9233077	Jun 17, 2034	DP		
		>A> 9233077*PED	Dec 17, 2034			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491	002	10905662	Aug 16, 2036	U-1399	ODE*	Aug 14, 2022
		>A> 8026284	Sep 22, 2027	U-1399	ODE*	Dec 22, 2024
		>A> 8026284*PED	Mar 22, 2028		PED	Feb 14, 2023
		>A> 9173851	Jun 17, 2034	DP		
		>A> 9173851*PED	Dec 17, 2034			
		>A> 9192590	Jan 26, 2027	U-1399		
		>A> 9192590*PED	Jul 26, 2027			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 213491 002	>A> 9198882	Jan 26, 2027	U-1399			
	>A> 9198882*PED	Jul 26, 2027				
	>A> 9233077	Jun 17, 2034	DP			
	>A> 9233077*PED	Dec 17, 2034				
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<u>CYTARABINE; DAUNORUBICIN - VYXEOS</u>						
N 209401 001	>A> 10028912	Sep 29, 2034	DP U-3149			
	>A> 10028912	Sep 29, 2034	DP U-3150			
	>A> 10166184	Oct 15, 2032	DP U-3149			
	>A> 10835492	Oct 15, 2032	U-3150			
	>A> 7850990	Jan 23, 2027	DP U-3147			
	>A> 8022279	Sep 14, 2027	DP U-3147			
	>A> 8092828	Apr 01, 2029	U-3147			
	>A> 8431806	Apr 22, 2025	DP U-3147			
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931			
	6087380*PED	Jun 28, 2022				
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	>A> 10973836	Mar 09, 2040	U-3127			
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</u>						
N 214231 001	>A> 10442847	Feb 03, 2035	DS DP		>A> NCE	Mar 22, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</u>						
N 214231 002	>A> 10442847	Feb 03, 2035	DS DP		>A> NCE	Mar 22, 2026
<u>DEFERIPRONE - DEFERIPRONE</u>						
A 208800 001					PC	Mar 27, 2021
<u>DEFERIPRONE - FERRIPROX</u>						
N 212269 001	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 001	>A> 10973870	Feb 10, 2029		U-1978		
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N 022201 002	>A> 10973870	Feb 10, 2029		U-1978		
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 001	>A> 10959996	Mar 07, 2036		U-3055	>A> NCE	Apr 03, 2022
	>A> 10959996*PED	Sep 07, 2036			>A> ODE-134	Apr 03, 2024
	>A> 8524733	Mar 27, 2031	DS DP		>A> PED	Oct 03, 2022
	>A> 8524733*PED	Sep 27, 2031			>A> PED	Oct 03, 2024
	>A> 9233959	Sep 18, 2033	DP			
	>A> 9233959*PED	Mar 18, 2034				
	>A> 9296739	Sep 18, 2033	DP			
	>A> 9296739*PED	Mar 18, 2034				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
	>A> 9814708	Sep 18, 2033	DP			
	>A> 9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 002	>A> 10959996	Mar 07, 2036		U-3055	>A> NCE	Apr 03, 2022
	>A> 10959996*PED	Sep 07, 2036			>A> ODE-134	Apr 03, 2024
	>A> 8524733	Mar 27, 2031	DS DP		>A> PED	Oct 03, 2022
	>A> 8524733*PED	Sep 27, 2031			>A> PED	Oct 03, 2024
	>A> 9233959	Sep 18, 2033	DP			
	>A> 9233959*PED	Mar 18, 2034				
	>A> 9296739	Sep 18, 2033	DP			
	>A> 9296739*PED	Mar 18, 2034				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
	>A> 9814708	Sep 18, 2033	DP			
	>A> 9814708*PED	Mar 18, 2034				
<u>DEUTETRABENAZINE - AUSTEDO</u>						
N 208082 003	>A> 10959996	Mar 07, 2036		U-3055	>A> NCE	Apr 03, 2022
	>A> 10959996*PED	Sep 07, 2036			>A> ODE-134	Apr 03, 2024
	>A> 8524733	Mar 27, 2031	DS DP		>A> PED	Oct 03, 2022
	>A> 8524733*PED	Sep 27, 2031			>A> PED	Oct 03, 2024
	>A> 9233959	Sep 18, 2033	DP			
	>A> 9233959*PED	Mar 18, 2034				
	>A> 9296739	Sep 18, 2033	DP			
	>A> 9296739*PED	Mar 18, 2034				
	>A> 9550780	Sep 18, 2033	DS DP U-1995			
	>A> 9550780	Sep 18, 2033	DS DP U-3055			
	>A> 9550780*PED	Mar 18, 2034				
	>A> 9814708	Sep 18, 2033	DP			
	>A> 9814708*PED	Mar 18, 2034				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994 001					>A> NCE	May 07, 2026

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994	002				>A> NCE	May 07, 2026
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</u>						
N 212994	003				>A> NCE	May 07, 2026
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	001				CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	002				CGT	Sep 26, 2021
<u>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</u>						
A 212317	003				CGT	Sep 26, 2021
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	001	>A> 10391160	Mar 13, 2035	U-3148		
		>A> 10555993	Mar 13, 2035	U-3148		
		>A> 10959972	Nov 16, 2035	U-1384		
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063	002	>A> 10391160	Mar 13, 2035	U-3148		
		>A> 10555993	Mar 13, 2035	U-3148		
		>A> 10959972	Nov 16, 2035	U-1384		
<u>DROSPIRENONE - SLYND</u>						
N 211367	001	>A> 10987364	Jun 28, 2031	DP		
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154	001	>A> 7732430	Mar 02, 2025	DP U-3152	>A> NCE	Apr 15, 2026
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	001	>A> 10959982	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	002	>A> 10959982	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	003	>A> 10959982	Apr 13, 2037	DP		
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516	004	>A> 10959982	Apr 13, 2037	DP		
<u>EDARAVONE - RADICAVA</u>						
N 209176	002				>A> ODE*	May 05, 2024
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	001	7365205	Apr 18, 2027	DS		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	002	7365205	Apr 18, 2027	DS		
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316	003	7365205	Apr 18, 2027	DS		
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	10864274	Oct 02, 2034	U-2720		
		7214506	Feb 22, 2026	U-281		
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388	001	10881659	Mar 14, 2034	U-2842		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10081621	Mar 25, 2031	DP U-2652		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-3032			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 001					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 002					PC	Mar 09, 2021
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</u>						
A 209721 003					PC	Mar 09, 2021
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 001	>A> 10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
	>A> 10960155	Jun 25, 2026	DP			
<u>EPINEPHRINE - AUVI-O</u>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
	>A> 10960155	Jun 25, 2026	DP			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	10912781	Oct 23, 2028	DP			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	10912781	Oct 23, 2028	DP			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ESTRADIOL - IMVEXXY</u>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	>A> RE48468	Oct 27, 2028	U-2097			
<u>ETEPLIRSEN - EXONDYS 51</u>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	>A> RE48468	Oct 27, 2028	U-2097			
<u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u>						
N 209405 001				>A> NDF		Mar 30, 2023
<u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u>						
A 213950 001					CGT	Aug 25, 2021
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u>						
A 212706 001					CGT	Jul 17, 2021
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	>A> 6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	>A> 6824822	Oct 09, 2022	DP			
	>A> 6824822*PED	Apr 09, 2023				
	>A> 7223440	Aug 31, 2021	DP			
	>A> 7223440*PED	Mar 03, 2022				
	>A> 7456254	Jun 30, 2025	DP U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2589			
	>A> 7456254	Jun 30, 2025	DP U-2590			
	>A> 7456254	Jun 30, 2025	DP U-2592			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE - BYDUREON BCISE</u>						
N 209210 001	>A> 7456254*PED	Dec 30, 2025				
	>A> 7563871	Apr 15, 2024	DP			
	>A> 7563871*PED	Oct 15, 2024				
	>A> 7612176	Apr 13, 2025	DP U-2589			
	>A> 7612176	Apr 13, 2025	DP U-2590			
	>A> 7612176	Apr 13, 2025	DP U-2592			
	>A> 7612176*PED	Oct 13, 2025				
	>A> 8329648	Aug 18, 2026	U-2588			
	>A> 8329648	Aug 18, 2026	U-2589			
	>A> 8329648	Aug 18, 2026	U-2590			
	>A> 8329648	Aug 18, 2026	U-2593			
	>A> 8329648	Aug 18, 2026	U-2594			
	>A> 8329648	Aug 18, 2026	U-2595			
	>A> 8329648	Aug 18, 2026	U-2596			
	>A> 8329648*PED	Feb 18, 2027				
	>A> 8361972	Mar 21, 2028	U-2588			
	>A> 8361972*PED	Sep 21, 2028				
	>A> 8431685	Apr 13, 2025	DP U-2589			
	>A> 8431685	Apr 13, 2025	DP U-2590			
	>A> 8431685	Apr 13, 2025	DP U-2597			
	>A> 8431685	Apr 13, 2025	DP U-2598			
	>A> 8431685*PED	Oct 13, 2025				
	>A> 8461105	Apr 13, 2025	DP U-2589			
	>A> 8461105	Apr 13, 2025	DP U-2590			
	>A> 8461105	Apr 13, 2025	DP U-2597			
	>A> 8461105	Apr 13, 2025	DP U-2598			
	>A> 8461105*PED	Oct 13, 2025				
	>A> 8501698	Jun 20, 2027	U-2588			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8895033	Oct 04, 2030	DP U-2589			
	>A> 8895033	Oct 04, 2030	DP U-2590			
	>A> 8895033	Oct 04, 2030	DP U-2597			
	>A> 8895033	Oct 04, 2030	DP U-2600			
	>A> 8895033	Oct 04, 2030	DP U-2601			
	>A> 8895033	Oct 04, 2030	DP U-2602			
	>A> 8895033*PED	Apr 04, 2031				
	>A> 8906851	Aug 18, 2026	U-2589			
	>A> 8906851	Aug 18, 2026	U-2590			
	>A> 8906851	Aug 18, 2026	U-2593			
	>A> 8906851	Aug 18, 2026	U-2597			
	>A> 8906851*PED	Feb 18, 2027				
	>A> 9238076	Apr 15, 2024	DP U-2589			
	>A> 9238076	Apr 15, 2024	DP U-2590			
	>A> 9238076	Apr 15, 2024	DP U-2597			
	>A> 9238076	Apr 15, 2024	DP U-2599			
	>A> 9238076*PED	Oct 15, 2024				
	>A> 9884092	Aug 18, 2026	U-2589			
	>A> 9884092	Aug 18, 2026	U-2590			
	>A> 9884092	Aug 18, 2026	U-2593			
	>A> 9884092	Aug 18, 2026	U-2594			
	>A> 9884092	Aug 18, 2026	U-2595			
	>A> 9884092	Aug 18, 2026	U-2596			
	>A> 9884092	Aug 18, 2026	U-2597			
	>A> 9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	>A> 6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	>A> 6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	>A> 7456254	Jun 30, 2025	DP U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2589			
	>A> 7456254	Jun 30, 2025	DP U-2590			
	>A> 7456254	Jun 30, 2025	DP U-2592			
	>A> 7456254*PED	Dec 30, 2025				
	>A> 7612176	Apr 13, 2025	DP U-2588			
	>A> 7612176	Apr 13, 2025	DP U-2589			
	>A> 7612176	Apr 13, 2025	DP U-2590			
	>A> 7612176	Apr 13, 2025	DP U-2592			
	>A> 7612176*PED	Oct 13, 2025				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	>A> 8329648	Aug 18, 2026	U-2588			
	>A> 8329648	Aug 18, 2026	U-2589			
	>A> 8329648	Aug 18, 2026	U-2590			
	>A> 8329648	Aug 18, 2026	U-2593			
	>A> 8329648	Aug 18, 2026	U-2594			
	>A> 8329648	Aug 18, 2026	U-2595			
	>A> 8329648	Aug 18, 2026	U-2596			
	>A> 8329648*PED	Feb 18, 2027				
	>A> 8361972	Mar 21, 2028	U-2588			
	>A> 8361972*PED	Sep 21, 2028				
	>A> 8431685	Apr 13, 2025	DP U-2588			
	>A> 8431685	Apr 13, 2025	DP U-2589			
	>A> 8431685	Apr 13, 2025	DP U-2590			
	>A> 8431685	Apr 13, 2025	DP U-2598			
	>A> 8431685*PED	Oct 13, 2025				
	>A> 8461105	Apr 13, 2025	DP U-2588			
	>A> 8461105	Apr 13, 2025	DP U-2589			
	>A> 8461105	Apr 13, 2025	DP U-2590			
	>A> 8461105	Apr 13, 2025	DP U-2598			
	>A> 8461105*PED	Oct 13, 2025				
	>A> 8501698	Jun 20, 2027	DP U-2588			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8906851	Aug 18, 2026	U-2588			
	>A> 8906851	Aug 18, 2026	U-2589			
	>A> 8906851	Aug 18, 2026	U-2590			
	>A> 8906851	Aug 18, 2026	U-2593			
	>A> 8906851*PED	Feb 18, 2027				
	>A> 9238076	Apr 15, 2024	DP U-2588			
	>A> 9238076	Apr 15, 2024	DP U-2589			
	>A> 9238076	Apr 15, 2024	DP U-2590			
	>A> 9238076	Apr 15, 2024	DP U-2599			
	>A> 9238076*PED	Oct 15, 2024				
	>A> 9884092	Aug 18, 2026	U-2588			
	>A> 9884092	Aug 18, 2026	U-2589			
	>A> 9884092	Aug 18, 2026	U-2590			
	>A> 9884092	Aug 18, 2026	U-2593			
	>A> 9884092	Aug 18, 2026	U-2594			
	>A> 9884092	Aug 18, 2026	U-2595			
	>A> 9884092	Aug 18, 2026	U-2596			
	>A> 9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	>A> 6515117*PED	Apr 04, 2026			PED	Aug 15, 2023
	>A> 6824822	Oct 09, 2022	DP			
	>A> 6824822*PED	Apr 09, 2023				
	>A> 7223440	Aug 31, 2021	DP			
	>A> 7223440*PED	Mar 03, 2022				
	>A> 7456254	Jun 30, 2025	DP U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2589			
	>A> 7456254	Jun 30, 2025	DP U-2590			
	>A> 7456254	Jun 30, 2025	DP U-2592			
	>A> 7456254*PED	Dec 30, 2025				
	>A> 7563871	Apr 15, 2024	DP			
	>A> 7563871*PED	Oct 15, 2024				
	>A> 7612176	Apr 13, 2025	DP U-2588			
	>A> 7612176	Apr 13, 2025	DP U-2589			
	>A> 7612176	Apr 13, 2025	DP U-2590			
	>A> 7612176	Apr 13, 2025	DP U-2592			
	>A> 7612176*PED	Oct 13, 2025				
	>A> 8216180	Jan 12, 2028	DP			
	>A> 8216180*PED	Jul 12, 2028				
	>A> 8329648	Aug 18, 2026	U-2588			
	>A> 8329648	Aug 18, 2026	U-2589			
	>A> 8329648	Aug 18, 2026	U-2590			
	>A> 8329648	Aug 18, 2026	U-2593			
	>A> 8329648	Aug 18, 2026	U-2594			
	>A> 8329648	Aug 18, 2026	U-2595			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	>A> 8329648	Aug 18, 2026	U-2596			
	>A> 8329648*PED	Feb 18, 2027				
	>A> 8361972	Mar 21, 2028	U-2588			
	>A> 8361972*PED	Sep 21, 2028				
	>A> 8431685	Apr 13, 2025	DP U-2588			
	>A> 8431685	Apr 13, 2025	DP U-2589			
	>A> 8431685	Apr 13, 2025	DP U-2590			
	>A> 8431685	Apr 13, 2025	DP U-2598			
	>A> 8431685*PED	Oct 13, 2025				
	>A> 8439864	Mar 25, 2028	DP			
	>A> 8439864*PED	Sep 25, 2028				
	>A> 8461105	Apr 13, 2025	DP U-2588			
	>A> 8461105	Apr 13, 2025	DP U-2589			
	>A> 8461105	Apr 13, 2025	DP U-2590			
	>A> 8461105	Apr 13, 2025	DP U-2598			
	>A> 8461105*PED	Oct 13, 2025				
	>A> 8501698	Jun 20, 2027	DP U-2588			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8690837	May 19, 2029	DP			
	>A> 8690837*PED	Nov 19, 2029				
	>A> 8721615	Jan 18, 2030	DP			
	>A> 8721615*PED	Jul 18, 2030				
	>A> 8758292	Nov 12, 2027	DP			
	>A> 8758292*PED	May 12, 2028				
	>A> 8827963	Feb 04, 2029	DP			
	>A> 8827963*PED	Aug 04, 2029				
	>A> 8906851	Aug 18, 2026	U-2588			
	>A> 8906851	Aug 18, 2026	U-2589			
	>A> 8906851	Aug 18, 2026	U-2590			
	>A> 8906851	Aug 18, 2026	U-2593			
	>A> 8906851*PED	Feb 18, 2027				
	>A> 8998876	Jan 07, 2030	DP			
	>A> 8998876*PED	Jul 07, 2030				
	>A> 9238076	Apr 15, 2024	DP U-2588			
	>A> 9238076	Apr 15, 2024	DP U-2589			
	>A> 9238076	Apr 15, 2024	DP U-2590			
	>A> 9238076	Apr 15, 2024	DP U-2599			
	>A> 9238076*PED	Oct 15, 2024				
	>A> 9320853	Mar 25, 2028	DP			
	>A> 9320853*PED	Sep 25, 2028				
	>A> 9884092	Aug 18, 2026	U-2588			
	>A> 9884092	Aug 18, 2026	U-2589			
	>A> 9884092	Aug 18, 2026	U-2590			
	>A> 9884092	Aug 18, 2026	U-2593			
	>A> 9884092	Aug 18, 2026	U-2594			
	>A> 9884092	Aug 18, 2026	U-2595			
	>A> 9884092	Aug 18, 2026	U-2596			
	>A> 9884092*PED	Feb 18, 2027				
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	>A> 10947183	Dec 20, 2036	DS DP			
	10950331	Sep 28, 2035	U-3098			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 001	10519252	Oct 20, 2023	DS DP U-2709			
	10519252	Oct 20, 2023	DS DP U-2710			
	10519252	Oct 20, 2023	DS DP U-2711			
	10519252	Oct 20, 2023	DS DP U-2712			
	10519252	Oct 20, 2023	DS DP U-3048			
	10519252	Oct 20, 2023	DS DP U-3049			
	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
<u>FERRIC CARBOXYMALTOSATE - INJECTAFER</u>						
N 203565 002	10519252	Oct 20, 2023	DS DP U-2709			
	10519252	Oct 20, 2023	DS DP U-2710			
	10519252	Oct 20, 2023	DS DP U-3048			
	10519252	Oct 20, 2023	DS DP U-3049			
	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	9376505	Oct 20, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	10933147	Dec 30, 2035	U-2450			
	>A> 10953112	Nov 28, 2026	U-1879			
	>A> 10967077	Dec 30, 2035	U-2450			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10918816	Dec 14, 2035	DP			
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 006	10918816	Dec 14, 2035	DP			
<u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u>						
N 214018 001	7504095	Jan 31, 2025	DP U-3092		NCE	Feb 26, 2026
					>A> ODE-342	Feb 26, 2028
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212642 001					NCE	Dec 01, 2025
					W	Dec 01, 2025

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u>						
N 212643 001					NCE W	Dec 01, 2025 Dec 01, 2025
<u>GLUCAGON - BAOSIMI</u>						
N 210134 001	10894133	Jan 03, 2038	DP			
<u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u>						
N 208437 001	10940110	Feb 26, 2029	DP U-1773			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>HYDROCORTISONE - ALKINDI SPRINKLE</u>						
N 213876 004	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001 >A>	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 002 >A>	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 001 >A>	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 002 >A>	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 003 >A>	10961251	Jun 03, 2033	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563 004 >A>	10961251	Jun 03, 2033	DP			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 002	10881632	Apr 29, 2030	U-3052			
	10894028	Jun 28, 2033	U-3053			
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	10918635	Apr 30, 2030	U-1455			
	10918635	Apr 30, 2030	U-172			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001 >A>	10980795	Jun 12, 2033	U-1848			
	>A> 10993914	Oct 15, 2036	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	>A> 10980795	Jun 12, 2033	U-1848			
	>A> 10993914	Oct 15, 2036	DP			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	>A> 10973827	Apr 02, 2029	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	>A> 10973827	Apr 02, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	>A> 10973827	Apr 02, 2029	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001					NPP	Dec 04, 2023
<u>LISINOPRIL - OBRELIS</u>						
N 208401 001	10940177	Nov 06, 2035	DP			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 001	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LONAFARNIB - ZOKINVY</u>						
N 213969 002	7838531	Jul 26, 2024	U-3070		ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023	U-3070			
<u>LORLATINIB - LORBRENA</u>						
N 210868 001	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096			
<u>LORLATINIB - LORBRENA</u>						
N 210868 002	10420749	Jul 27, 2036	DS DP U-2633		I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS DP U-3096			
<u>LOTEPREDNOL ETABONATE - LOTE PREDNOL ETABONATE</u>						
A 212450 001					>A> CGT	Nov 02, 2021
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001					>A> ODE-339	Nov 23, 2027
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	>A> 10960009	Dec 03, 2034	U-814			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	>A> 10946015	Nov 25, 2026	DP U-1445			
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MELOXICAM - ANJESO</u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE	Feb 26, 2026
	10322182	Apr 25, 2032	DP		>A> ODE-348	Feb 26, 2028
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	6992207	Jun 25, 2022	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10940128	Jun 14, 2030	DP U-3086			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	8680136	Aug 29, 2031	DS DP		>A> NCE >A> GAIN	Aug 29, 2022 Aug 29, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618 10905652	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618 10905652	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618 10905652	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618 10905652	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618 10905652	Mar 23, 2032 Mar 23, 2032	U-2357 DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 001	>A> 10966990	Jun 20, 2038	DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 002	>A> 10966990	Jun 20, 2038	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10874655 10874656 10874657 10925866	May 30, 2038 May 30, 2038 May 30, 2038 Apr 28, 2028	U-2371 U-2371 U-2371 U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - ZILXI</u>						
N 213690 001	10946101	Oct 01, 2030	U-1631			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	10842780 10842780*PED 6346532 6346532*PED 8772315 8772315*PED 8835474 8835474*PED RE44872 RE44872*PED	Sep 28, 2029 Mar 28, 2030 Mar 27, 2022 Sep 27, 2022 Oct 30, 2028 Apr 30, 2029 Nov 04, 2023 May 04, 2024 Nov 04, 2023 May 04, 2024	DP U-2996 DS DP U-2300 U-1527 U-1527		I-777 >A> I-855 >A> PED	Apr 27, 2021 Mar 25, 2024 Sep 25, 2024

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			>A> I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		>A> PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028			U-2300	
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023			U-1527	
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023			U-1527	
	RE44872*PED	May 04, 2024				
<u>MIRABEGRON - MYRBETRIO GRANULES</u>						
N 213801 001	>A> 10058536	Mar 31, 2036	DP U-3108		>A> NP	Mar 25, 2024
	>A> 6346532	Mar 27, 2022	DS		>A> PED	Sep 25, 2024
	>A> 7342117	Nov 04, 2023	DS			
	>A> 7982049	Nov 04, 2023	DP			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035			U-1384	
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 001					CGT	Aug 10, 2021
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
A 212451 002					CGT	Aug 10, 2021
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u>						
N 208854 001	>A> 10952968	May 13, 2033	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	>A> 10960155	Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u>						
N 209862 001	>A> 10960155	Jun 25, 2026	DP			
<u>NERATINIB MALEATE - NERLYNX</u>						
N 208051 001	10035788	Oct 15, 2028			U-2043	
	10035788	Oct 15, 2028			U-3047	
	10035788	Oct 15, 2028			U-3097	
	7982043	Oct 08, 2025			U-2043	
	7982043	Oct 08, 2025			U-3047	
	7982043	Oct 08, 2025			U-3097	
	8518446	Nov 20, 2030	DP U-2043			
	8518446	Nov 20, 2030	DP U-3047			
	8518446	Nov 20, 2030	DP U-3097			
	8669273	Jul 18, 2031			U-3047	
	8790708	Nov 05, 2030	DP U-2043			
	8790708	Nov 05, 2030	DP U-3047			
	8790708	Nov 05, 2030	DP U-3097			
	9139558	Oct 15, 2028			U-2043	
	9139558	Oct 15, 2028			U-3047	
	9139558	Oct 15, 2028			U-3097	
	9211291	Mar 24, 2030			U-2043	
	9211291	Mar 24, 2030			U-3097	
	9265784	Aug 04, 2029			U-3047	
	9630946	Oct 15, 2028			U-2043	
	9630946	Oct 15, 2028			U-3047	
	9630946	Oct 15, 2028			U-3097	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NETARSUDIL MESYLATE - RHOPRESSA</u>						
N 208254 001	10882840	Jul 11, 2026	U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	>A> 10961195	Sep 25, 2035	DS DP			
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 001					ODE-319	Aug 06, 2027
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					ODE-319	Aug 06, 2027
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820 001					CGT	Jun 05, 2021
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142	Aug 18, 2025	U-3037			
	10814092	Oct 17, 2025	U-3037			
	10926054	Aug 13, 2029	DP			
	7947227	Oct 17, 2026	U-3037			
	8057742	Jan 18, 2026	U-3037			
	8226916	Aug 18, 2025	U-3037			
	8607785	Jul 14, 2030	DP			
	8609028	Aug 18, 2025	U-3037			
	8821801	Aug 18, 2025	DP			
	8944049	Aug 13, 2029	DP			
	9522249	Aug 18, 2025	DP			
	9701538	Jan 28, 2029	DP			
	9956373	Aug 18, 2025	U-3037			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2103			
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2481			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2103			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2481			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8859562	Aug 04, 2031	U-2832			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 8859562	Aug 04, 2031	U-2833			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 8071579	Aug 12, 2027	U-2101			
	>A> 8071579	Aug 12, 2027	U-2103			
	>A> 8071579	Aug 12, 2027	U-2480			
	>A> 8071579	Aug 12, 2027	U-2481			
	>A> 8071579	Aug 12, 2027	U-2482			
	>A> 8071579	Aug 12, 2027	U-2483			
	>A> 8071579	Aug 12, 2027	U-2716			
	>A> 8071579	Aug 12, 2027	U-2819			
	>A> 8071579	Aug 12, 2027	U-2820			
	>A> 8071579	Aug 12, 2027	U-2821			
	>A> 8071579	Aug 12, 2027	U-2822			
	>A> 8071579	Aug 12, 2027	U-2823			
	>A> 8071579	Aug 12, 2027	U-2824			
	>A> 8071579	Aug 12, 2027	U-2832			
	>A> 8071579	Aug 12, 2027	U-2833			
	>A> 8859562	Aug 04, 2031	U-2101			
	>A> 8859562	Aug 04, 2031	U-2103			
	>A> 8859562	Aug 04, 2031	U-2480			
	>A> 8859562	Aug 04, 2031	U-2481			
	>A> 8859562	Aug 04, 2031	U-2482			
	>A> 8859562	Aug 04, 2031	U-2483			
	>A> 8859562	Aug 04, 2031	U-2716			
	>A> 8859562	Aug 04, 2031	U-2819			
	>A> 8859562	Aug 04, 2031	U-2820			
	>A> 8859562	Aug 04, 2031	U-2821			
	>A> 8859562	Aug 04, 2031	U-2822			
	>A> 8859562	Aug 04, 2031	U-2823			
	>A> 8859562	Aug 04, 2031	U-2824			
	>A> 8859562	Aug 04, 2031	U-2832			
	>A> 8859562	Aug 04, 2031	U-2833			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002					NCE	Oct 30, 2025
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003					NCE	Oct 30, 2025
<u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u>						
N 214155 001	>A> 8420592	Aug 29, 2029	U-3101			
	>A> 9649352	Jul 16, 2035	DS DP			
	>A> 9682061	Apr 26, 2030	U-3101			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEO</u>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 007	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 003	RE47739	Mar 05, 2027	DS DP			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	10391075	Feb 12, 2027	U-2622			
	10391075	Feb 12, 2027	U-3069			
	8778997	May 07, 2027	U-1627			
	8778997	May 07, 2027	U-2622			
	8778997	May 07, 2027	U-3069			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	>A> 10961240	Jul 24, 2038	U-2606			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001					ODE-331	Oct 13, 2027
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002					ODE-331	Oct 13, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003					M-14 PED	Nov 20, 2023 May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004					M-14 PED	Nov 20, 2023 May 20, 2024
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
	9029533	Dec 22, 2026	U-1283			
	9029533	Dec 22, 2026	U-1699			
	9029533	Dec 22, 2026	U-1700			
	9029533	Dec 22, 2026	U-1701			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	9029533	Dec 22, 2026	U-836			
	9493470	Dec 12, 2033	DS DP U-1700			
	9493470	Dec 12, 2033	DS DP U-1948			
<u>PONESIMOD - PONVORY</u>						
N 213498 001	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	>A> 10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 009 >A>	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010 >A>	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	>A> 8273779	Dec 17, 2025	U-2774			
	>A> 9000018	Nov 16, 2024	U-3102			
	>A> 9062014	May 06, 2032	DS DP U-2774			
	>A> RE43728	Nov 16, 2024	DS DP			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					>A> ODE-340	Dec 01, 2027
					>A> ODE-341	Dec 01, 2027
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3068			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001 >A>	10966966	Aug 12, 2040	U-3153			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001					ODE-334	Aug 07, 2027
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>ROLAPITANT HYDROCHLORIDE - VARUBI</u>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	9517226	Aug 22, 2033	U-3084		M-82	Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	9517226	Aug 22, 2033	U-3084		M-82	Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	9517226	Aug 22, 2033	U-3084		M-82	Feb 16, 2024
	9937143	Aug 22, 2033	U-3084			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139	Aug 14, 2035	DS DP U-2584			
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10933120	Mar 15, 2033	DP			
	>A> 10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10933120	Mar 15, 2033	DP			
	>A> 10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10933120	Mar 15, 2033	DP			
	>A> 10960052	Dec 16, 2031	DP			
<u>SETMELANOTIDE ACETATE - IMCIVREE</u>						
N 213793 001					ODE-336	Nov 25, 2027
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001					>A> ODE*	Aug 28, 2026
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 002					>A> ODE* >A> ODE* >A> PED	Apr 07, 2024 Aug 28, 2026 Oct 07, 2024
<u>SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI</u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
<u>SOLIFENACIN SUCCINATE - VESICARE LS</u>						
N 209529 001	9918970	May 18, 2031	DP			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	>A> 10959976	Jun 01, 2038	U-3151			
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
	>A> 10959976	Jun 01, 2038	U-3151			
<u>SPIRONOLACTONE - CAROSPIR</u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u>SUCROFERRIC OXYHYDROXIDE - VELPHORO</u>						
N 205109 001	10925896	Nov 13, 2028	DP			
	10925897	Nov 13, 2028	DP			
	10933090	Nov 13, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUFENTANIL CITRATE - DSUVIA</u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 001					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 002					ODE*	May 24, 2025
<u>TACROLIMUS - ASTAGRAF XL</u>						
N 204096 003					ODE*	May 24, 2025
<u>TAFENOQUINE SUCCINATE - ARAKODA</u>						
N 210607 001	10888558	Dec 02, 2035	U-2582			
<u>TAFLUPROST - ZIOPTAN</u>						
N 202514 001	10864159	May 28, 2029	DP U-778			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	10610511	Oct 10, 2034	U-2615		I-850	Dec 01, 2023
	10610511	Oct 10, 2034	U-3007		ODE-330	Dec 01, 2027
	10945988	Jan 25, 2033	U-2149			
	>A> 10980770	Jan 25, 2033	U-3106			
	>A> 10980770	Jan 25, 2033	U-3107			
<u>TASIMELTEON - HETLIOZ LQ</u>						
N 214517 001	>A> 10980770	Jan 25, 2033	U-3106		NP ODE-329	Dec 01, 2023 Dec 01, 2027
<u>TAVABOROLE - TAVABOROLE</u>						
A 211963 001					PC	Apr 17, 2021
<u>TEPOTINIB HYDROCHLORIDE - TEPMETKO</u>						
N 214096 001	8329692	Oct 30, 2029	DS DP		NCE	Feb 03, 2026
	8580781	Mar 19, 2030	DS DP		ODE-325	Feb 03, 2028
	8658643	Jul 04, 2028		U-3077		
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028		U-3078		
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028		U-3077		
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	>A> 6794410	Sep 12, 2026		U-1285		
	>A> 6794410*PED	Mar 12, 2027				
	>A> 8802735	Sep 14, 2030	DP			
	>A> 8802735*PED	Mar 14, 2031				
	>A> 9186346	Feb 04, 2034		U-1786		
	>A> 9186346*PED	Aug 04, 2034				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	>A> 6794410	Sep 12, 2026		U-1285		
	>A> 6794410*PED	Mar 12, 2027				
	>A> 8802735	Sep 14, 2030	DP			
	>A> 8802735*PED	Mar 14, 2031				
	>A> 9186346	Feb 04, 2034		U-1786		
	>A> 9186346*PED	Aug 04, 2034				
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001					I-851	May 28, 2023
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002					I-851	May 28, 2023
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 001 >A>	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</u>						
N 207981 002 >A>	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u>TIRBANIBULIN - KLISYRI</u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2022	DS DP U-3100		>A> NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2022	DS DP U-3100		>A> NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 002	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 003	10905694	Apr 07, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 004	10905694	Apr 07, 2030	DP			
<u>TOLVAPTAN - JYNARQUE</u>						
N 204441 005	10905694	Apr 07, 2030	DP			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					>A> I-856	Mar 31, 2024
<u>TRILACICLIB DIHYDROCHLORIDE - COSELA</u>						
N 214200 001	10085992	Mar 14, 2034		U-3081	NCE	Feb 12, 2026
	10189849	Oct 25, 2031	DS			
	10189850	Oct 25, 2031	DP			
	10927120	Oct 25, 2031	DP			
	>A> 10966984	Mar 14, 2034		U-3079		
	>A> 10966984	Mar 14, 2034		U-3080		
	8598186	Oct 25, 2031	DS DP			
	8598197	Oct 25, 2031	DS DP			
	9487530	Mar 14, 2034		U-3079		
	9487530	Mar 14, 2034		U-3080		
	9957276	Oct 25, 2031	DS			
<u>UMBRALISIB TOSYLATE - UKONIQ</u>						
N 213176 001	10072013	Jul 02, 2033		U-3063	NCE	Feb 05, 2026
	10072013	Jul 02, 2033		U-3064	>A> ODE-343	Feb 05, 2028
	10414773	May 26, 2035	DS DP	U-3063	>A> ODE-344	Feb 05, 2028
	10414773	May 26, 2035	DS DP	U-3064		
	10570142	Jul 02, 2033	DS DP	U-3063		
	10570142	Jul 02, 2033	DS DP	U-3064		
	10947244	May 26, 2035		U-3063		
	10947244	May 26, 2035		U-3064		
	9150579	Jul 02, 2033	DS DP			
	9669033	Jul 02, 2033		U-3063		
	9669033	Jul 02, 2033		U-3064		
	9969740	May 26, 2035	DS DP	U-3063		
	9969740	May 26, 2035	DS DP	U-3064		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 001	10874648	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-3046		
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
<u>VALBENAZINE TOSYLATE - INGREZZA</u>						
N 209241 002	10874648	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-3046		
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	>A> 10959946	Mar 13, 2035	DP			
	>A> 10959947	Mar 13, 2035	DP	U-3104		
	>A> 10959947	Mar 13, 2035	DP	U-3105		
	>A> 10959948	Mar 13, 2035	DP	U-3104		
	>A> 10959948	Mar 13, 2035	DP	U-3105		
	>A> 10959949	Mar 13, 2035	DP	U-3104		
	>A> 10959949	Mar 13, 2035	DP	U-3105		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	>A> 10959946	Mar 13, 2035	DP			
	>A> 10959947	Mar 13, 2035	DP U-3104			
	>A> 10959947	Mar 13, 2035	DP U-3105			
	>A> 10959948	Mar 13, 2035	DP U-3104			
	>A> 10959948	Mar 13, 2035	DP U-3105			
	>A> 10959949	Mar 13, 2035	DP U-3104			
	>A> 10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	>A> 10959946	Mar 13, 2035	DP			
	>A> 10959947	Mar 13, 2035	DP U-3104			
	>A> 10959947	Mar 13, 2035	DP U-3105			
	>A> 10959948	Mar 13, 2035	DP U-3104			
	>A> 10959948	Mar 13, 2035	DP U-3105			
	>A> 10959949	Mar 13, 2035	DP U-3104			
	>A> 10959949	Mar 13, 2035	DP U-3105			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VEROUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 001	>A> 9358204	Feb 07, 2033	DP		>A> NCE	Apr 02, 2026
	>A> 9603853	Feb 07, 2033	U-727			
	>A> 9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 002	>A> 9358204	Feb 07, 2033	DP		>A> NCE	Apr 02, 2026
	>A> 9603853	Feb 07, 2033	U-727			
	>A> 9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	>A> 9358204	Feb 07, 2033	DP		>A> NCE	Apr 02, 2026
	>A> 9603853	Feb 07, 2033	U-727			
	>A> 9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP U-3039		ODE-280	Aug 12, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037	U-3056		NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP U-3056			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					>A> M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					>A> M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					>A> M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					>A> M-187	Jan 22, 2024
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	>A> 10927117	Aug 15, 2037	DS DP			

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41ST Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm